Calliditas Therapeutics AB (CALT) 20-F 26 Apr 23 2022 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2022 shares
Ifrs Statement
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity Registrant Name	Calliditas Therapeutics AB
Entity File Number	001-38097
Entity Incorporation, State or Country Code	V7
Entity Address, Address Line One	Kungsbron 1, D5
Entity Address, City or Town	Stockholm
Entity Address, Country	SE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding	59,572,587
Entity Shell Company	false
Document Accounting Standard	International Financial Reporting Standards
ICFR Auditor Attestation Flag	true
Entity Central Index Key	0001795579
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Period End Date	Dec. 31, 2022
Amendment Flag	false
Auditor Name	Ernst & Young AB
Auditor Firm ID	1433
Auditor Location	Stockholm
Entity Address, Postal Zip Code	111 22
American Depositary Shares, Each Representing Two Common Shares, Quota Value SEK 0.04 Per Share
Ifrs Statement
Title of 12(b) Security	American Depositary Shares, each representing two common shares, quota value SEK 0.04 per share
Trading Symbol	CALT
Security Exchange Name	NASDAQ
Ordinary shares
Ifrs Statement
Title of 12(b) Security	Common shares, quota value SEK 0.04 per share *
No Trading Symbol Flag	true
Security Exchange Name	NASDAQ
Business Contact
Ifrs Statement
Entity Address, Address Line One	Kungsbron 1, D5
Entity Address, City or Town	Stockholm
Entity Address, Country	SE
Contact Personnel Name	Renée Aguiar-Lucander
City Area Code	+46 (0)
Local Phone Number	8 411 3005
Contact Personnel Email Address	renee.lucander@calliditas.com
Entity Address, Postal Zip Code	111 22

Consolidated Statements of Inco

Consolidated Statements of Income - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statements of Income
Net sales	kr 802,879		kr 874
Cost of sales	(15,201)
Gross profit	787,678	kr 229,347	874
Research and development expenses	(414,749)	(357,485)	(241,371)
Marketing and selling expenses	(515,190)	(179,603)	(38,964)
Administrative expenses	(259,469)		(102,760)
Other operating income	2,862	259	2,501
Other operating expenses	(23,074)	(6,344)
Operating loss	(421,943)	(524,456)	(379,720)
Financial income	50,195	20,336	547
Financial expenses	(37,669)	(9,253)	(56,978)
Loss before income tax	(409,417)	(513,373)	(436,151)
Income tax expense	(2,851)	3,836	(360)
Loss for the year	(412,268)	(509,537)	(436,511)
Attributable to:
Equity holders of the Parent Company	kr (412,268)	(500,293)	(433,494)
Non-controlling interests		kr (9,244)	kr (3,017)
Loss per share
Before dilution to ordinary equity holders of the Parent Company	kr (7.78)	kr (9.84)	kr (9.66)
After dilution to ordinary equity holders of the Parent Company	kr (7.78)	kr (9.84)	kr (9.66)

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statements of Comprehensive Income
Loss for the year	kr (412,268)	kr (509,537)	kr (436,511)
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:
Exchange differences on translation of foreign operations	36,287	(20,111)	(9,352)
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	36,287	(20,111)	(9,352)
Other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods:
Remeasurement gain on defined benefit plans	2,763	1,993	1,216
Other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods	2,763	1,993	1,216
Other comprehensive income/(loss) for the year	39,050	(18,118)	(8,137)
Total comprehensive loss for the year	(373,218)	(527,655)	(444,648)
Attributable to:
Equity holders of the Parent Company	kr (373,218)	(519,189)	(438,343)
Non-controlling interests		kr (8,466)	kr (6,305)

Consolidated Statements of Fina

Consolidated Statements of Financial Position - SEK (kr) kr in Thousands	Dec. 31, 2022	Dec. 31, 2021
Non-current assets
Intangible assets	kr 483,841	kr 399,418
Equipment	7,468	6,309
Right-of-use assets	24,452	33,300
Non-current financial assets	11,210	3,915
Deferred tax assets	13,799	4,196
Total non-current assets	540,770	447,138
Current assets
Inventories	3,647	889
Accounts receivable	78,703
Other current assets	10,018	11,343
Prepaid expenses and accrued income	70,741	45,032
Cash	1,249,094	955,507
Total current assets	1,412,204	1,012,772
TOTAL ASSETS	1,952,973	1,459,910
Equity
Share capital	2,383	2,094
Additional paid-in capital	2,590,890	2,459,741
Reserves	9,307	(26,979)
Retained earnings including net loss for the year	(1,836,317)	(1,426,574)
Equity attributable to equity holders of the Parent Company	766,264	1,008,281
Non-current liabilities
Provisions	11,792	14,530
Contingent consideration	75,880	54,399
Pension liabilities	884	3,182
Deferred tax liabilities	39,752	30,856
Non-current interest-bearing liabilities	713,030	189,164
Non-current lease liabilities	15,792	24,052
Other non-current liabilities	4,350
Total non-current liabilities	861,479	316,183
Current liabilities
Accounts payable	160,404	67,971
Current tax liabilities	5,684	1,221
Other current liabilities	22,697	12,702
Accrued expenses and deferred revenue	136,446	53,553
Total current liabilities	325,231	135,446
TOTAL EQUITY AND LIABILITIES	kr 1,952,973	kr 1,459,910

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - SEK (kr) kr in Thousands	Share Capital	Additional Paid-in Capital	Translation Reserve	Retained Earnings Including Net Loss for the Year	Net Loss For the Year	Non-controlling interests	Total
Opening balance equity attributable to equity holders of the Parent Company at Dec. 31, 2019	kr 1,548	kr 1,274,664	kr (45)	kr (488,096)	kr 788,071		kr 788,071
Loss for the year				(433,494)	(433,494)	kr (3,017)	(436,511)
Other comprehensive income/(loss)			(6,045)	1,196	(4,849)	(3,288)	(8,137)
Total comprehensive loss for the year			(6,045)	(432,298)	(438,343)	(6,305)	(444,648)
Transactions with owners:
New share issue	397	890,990			891,388		891,388
Costs attributable to new share issue		(97,686)			(97,686)		(97,686)
Exercise of warrants	52	59,199			59,251		59,251
Share-based payments		6,012			6,012		6,012
Non-controlling interests from business combinations						136,084	136,084
Purchase of non-controlling interests				1,798	1,798	(83,970)	(82,172)
Total transactions with owners	449	858,516		1,798	860,763	52,114	912,877
Closing balance equity at Dec. 31, 2020	1,998	2,133,179	(6,090)	(918,596)	1,210,491	45,809	1,256,300
Loss for the year				(500,293)	(500,293)	(9,244)	(509,537)
Other comprehensive income/(loss)			(20,889)	1,993	(18,896)	778	(18,118)
Total comprehensive loss for the year			(20,889)	(498,300)	(519,189)	(8,466)	(527,655)
Transactions with owners:
New share issue	96	323,904			324,000		324,000
Costs attributable to new share issue		(20,909)			(20,909)		(20,909)
Share-based payments		23,567			23,567		23,567
Purchase of non-controlling interests				(9,678)	(9,678)	(39,625)	(49,303)
Contribution from non-controlling interests						2,282	2,282
Total transactions with owners	96	326,562		(9,678)	316,980	kr (37,343)	279,637
Closing balance equity at Dec. 31, 2021	2,094	2,459,741	(26,979)	(1,426,574)	1,008,281		1,008,281
Loss for the year				(412,268)	(412,268)		(412,268)
Other comprehensive income/(loss)			36,286	2,763	39,050		39,050
Total comprehensive loss for the year			36,286	(409,505)	(373,218)		(373,218)
Transactions with owners:
Issuance of treasury shares	236				236		236
Repurchase of treasury shares				(236)	(236)		(236)
Costs attributable to new share issue							0
Exercise of warrants	53	95,070		(2)	95,121		95,121
Share-based payments		36,080			36,080		36,080
Total transactions with owners	290	131,150		(238)	131,201		131,201
Closing balance equity at Dec. 31, 2022	kr 2,383	kr 2,590,890	kr 9,307	kr (1,836,317)	kr 766,264		kr 766,264

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Operating loss	kr (421,943)	kr (524,456)	kr (379,720)
Adjustments for non-cash items	61,260	66,676	15,465
Interest received	3,553	102	1,912
Interest paid	(35,252)	(5,432)	(393)
Income taxes paid	(7,392)	(3,949)	(528)
Cash flow used in operating activities before changes in working capital	(399,774)	(467,058)	(363,264)
Cash flow from changes in working capital
Changes in inventory	(2,758)	(949)
Changes in operating receivables	(91,878)	(11,712)	8,033
Changes in operating liabilities	183,056	18,131	46,050
Cash flow used in operating activities	(311,354)	(461,588)	(309,181)
Investing activities
Acquisition of a subsidiary, net of cash acquired			(172,602)
Purchase of equipment	(2,512)	(6,588)
Investments in non-current financial assets	(2,633)	(1,686)	(5)
Purchase of intangible assets		(16,066)
Cash flow used in investing activities	(5,144)	(24,340)	(172,607)
Financing activities
New share issue		324,000	891,388
Costs attributable to new share issue		(20,909)	(95,937)
Issuance of treasury shares	236
Repurchase of treasury shares	(236)
Exercise of warrants	95,121		59,251
Purchase of non-controlling interests		(49,303)	(82,172)
Contribution from non-controlling interests		2,282
New borrowings	491,745	199,524
Costs attributable to new loans	(1,260)	(14,858)
Repayment of lease liabilities	(9,615)	(5,575)	(3,972)
Cash flow from financing activities	575,990	435,162	768,558
Net increase/(decrease) in cash	259,493	(50,766)	286,770
Cash at beginning of the year	955,507	996,304	753,540
Exchange-rate difference in cash	34,094	9,969	(44,006)
Cash at the end of the year	kr 1,249,094	kr 955,507	kr 996,304

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2022
Description of Business
Description of Business	Description of Business Calliditas Therapeutics AB (publ) (“Calliditas” or the “Parent Company”), with corporate registration number 556659-9766, and its subsidiaries (collectively, the “Group”) conduct development and commercial activities in pharmaceuticals. These consolidated financial statements encompass the Group, domiciled in Stockholm, Sweden, and its subsidiaries for the year ended December 31, 2022, 2021 and 2020, respectively. Calliditas is a commercial stage biopharma company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. The registered address of the corporate headquarters is Kungsbron 1, D5, Stockholm, Sweden. Calliditas was founded as a public limited liability company under the laws of Sweden on February 20, 2004 under the name Pharmalink AB and registered with the Swedish Companies Registration Office on April 15, 2004. As of December 31, 2022, Calliditas is the Parent Company of four subsidiaries located in Sweden, France and in the United States. The Swedish subsidiary is Nefecon AB which is conducting no operating activities. The subsidiaries in the United States are Calliditas Therapeutics US Inc and Calliditas NA Enterprises Inc, who are conducting commercialization activates in the United States, respectively. The French subsidiary is Calliditas Therapeutics France SAS located in France which is conducting preclinical activities. The Board of Directors (the “Board”) approved, and authorized for issuance, these consolidated financial statements on April 25, 2023.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Significant Accounting Policies	Note 1 Significant Accounting Policies Basis for Preparation These consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) published by the International Accounting Standards Board (IASB). The accounting policies stated below have, unless otherwise stated, been applied consistently over all periods presented in the consolidated financial statements. The Group’s accounting policies have been applied consistently by the Group’s companies. The consolidated financial statements provide comparative information in respect of the previous period and an additional comparative period. Functional Currency and Reporting Currency The Parent Company’s functional currency is Swedish Kronor (SEK), which is also the presentation currency of the Group. This means that the financial statements are presented in Swedish kronor (SEK) and all amounts, unless otherwise stated, are rounded to the nearest thousand (SEK 000s). Basis for Valuation and Current versus Non-Current Classification The consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets (including derivative financial instrument) and contingent consideration that have been measured at fair value through profit or loss. The Group presents assets and liabilities in the statement of financial position based on current/non-current classification. An asset is current when it is expected to be realized within twelve months after the reporting period. All other assets are classified as non-current. A liability is current when it is due to be settled within twelve months after the reporting period. The Group classifies all other liabilities as non-current. Basis for Consolidation The consolidated financial statements comprise the financial statements of the Parent Company and its subsidiaries as of December 31, 2022. Control is achieved when the Parent Company has control over the investee, the Parent Company is exposed to or has rights to variable returns from its involvement in the investee, and the Parent Company has the ability to use its power over the investee to affect the amount of the investor’s returns, which normally means that the Parent Company owns more than half of the number of votes for all of the shares and participations. The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes of the control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary. All subsidiaries are consolidated using the acquisition method. The cost of an acquisition is measured as the fair value of assets that have been provided as payment along with any liabilities taken over or which have arisen at the acquisition date. With the acquisition method, the fair value of acquired identifiable assets, assumed liabilities and contingent liabilities in a business combination, regardless of the scope of any non-controlling interest, are measured at fair value as of the acquisition date. Any surplus arising from the difference between cost and fair value of identifiable acquired assets, liabilities and contingent liabilities is recognized as goodwill. If the cost amount is less than the fair value of the acquired net assets, it is recognized in the consolidated statements of income. Subsidiaries that were acquired during the financial year are included in the consolidated financial statements as soon as the controlling interest has been transferred to the Group. Subsidiaries that were disposed during the financial year are included in the consolidated financial statements up until the date when the controlling interest no longer exists. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree’s identifiable net assets. Acquisition-related costs are expensed as incurred and included in administrative and selling expenses in the consolidated statements of income. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation. New and Amended Standards and Interpretations Updated standards and interpretations from IASB and IFRIC interpretations that came into effect for the year ended December 31, 2022 have had no material impact on the Group. The Group has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective. Future Standards and New Interpretations Other future or altered standards or interpretations that the IASB has published are not expected to have any significant impact on the financial statements for the Group. Revenue The Group is in the business of identifying, developing and commercializing novel treatments in orphan indications. Operating revenue mainly comprises of product sales, outlicensing of Nefecon to our partnerships in Europe, China and Japan and royalty revenue. Revenue is recognized as follows: ​ Product Sales Revenue from product sales is recognized at the transaction price of goods sold excluding sales tax, rebates and returns. At the time of delivery, when the control of the goods passes to the customer, the revenue is recognized in full, as this represents the single performance obligation in the transaction. The customer is defined as the specialty pharmacy who dispenses the good to the end user. As the final price is related to the rebate paid to the patients’ insurance company or government payer, the transaction price is not known upon delivery. This is accounted for by an accrued estimated rebate deduction in the Group based on calculation models considering statistical data, actual amounts incurred and/or historical trends. These liabilities for expected returns and rebates are based on estimates of the amounts received or to be claimed on the related sales. Furthermore, the Group estimates the liability for expected returns of obsolete medicines. Outlicensing of Product Revenue attributable to outlicensing Nefecon consisted of the agreement with STADA for Europe, the expansion of Everest Medicines to South Korea and the agreement with Viatris for Japan. Revenue for outlicensing is recognized at a point in time, which occurs when control over the intangible asset is transferred to the counterparty, which was at the time when the agreements with the parties were signed. These contracts with customers consist of fixed remuneration as well as variable remuneration in the form of regulatory and commercial milestones, and sales-based royalties. Variable remuneration (for example, attributable to future regulatory milestones) are initially considered constrained, as there is significant uncertainty as to whether these will occur. Compensation attributable to sales-based milestones or royalties are not recognized until the sale that results in the right to milestones or royalties arises. Royalty Revenue Calliditas is entitled to royalties on sold goods, as per agreement. Revenue recognition is based on royalty reports received, which are based on actual net sales statistics of the licensee. Accrued royalty revenue is recognized on the balance sheet under prepaid expenses and accrued income. Financial Income Financial income consists of interest income and foreign exchange gains. Interest income is recognized in accordance with the effective interest method. Effective interest is the interest that discounts estimated future receipts and payments during a financial instrument’s anticipated duration to the financial assets or liability’s recognized net value. The calculation contains all costs included in the effective interest paid by the parties to the contract, transaction costs and all other premiums and discounts. Dividends received are recognized when the right to receive a dividend has been established. Foreign exchange gains and losses are netted. Cost of Sales Cost of sales includes the cost of inventory sold, labor costs, manufacturing overhead expenses and reserves for expected scrap, as well as shipping and freight costs. Cost of sales also includes royalty costs related to in-license agreements. Research and Development Research and development expenses consist primarily of costs incurred for the Group’s development activities, including the development of the Group’s product candidates. The Group expenses research and development costs as incurred. The Group recognizes external development costs based on an evaluation of the progress to completion of specific tasks using information provided by Calliditas’ service providers. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as a prepaid expense or accrued expense. Research and development tax credits are recognized in Sweden and in France. In Sweden tax credits are recognized on social security costs and in France tax credits are recognized on accredited suppliers. These research and development tax credits are recognized as an offset to research and development expenses in the consolidated statements of income. Marketing and Selling Expenses Marketing and selling expenses consist of salaries and other related costs for personnel in the Group and market access, commercialization and business development. Administrative Expenses Administrative expenses consist of salaries and other related costs for personnel in the Group, finance, corporate and administrative functions. Administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, related travel expenses and facility-related expenses, which include allocated expenses for rent and maintenance of facilities and other operating costs. Employee Benefits Short-term benefits Current employee benefits such as salaries, social security costs, vacation pay and bonuses are expensed during the period in which employees perform the service. Pensions The Group has both defined-contribution and defined-benefit pension plans, and most employees are covered by and recognized in the defined-contribution pension plans. Employees in France and Switzerland are covered by defined-benefit pension plans. All other employees were covered by defined-contribution pension plans. See Note 27 Pension Liabilities for more information. Defined-contribution pension plans A defined-contribution pension plan is a pension plan according to which the Group pays fixed premiums to a separate legal entity. The Group does not have any legal or informal obligation to pay further premiums if this legal entity does not have sufficient assets to pay the full remuneration to employees corresponding to their service during the current or previous periods. The Group therefore has no further risk. The Group’s obligations relating to fees for defined-contribution plans are expensed in profit or loss as they are accrued due to the employee performing services for the Group over a period. Defined-benefit pension plans In defined-benefit plans, the pension is determined as a percentage of the pensionable final salary, based on the employee’s length of service and average final salary. The Group is responsible for ensuring that the established benefits are paid out. The defined-benefit pension obligations are recognized in the consolidated statements of financial position as the net total of the estimated present value of the obligations and the fair value of the plan assets, which are recognized as a provision or a non-current financial receivable. For defined-benefit plans, pension expense and commitments are calculated using the applicable principles of IAS 19. This calculation is performed at least annually by independent actuaries. The Group’s obligations are measured at the present value of expected future payments. Actuarial gains and losses may arise in connection with the determination of the present value of the obligations and the fair value of plan assets. These arise either because the fair value differs from the previous assumption, or the assumptions change. Actuarial gains and losses are recognized in the consolidated statements of comprehensive income in the period in which they arise. Interest expense, less the estimated return on plan assets, is classified as a financial expense. Other cost items in the pension expense are charged to operating profit. Severance pay An expense for remuneration in connection with termination of employment of personnel is recognized only if the Group is committed, without any realistic possibility of withdrawal, by a formal detailed plan to eliminate a position in advance of when that position would normally expire. When remuneration is paid as an offer to encourage voluntary termination of employment, the cost is recognized if it is probable that the offer will be accepted and the number of employees that will accept the offer can be reliably estimated. ​ Share-based payments Share-based payments in the Group refers to option programs and performance-based share award programs, which are regulated by equity instruments. In cases where the fair value of the instrument exceeds what the employee paid, the difference is recognized as a personnel cost. The fair value of options is determined at the grant date using the Black-Scholes model for pricing of options. The valuation of the performance share awards is based on a discounted model with Monte Carlo simulation of the share price’s development for the share-related parts and with estimated probabilities for the outcome of the market conditions. The cost is recognized, together with a corresponding increase in equity, during the period in which the service conditions are met, up to and including, the date on which the employees concerned are fully eligible for compensation. Social security costs attributable to equity-related instruments to employees as remuneration for purchased services shall be expensed over the periods during which the services are performed. The cost should then be measured using the same valuation model used when the options were issued. The provision recognized must be revalued at each reporting period on the basis of a calculation of the social security costs that may be paid when the instruments are resolved. Leases Lessee The Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities for future remaining lease payments and right-of-use assets representing the right to use the underlying assets. Right-of-use assets The Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the estimated lease term, which currently is two to four years for the Group’s leases. Lease liabilities At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments less any lease incentives receivable and variable lease payments that depend on an index or a rate. In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the commencement date, because the interest rate implicit in the lease is not readily determinable. Following the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, or a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments). The Group’s lease liabilities are included in Non-current lease liabilities and other current liabilities in the consolidated statements of financial position (see Note 8 Leases and 19 Financial and Non-Financial Assets and Liabilities). Short-term leases and leases of low-value assets The Group applies the short-term lease recognition exemption to its short-term leases of equipment (i.e., those leases that have a lease term of twelve months or less from the commencement date). It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered to be low value. Lease payments on short-term leases and leases of low value assets are recognized as an expense on a straight-line basis over the lease term. Financial Expenses Financial expenses mainly consist of interest expenses, realized and unrealized losses on foreign exchange derivative instruments and unrealized foreign exchange losses. Foreign exchange gains and losses are netted. Taxes Income tax comprises current tax and deferred tax. Income tax is recognized in net profit for the year, except when the underlying transaction is recognized in other comprehensive income or equity with the related tax effect recognized in other comprehensive income and in equity. Current tax is the tax that is to be paid or received in the current year, with the application of the tax rates that have been enacted or substantively enacted by the end of the reporting period. Current tax also includes adjustments of current tax attributable to prior periods. Deferred tax is recognized on all temporary differences that arise between the tax value of assets and liabilities and their carrying amounts. Temporary differences attributable to participations in Group companies is not recognized, since it is unlikely that such a reversal will take place in the foreseeable future. The valuation of deferred tax is based on how the underlying assets or liabilities are expected to be realized or settled. Deferred tax is measured with the application of the tax rates and tax rules decided or announced on the closing date, and that are expected to apply when the deferred tax asset in question is realized or the deferred tax liability is settled. Deferred tax liabilities and deferred tax assets are offset as far as possible within the framework of local laws and regulations on taxation. Deferred tax assets on deductible temporary differences and loss carryforwards are recognized only to the extent that it is probable that it will be possible to utilize these, or to the extent that there are temporary differences which these can be utilized to offset. A provision for deferred tax assets will be recognized when it is no longer deemed probable that they can be utilized. Intangible Assets Intangible assets in the Group consist of licenses and similar rights and goodwill. Licenses and similar rights Intangible assets with a finite useful life are recognized at initial recognition at cost less accumulated amortization and any accumulated impairment losses. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. When determining the amortized amount of the assets, the residual value of the asset is taken into account, when applicable. Goodwill Goodwill arising in a business combination comprises the difference between the cost of the business combination and the fair value of identifiable assets acquired, liabilities assumed, and any contingent liabilities recognized at the acquisition date. Goodwill on business combinations is included in intangible assets and measured at cost less any accumulated impairment losses. Goodwill is allocated to the cash-generating units, which is the full Group, and tested annually for impairment requirement, or whenever there is any indication of impairment. There is no amortization of goodwill and impairment of goodwill is not reversed. Research and development expenses Development expenditures are recognized as an intangible asset when related development projects meet the criteria for capitalization. The most important criteria for capitalization are that the final product of the development process will generate future economic benefits or the ability of cost-savings capacity, including the technical feasibility of completing the intangible asset. Research and development expense are otherwise recognized as operating expenses. Full market approval has not yet been obtained for the Group’s products and, accordingly, the Group deems that the conditions for capitalizing development expenditures are not met. Amortization Amortization of the intangible assets begins when the asset can be used, that is, when it is in the place and in the condition required to be able to use it in the manner intended by the Group’s management. The Group’s expected finite useful life is: – Licenses and similar rights – 6-15 years Until full market approval from regulatory authorities has been granted, amortization of “Licenses and Similar Rights” will not commence. As market approval has not yet been obtained, no other costs have been capitalized. Following market approval from regulatory authorities, “Licenses and Similar Rights” will be amortized on a straight-line basis over the expected useful life. Until a market approval of the product has been obtained, the asset is assessed for impairment at least once a year, and when there is an indication that the asset may be impaired. Equipment Equipment is recognized in the consolidated statement of financial position at cost less accumulated depreciation and impairment. Such cost includes the cost price and expenses directly attributable to the asset. Repairs and maintenance costs are expensed as incurred, while expenses for improvements are recognized as investments and added to the cost of the assets. An item of equipment and any significant part initially recognized is derecognized upon disposal (i.e., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of income when the asset is derecognized. Depreciation Equipment is depreciated on a straight-line basis over the expected useful life. The Group’s expected useful life is: – Equipment – 5 years – Computers – 5 years The residual values, useful lives, and methods of depreciation of equipment are reviewed at each financial year and adjusted prospectively, if appropriate. If there is an indication that an asset needs to be impaired, the asset is written down to its recoverable amount if this is lower than the carrying amount. The recoverable amount corresponds to the highest of net realizable value and value in use. Impairment of Non-Financial Assets Goodwill and intangible assets not yet available for use, are not amortized but the Group assesses for impairment at each reporting date, and when there is an indication that an asset may be impaired. Equipment that is depreciated is assessed for impairment whenever events or changes in circumstances indicate that the carrying amount is not recoverable. An impairment loss is made by the amount by which the asset’s carrying amount exceeds its recoverable amount. An asset’s recoverable amount is the higher of an asset’s or cash generating units’ (“CGU”) fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators. ​ The Group bases its impairment measurement on intangible assets on a probability-adjusted cash flow model. The value of licenses is measured by estimating the expected future cash flows and present value adjustments to take into account the development risk. The valuation takes into account cash flow from potential commercialization during the expected useful life and does not include calculation of any residual value thereafter. The most critical assumptions mainly consist of assumptions about the timing of potential commercialization, market size, market share and probability of reaching the market. When assessing the impairment requirement for goodwill, this is grouped at the lowest levels for which there are separately identifiable cash flows. Calliditas has made the assessment that the Group’s operations as a whole comprise a cash-generating unit. Impairment losses of continuing operations are recognized in the statement of income in expense categories consistent with the function of the impaired asset. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset’s recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Financial Assets and Financial Liabilities A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial instruments are classified at initial recognition, including on the basis of the purpose for which the instrument was acquired and managed. This classification determines the valuation of the instruments. Initial recognition and measurement of financial assets The Group’s financial assets consist of non-current financial assets, accounts receivable and cash, which are recognized at amortized cost. The instruments are classified into: – Amortized cost, or – Fair value through profit or loss Financial assets at amortized cost are initially measured at fair value with the addition of transaction costs. Following the initial recognition, the assets are measured at amortized cost less a provision for losses on expected credit losses. Assets classified at amortized cost are held according to the business model to collect contractual cash flows that are only payments of capital amount and interest on the outstanding capital amount. Initial recognition and measurement of financial liabilities The Group’s financial liabilities consist of contingent consideration, non-current interest-bearing liabilities, other non-current liabilities, lease liabilities, accounts payable and other current liabilities, all of which, except contingent consideration, are recognized as amortized cost. Contingent consideration is recognized at fair value through profit or loss. The instruments are classified into: – Amortized cost, or – Fair value through profit or loss Financial liabilities at amortized costs are initially measured at fair value, net of transaction costs. Subsequently periods are measured at amortized cost using the effective interest (EIR) method. Financial liabilities classified at fair value are measured both initially and in subsequent periods at fair value in the Group’s consolidated statements of financial position, where changes in fair value are recognized in the Group’s consolidated statements of income. The components of the change in fair value relating to exchange rate effects are recognized in net financial items and other changes in fair value are recognized in operating profit or loss. Recognition and derecognition A financial asset or financial liability is recognized in the consolidated statement of financial position when the Group becomes a party in accordance with the contractual terms of the instrument. Debt is recognized when the counterparty has performed and a contractual obligation exists to pay, even if an invoice has not yet been received. A financial asset is derecognized from the consolidated statement of financial position when the rights in the agreement are realized, expire or the Group loses control of them. A financial liability is derecognized from the consolidated statement of financial position when the contractual obligation is fulfilled or otherwise extinguished. The same applies to part of a financial asset or financial liability. Gains and losses from derecognition from the consolidated statement of financial position are recorded in the consolidated statement of income. A financial asset and financial liability are offset and recognized with a net amount in the consolidated statement of financial position only when there is a legal right to set off the amounts and that there is an intention to settle the items with a net amount or to simultaneously realize the asset and settle the debt. Impairment of financial assets The Group’s impairment model is based on expected credit losses and takes into account forward-looking information. The valuation of expected credit losses takes into account any collateral and other credit enhancements in the form of guarantees. See Note 20 Financial Risks for information on considerations relating to accounts receivable and deposits. Inventory Inventory is recognized as the lower of the acquisition cost and the net realizable value. The acquisition cost for completed goods and goods being manufactured comprises raw materials and other direct costs and applicable indirect manufacturing costs. The net realizable value is the estimated sale price in operating activities. By continuously monitoring inventory, we ensure that it is dispatched based on its shelf life and moving average basis. When necessary, impairment of inventory is performed within the frame of normal business operations and is recognized in costs of goods sold. Accounts Receivable Accounts receivable are reported at amortized cost. A provision for expected credit losses is recorded based on the Group’s forward looking expected credit losses (ECL). An analysis of expected credit losses is performed, taking into account historical, current and forward looking factors. The effect of recognition of the provision amount is reported in the statement of income. Cash Cash is entirely comprised of cash at banks. Equity Common shares, other contributed capital and retained earnings are classified as equity. Financial instruments that meet the criteria for classification as equity are recognized as equity even if the financial instrument is legally structured as a liability. Transaction costs that are directly attributable to the issue of new shares or options are recognized net after tax in equity as a deduction from the issue proceeds. When Calliditas shares are repurchased, the amount of the consideration paid is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are

Significant Accounting Judgemen

Significant Accounting Judgements, Estimates and Assumptions	12 Months Ended
	Dec. 31, 2022
Significant Accounting Judgements, Estimates and Assumptions
Significant Accounting Judgements, Estimates and Assumptions	Note 2 Significant Accounting Judgements, Estimates and Assumptions The preparation of the Group’s consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the recorded amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. Judgements, estimates and assumptions are evaluated on an ongoing basis. Changes in judgements, estimates and assumptions are recognized in the period the change has occurred if the change only affects that period, and future period if the change affects both the current period and future periods. Revenue Recognition Outlicensing of Product Revenue for the outlicensing of Nefecon is recognized at the point in time when control of the intellectual property is transferred, while revenue for the provision of certain regulatory services is reported over time as the services are performed. The revenue allocated to the performance obligation for outlicensing is based on the residual approach and consists of the total transaction price for each contract after deducting the stand- alone selling price of all other performance obligations, and the allocation of revenue to the performance obligation for regulatory services is based on the expected costs to provide the service, with the addition of a profit margin based on comparable companies. The identification of and allocation of the transaction price between these performance obligations hence has a significant impact on the Group’s revenue recognition, as the revenue recognition patterns differ between the performance obligations. Specifically, the significant accounting judgments and estimates within revenue recognition include determining which promises within each contract are distinct, estimating the expected costs to fulfil the performance obligations that are not based on the residual method, and determining an appropriate profit margin for these. The Group determines the expected costs to complete these performance obligations through an input model based on the expected hours of work required by the Group’s personnel, as well as expected costs to be incurred from the Group’s suppliers. The Group then determines an appropriate profit margin by identifying comparable peer companies that provide such services separately and bases the margin rate on these. The Group then recognizes revenue for the performance obligation to provide regulatory services as these costs are incurred. These estimates are forward-looking and could be affected by differences between expected and actual costs incurred to fulfil the performance obligations. Management’s estimate of the total costs as a measure of progress to completion of the performance obligation hence requires the use of assumptions and estimates. The revenue contracts also contain variable remuneration in the form of regulatory and commercial milestones. Variable remuneration is initially considered constrained, as there is significant uncertainty as to whether the associated milestones will occur. Compensation attributable to sales-based milestones or royalties is not recognized until the sale that results in the right to the royalties have occurred. Determining whether the criteria for recognition of the variable remuneration has been met hence has significant effects on revenue recognition and requires significant judgment by Management. ​ Gross to Net Accounting Revenue from product sales in the United States is recognized when product is received by the customer and title passes, typically at the time of delivery. There are various sales deductions and rebates that are deducted from the gross sales as part of the revenue recognition process. As the actual sales deductions are not known at the point of sale, estimates are made in determining the initial deduction of rebates, and are then subject to true-up as actual data is obtained. For sales of TARPEYO, returns allowances and prompt pay discounts are estimated based on contract terms and historical return rates or industry averages, if available and those estimates are recorded as a reduction of accounts receivable and as other current liabilities, respectively. Similarly determined estimates are recorded for relating to specialty pharma fees, co-pay support redemptions, Medicare/Medicaid and other rebates, and these estimates are reflected as a component in the accrued expenses and deferred revenue and as a reduction of revenue. Once all related variable considerations are resolved and uncertainties as to collectable amounts are eliminated, estimates are adjusted to actual amounts. Accruals for these estimated amounts is reviewed and adjusted on no less than a quarterly basis. Intangible Assets The Group’s intangible assets are essentially attributable to the Group acquiring the rights to the NOX platform, as well as goodwill in connection with the acquisition of Genkyotex SA. As well as to the previous in-licensing agreement of Budenofalk 3mg oral capsule from the German pharmaceutical company Dr Falk Pharma GmbH. For goodwill and intangible assets not yet available for use the Group assesses for impairment at each reporting date based on their recoverable amounts, including key assumptions such as the timing of potential commercialization, market size, market share, probability of reaching the market and the discount rates. See below and Note 15 Intangible Assets and Impairment Testing. Goodwill and intangible assets, not yet available for use The Group conducts impairment testing, at least annually, for goodwill and intangible assets, not yet available for use, in accordance with the policy described in Note 1 Significant Accounting Policies. The recoverable amount of the cash-generating unit is determined by calculating the value in use. This calculation requires certain judgments and assumptions to be made, see Note 15 Intangible Assets and Impairment Testing. As of December 31, 2022, the Group’s goodwill amounted to SEK 45,784 and other intangible assets amounted to SEK 438,057. There is no Capitalization of intangible assets The Group capitalizes expenditures for the development of pharmaceuticals to the extent that it is expected to meet the criteria in accordance with IAS 38 — Intangible Assets. The decision to capitalize is based on significant judgments made by management, including the technical feasibility of completing the intangible asset so that it will be available for use or sale and assumptions used to demonstrate that the asset will generate probable future economic benefits (e.g., projected cash flow projections, discount rate). The Group’s expenditures for the development of pharmaceuticals were not deemed to meet the capitalization criteria for the year ended December 31, 2022, and was thus expensed. Capitalization of expenditures are generally made in late stage of the development, for example after full approval, depending on when the criteria are deemed to have been met. The reason for this is that before then it is uncertain whether the expenditure will generate future economic benefits and that financing the completion of the asset is not yet guaranteed. US Food and Drug Administration (FDA) has granted accelerated approval for TARPEYO ® ® Allowance for Expected Credit Losses for Accounts Receivable Management makes allowance for expected credit losses for accounts receivable equal 12 months. The estimate is based on any increased credit risk, on an individual or collective basis, considering reasonable and supportable information, including that which is forward-looking. The allowance for expected credit risk is an estimate based on maturity structure accounts receivable and specific customer knowledge. Generally, invoices are due for payment within 30-45 days. Loss Carryforwards The Groups tax losses carried forward have not been recognized as deferred tax assets in the statement of financial position as of December 31, 2022, except for such circumstances where there are future temporary differences that such losses can be used to offset. Deferred tax assets will be recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. The Group has identified an uncertain tax position in relation to the ability to use tax loss carried forward in France due to transactions performed historically. The related tax losses carried forward has not been recognized as deferred tax assets in the consolidated statements of financial position. Assumptions for The Valuation of Pension Benefits The valuation of pension commitments and pension expenses is based on the actuarial assumptions specified in Note 28 Pension Liabilities. Key Sources of Estimation Uncertainty The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	12 Months Ended
	Dec. 31, 2022
Revenue from Contracts with Customers
Revenue from Contracts with Customers	Note 3 Revenue from Contracts with Customers The Group’s revenues in 2022 primarily consisted of net sales of TARPEYO in the U.S., milestone fees from STADA for the conditional approval and commercialization of Kinpeygo in Europe and the milestone fee from Viatris to register and commercialize Nefecon for the treatment of IgA nephropathy (IgAN) in Japan. In addition, net sales also consisted of the milestone fee from Everest Medicines for the extension of the license agreement for South Korea. The recognition of revenue is associated with significant accounting judgments and estimates, for additional information see Note 2. Set out below is the Group’s revenue from contracts with customers: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Type of goods or service ​ 2022 ​ 2021 ​ 2020 Product sales 375,515 — — Outlicensing of product 421,689 225,252 — Royalty income ​ 2,287 ​ — ​ — Performance of certain regulatory services ​ 3,387 ​ 4,095 ​ — Provision of drugs ​ — ​ — ​ 874 Total 802,879 229,347 874 ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Geographical markets ​ 2022 ​ 2021 ​ 2020 USA ​ 372,247 ​ — ​ — Europe* 143,955 201,878 — Asia ​ 286,677 ​ 27,469 ​ 874 Total 802,879 229,347 874 ​ * No net sales was recorded in Sweden in 2022, 2021 and 2020, respectively. ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Revenue from major customers 2022 2021 2020 Customer A ​ 372,247 — — Customer B ​ 80,643 27,469 874 Customer C ​ 143,955 201,879 — Customer D ​ 206,034 — — Total ​ 802,879 229,348 874 ​ As of December 31, 2022, the total liability for expected returns and rebates amounts to SEK 24,294, which are recognized in other current liabilities and accrued expenses and deferred revenue. In addition, there are no other performance obligations. No liability for expected returns and rebates was recorded as of December 31, 2021. ​ Contract assets comprise of accrued royalties and amounts to SEK 2,287 as of December 31, 2022. No contract assets were recorded December 31, 2021. Changes in contract asset balances are entirely attributable to the ordinary operations of the Group where sales have commenced during the year. Contract liabilities comprises of accrued rebates on sales and amounts to SEK 15,849 as of December 31, 2022 and deferred revenue amounts to SEK 3,387 as of December 31, 2021. Opening balance comprise prepaid income which has been recognized as revenue during the year.

Other Operating Income

Other Operating Income	12 Months Ended
	Dec. 31, 2022
Other Operating Income
Other Operating Income	Note 4 Other Operating Income ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Exchange rate differences — 149 2,501 Pass through costs ​ 439 ​ — ​ — Net gains on disposal of equipment ​ — ​ 110 ​ — Other income ​ 2,423 ​ — ​ — Total 2,862 259 2,501 ​

Other Operating Expenses

Other Operating Expenses	12 Months Ended
	Dec. 31, 2022
Other Operating Expenses
Other Operating Expenses	Note 5 Other Operating Expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Exchange rate differences 7,133 1,807 — Net loss on disposal of equipment — 67 — Change in value of the contingent consideration at fair value 15,941 4,470 — Total 23,074 6,344 — ​

Auditor's Fee

Auditor's Fee	12 Months Ended
	Dec. 31, 2022
Auditors' Fee
Auditors' Fee	Note 6 Auditors’ Fee ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 EY ​ Audit services 13,369 6,235 4,449 Other audit activities ​ 3,370 ​ 2,105 ​ 3,774 Tax advice — 73 — Total ​ 16,739 ​ 8,413 ​ 8,223 ​ ​ ​ ​ ​ ​ ​ KPMG ​ ​ ​ ​ ​ ​ Audit services ​ — ​ 472 ​ 102 Other audit activities ​ — ​ 1,178 ​ 2,552 Total ​ — ​ 1,650 ​ 2,654 ​ ​ ​ ​ ​ ​ ​ Other auditors ​ ​ ​ ​ ​ ​ Audit services ​ — ​ 471 ​ 102 Other audit activities ​ — ​ 79 ​ — Total ​ — ​ 550 ​ 102 ​ ​ ​ ​ ​ ​ ​ Total Audit Fee ​ 16,739 ​ 10,613 ​ 10,979 ​ Audit services relate to the statutory audit of the financial statements and the accounts, as well as the management of the Board of Directors and the CEO. This includes other responsibilities that it is incumbent upon the company’s auditor to perform including providing advice or any other assistance that may result from observations in such review or the conduct of such other responsibilities. Other audit activities are those services in accordance with a special agreement on financial statements.

Costs according to Type of Cost

Costs according to Type of Cost	12 Months Ended
	Dec. 31, 2022
Costs according to Type of Cost
Costs according to Type of Cost	Note 7 Costs according to Type of Cost ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Raw materials and consumables ​ 3,179 ​ — ​ — Other external expenses 939,566 549,079 ​ 311,329 Personnel costs 248,952 164,206 ​ 68,943 Depreciation on equipment’s and right-of-use assets 12,913 34,433 ​ 2,823 Other operating expenses 23,074 6,344 ​ — Total 1,227,684 754,062 ​ 383,095 ​

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases
Leases	Note 8 Leases ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Right-of-use assets ​ ​ ​ ​ Opening balance ​ 37,198 ​ 9,595 Additional agreements ​ — ​ 34,944 Revaluation agreements ​ (474) ​ — Termination of agreement ​ — ​ (7,625) Exchange differences ​ 3,485 ​ 284 Closing balance ​ 40,209 ​ 37,198 ​ ​ ​ ​ ​ Depreciation ​ ​ Opening balance ​ (3,898) ​ (4,351) Depreciation ​ (10,807) ​ (5,711) Revaluation agreements ​ 47 ​ — Termination of agreement ​ — ​ 6,456 Exchange differences ​ (1,099) ​ (292) Closing balance ​ (15,757) ​ (3,898) ​ ​ ​ ​ ​ Net book value ​ 24,452 ​ 33,300 ​ Depreciation on right-of-use assets is included in the consolidated statements of income under Research and development expenses amounted to SEK 1,073, SEK 997 and SEK 165 in 2022, 2021 and 2020, respectively, under Marketing and selling expenses amounted to SEK 3,743, SEK 1,522 and SEK - in 2022, 2021 and 2020, respectively, and under Administrative expenses amounted to SEK 5,991 , ​ ​ ​ ​ ​ ​ ​ December 31, Lease liabilities 2022 2021 Non-current lease liabilities ​ 15,792 ​ 24,052 Current lease liabilities ​ 10,374 ​ 9,591 Total 26,165 ​ 33,642 ​ Lease liabilities are included in the consolidated statements of financial position under Non-current lease liabilities and Other current liabilities. Changes in liabilities arising from financing activities, see Note 23 Cash for further information on leasing liabilities. ​ ​ ​ ​ ​ ​ ​ ​ December 31, Maturity analysis on future lease liabilities 2022 2021 <12 months ​ 16,467 11,909 1-2 years ​ 12,613 11,231 >2 years ​ 10,053 16,256 ​ ​ 39,133 39,396 ​ ​ Future lease payments in accordance with the above are undiscounted. The leases primarily comprise of leased premises for the Group. The lease agreements for leased premises have terms ending 2023 until 2026 respectively and can be extended unless one of the parties terminates the lease agreements. The Group cannot determine with reasonable certainty whether the extensions will take place based on the Group’s development and has therefore not expected utilization after the terms ending. Future lease payments are linked to the development in the CPI index, but with a limitation on negative index change. Index adjustments are included in the lease liability when they come into force and are then adjusted against the right-of-use asset. Lease of low-value assets consists mainly of storage and office equipment. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 ​ 2021 2020 Interest expenses attributable to lease liabilities ​ 1,604 ​ 590 388 Expenses attributable to short-term lease ​ — ​ 633 731 Expenses attributable to leasing agreements with low value ​ 214 ​ 146 103 Expenses attributable to variable lease payments that are not included in lease liabilities ​ 303 ​ 446 344 Expenses attributable to lease depreciation ​ 10,807 ​ 5,711 ​ 2,786 Total expensed during the year ​ 12,928 ​ 7,526 ​ 4,352 ​ ​ ​ ​ ​ ​ ​ This year’s lease payments in the Group ​ 13,231 ​ 6,659 4,930 ​

Employees and Personnel Costs

Employees and Personnel Costs	12 Months Ended
	Dec. 31, 2022
Employees and Personnel Costs
Employees and Personnel Costs	Note 9 Employees and Personnel Costs Average Number of Employees ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 ​ 2021 ​ 2020 ​ Number % of Male Number % of Male Number % of Male ​ ​ of Empl. ​ Empl. ​ of Empl. ​ Empl. ​ of Empl. ​ Empl. Parent Company ​ ​ ​ ​ ​ Sweden 45 33 % 29 40 % 16 ​ 44 % ​ 45 33 % 29 40 % 16 ​ 44 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Subsidiaries ​ ​ ​ ​ ​ France ​ 2 ​ — ​ 3 ​ 26 % — ​ — ​ Switzerland ​ 6 ​ 53 % 6 ​ 47 % 2 ​ 50 % United States 33 52 % 18 62 % 5 ​ 100 % ​ 41 51 % 27 55 % 7 ​ 86 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total for the Group 86 41 % 56 47 % 23 ​ 57 % ​ Wages and Salaries, Pension Costs and Social Security Costs to the Board, Executive Management and Other Employees ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Wages and Salaries 2022 2021 2020 Parent Company ​ ​ ​ ​ Board and Executive Management 1) 33,471 ​ 27,792 19,211 Other employees 52,126 ​ 33,370 15,598 ​ ​ ​ ​ ​ ​ ​ Subsidiaries ​ ​ ​ Board and Executive Management 14,493 ​ 4,983 3,184 Other employees ​ 90,055 ​ 57,452 ​ 11,615 Total 190,145 ​ 123,597 49,608 ​ 1) Executive Management includes the Board, CEO and other executive management. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Social Security Costs and Pension Costs 2022 2021 2020 Parent Company ​ ​ ​ Pension costs for the Board and Executive Management 2,167 1,785 ​ 1,748 Pension costs to other employees 6,582 4,084 ​ 1,666 Social security costs 17,393 17,088 ​ 12,330 ​ ​ ​ ​ ​ ​ ​ Subsidiaries ​ Pension costs for the Board and Executive Management ​ 616 ​ 167 ​ 129 Pension costs to other employees ​ 2,647 ​ 928 ​ 506 Social security costs 6,484 8,596 ​ 225 Total 35,889 32,648 ​ 16,604 ​ Gender Distribution Among the Board and Executive Management ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 2020 ​ Percentage of women on the Board ​ 67 % 60 % 60 % Percentage of men on the Board 33 % 40 % 40 % Percentage of women among other executive management 38 % 33 % 33 % Percentage of men among other executive management 62 % 67 % 67 % ​ Disclosures Regarding Total Remuneration of The Board and Executive Management ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2022 ​ Base Salary, ​ Variable Other Share-Based ​ ​ ​ Board Fee ​ Pension Costs ​ Remuneration ​ Remuneration ​ Payments ​ Total Chairman of the Board Elmar Schnee 975 — — — 647 1,622 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board members Hilde Furberg 413 — — — 239 651 Diane Parks 490 — — — 239 729 Lennart Hansson (until May, 2022) 200 — — — 33 233 Molly Henderson 590 — — — 227 817 Henrik Stenqvist (from May, 2022) 275 — — — 74 349 Elisabeth Björk (from May, 2022) 188 — — — 74 261 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Executive Management CEO, Renée Aguiar-Lucander 5,938 760 2,293 — 4,056 13,048 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other executive management (7 people) 17,784 2,023 5,146 — 8,083 33,037 of which relates to subsidiaries 7,516 616 3,152 — 3,824 15,109 Total 26,853 2,783 7,440 — 13,671 50,747 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2021 ​ Base Salary, ​ Variable Other Share-Based ​ ​ ​ Board Fee ​ Pension Costs ​ Remuneration ​ Remuneration ​ Payments ​ Total Chairman of the Board Elmar Schnee 898 — — — 465 1,363 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board members Hilde Furberg 336 — — — 162 498 Lennart Hansson 360 — — — 162 522 Diane Parks ​ 421 ​ — ​ — ​ — ​ 162 ​ 583 Molly Henderson 539 — — — 124 663 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Executive Management ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CEO, Renée Aguiar-Lucander ​ 4,860 ​ 760 ​ 1,840 ​ — ​ 3,270 ​ 10,730 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other executive management (5 people) ​ 11,279 ​ 1,193 ​ 2,335 ​ — ​ 5,561 ​ 20,368 of which relates to subsidiaries 2,775 167 694 — 1,515 5,151 Total 18,693 1,953 4,175 — 9,906 34,727 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2020 ​ Base Salary, ​ Variable Other Share-Based ​ ​ ​ Board Fee ​ Pension Costs ​ Remuneration ​ Remuneration ​ Payments ​ Total Chairman of the Board Elmar Schnee 834 — — — 310 1,144 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board members Thomas Eklund (until June, 2022) 72 — — — 43 115 Hilde Furberg ​ 273 ​ — ​ — ​ — ​ 106 ​ 379 Lennart Hansson 281 — — — 106 387 Bengt Julander (until June, 2022) ​ 58 ​ — ​ — ​ — ​ — ​ 58 Diane Parks ​ 379 ​ — ​ — ​ — ​ 106 ​ 485 Molly Henderson (from June, 2022) ​ 345 ​ — ​ — ​ — ​ 37 ​ 382 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Executive Management ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CEO, Renée Aguiar-Lucander ​ 3,401 ​ 678 ​ 1,357 ​ — ​ 1,094 ​ 6,530 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other executive management (5 people) ​ 9,816 ​ 1,198 ​ 1,760 ​ 472 ​ 2,018 ​ 15,264 of which relates to subsidiaries 2,547 129 636 — — 3,312 Total 15,459 1,876 3,117 472 3,820 24,744 ​ ​ Other Remuneration Other remuneration comprises of fees for services rendered to the Parent Company. Management services purchased from Cordcom Consultants KB amounted to SEK –, SEK – and SEK 472 in 2022, 2021 and 2020, respectively, and relates to the functions of a Head of Communications and Investor Relations that were outsourced to this entity. Remuneration of Executive Management Remuneration of the CEO and other executive management comprises base salary, pension benefits and variable remuneration. Other executive management comprise the seven (five) individuals who, together with the CEO, comprise Executive Management. Other executive management are: Chief Financial Officer, Chief Medical Officer, Vice President Regulatory Affairs, President, North America, Vice President Operations, Group General Counsel and Head of Human Resources. Pensions All pension commitments are defined-contribution plans for executive management, as well as board members. The guidelines shall apply to management. The payments made by the Group for defined contribution plans are recognized as expense in the statements of consolidated operations for the period to which they relate. The age of retirement for the CEO is 65 and the pension premium is 20% of base salary. Pension commitments for other Swedish executive management are between 15% and 20% of base salary. The age of retirement is 65 for all other executive management. Defined-benefit pension plans occurs only if required by law or other regulations. In such cases, the defined-benefit level shall be limited to the mandatory level. There are no other pension obligations. Variable Remuneration Variable remuneration refers to a variable bonus based on a fixed percentage of base salary. Outcome is based on a vesting period of one year and depends on fulfillment of a combination of predetermined personal targets and business targets. The maximum outcome for the CEO and for other executive management is 60% according to the guidelines for remuneration to executive management. Severance Pay A notice period of six months applies if employment is terminated by the CEO. A notice period of twelve months applies if employment is terminated by the Group. The CEO is not entitled to separate severance pay but is eligible to receive a salary during the period of notice. A mutual notice period of three Guidelines for Executive Remuneration At the 2022 Annual General Meeting the most recently adopted guidelines for executive remuneration was approved. Remuneration within the Group shall be based on principles of performance, competitiveness and fairness. Executive management refer to the CEO and other members of the executive management, as well as board members. The guidelines shall apply to employment agreements concluded after the listing on Nasdaq Stockholm, as well as to changes in existing agreements after the listing. The remuneration to the executive management may consist of fixed remuneration, variable remuneration, share and share price-related incentive programs, pension and other benefits. If local conditions justify variations in the remuneration principles, such variations may occur. The fixed remuneration shall reflect the individual’s responsibility and experience level. The fixed remuneration shall be reviewed annually. The executive management may be offered variable remuneration paid in cash. Such remuneration may not exceed 60 percent of the annual fixed remuneration. Variable remuneration shall be connected to predetermined and measurable criteria, designed with the aim of promoting the Groups long-term value creation. Remuneration and other terms of employment for the CEO are prepared by the Remuneration Committee and decided by the Board of Directors. Remuneration and other terms of employment for other members of the executive management are decided by the CEO, in accordance with principles decided by the Board of Directors and the Remuneration Committee. The Board of Directors is entitled to deviate from the guidelines if the Board of Directors, in a certain case, deems that there are good reasons for the deviation. Decisions as to the current remuneration levels and other conditions for employment of the CEO and the other members of the executive management have been resolved by the Board of Directors. There are no previous payments that have not been due.

Share-Based Payments

Share-Based Payments	12 Months Ended
	Dec. 31, 2022
Share-Based Payments
Share-Based Payments	Note 10 Share-Based Payments ​ Option Program Calliditas implements option programs for employees and key consultants in Calliditas. The options are granted free of charge to participants of the program. The options have a three-year vesting period calculated from the grant date, provided that, with customary exceptions, the participants remain as employees of, or continue to provide services to, Calliditas. Once the options are vested, they can be exercised within a one-year period. Each vested option entitles the holder to acquire one share in Calliditas at a predetermined price. The price per share is to be equivalent to 115% of the weighted average price that the company’s shares were traded for on Nasdaq Stockholm during the ten trading days preceding the grant date. The options have, at the time of each issue, been valued according to the Black & Scholes valuation model. Changes and holdings of options for CEO, other executive management and other employees on the opening and closing balance are presented below. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding as of Holder January 1, 2021 Change December 31, 2021 Change ​ December 31, 2022 Renée Aguiar-Lucander, CEO 225,000 71,000 296,000 295,000 591,000 Other executive management 415,000 120,000 535,000 ​ 520,000 ​ 1,055,000 Other employees and consultants 449,000 1,009,000 1,458,000 ​ 848,166 ​ 2,306,166 Total 1,089,000 1,200,000 2,289,000 ​ 1,663,166 ​ 3,952,166 ​ Calculation of fair value of option program (ESOP) The fair value on the grant date was calculated using an adapted version of the Black & Scholes valuation model, which takes into consideration the exercise price, the term of the options, share price on the grant date and expected volatility in the share price, and risk-free interest for the term of the options. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value Upon ​ ​ No. of Shares ​ ​ ​ ​ ​ Issue of the Options, Exercise ​ ​ Covered by ​ Grant Date Exercised Date SEK Price, SEK Volatility Options ESOP 2020:1 July 1, 2020 July 1, 2023 22.14 121.43 39.60 % 836,500 ESOP 2020:2 September 17,2020 September 17,2023 22.50 116.78 41.60 % 104,000 ESOP 2020:3 ​ February 4, 2021 February 4, 2024 ​ 30.41 ​ 145.05 ​ 44.30 % 37,000 ESOP 2020:4 ​ March 9, 2021 ​ March 9, 2024 ​ 30.41 ​ 141.26 ​ 45.20 % 394,166 ESOP 2021:1 ​ June 14, 2021 ​ June 14, 2024 ​ 35.88 ​ 140.71 ​ 46.00 % 500,000 ESOP 2021:2 ​ September 29, 2021 ​ September 29, 2024 ​ 25.72 ​ 109.38 ​ 47.50 % 329,500 ESOP 2021:3 ​ March 17, 2022 ​ March 17, 2025 ​ 27.64 ​ 93.77 ​ 43.84 % 650,000 ESOP 2022:1 ​ September 27, 2022 ​ September 27, 2025 ​ 26.57 ​ 94.66 ​ 45.14 % 1,101,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 3,952,166 ​ The total cost of the outstanding option program is presented below. These costs do not affect the Groups consolidated statements of cash flows. The Group has in total 5,000,000 warrants which are set aside to secure the delivery of shares in connection with the utilization of the option programs. For additional information see Note 25 Equity. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Share-based payments ​ 34,549 ​ 24,737 ​ 5,304 Provisions attributable to changes in social security costs (Share-based payments) 234 9,992 ​ 3,164 Total 34,783 34,729 ​ 8,468 ​ Share Awards Calliditas implements share awards programs which is a performance-based long-term incentive program for members of the Board of Directors in Calliditas. Calliditas currently has three share award programs ongoing at year-end. For each share award program, the share awards are vested by 1/3 at the end of each period, provided that the participant is still a member of the Board of Calliditas that day. In addition to these conditions for vesting, for each share award program, the share awards are subject to performance-based vesting based on the development of Calliditas share price. If Calliditas share price has increased by more than 60 percent, 100 percent of the share awards shall be earned, and if the share price has increased by 20 percent, 33 percent of the share awards shall be vested. In the event of an increase in the share price by between 20 and 60 percent, vesting will be linear. If the share price has increased by less than 20 percent, no vesting will take place. Each share award entitles the holder to receive a share in Calliditas free of charge, provided that the holder is still a member of the Board of Calliditas at the relevant vesting date. Changes and holdings of share awards for the Board on the opening and closing balance are presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board LTIP 2019 Share Awards Outstanding as of Holder January 1, 2021 Change December 31, 2021 Change December 31, 2022 Elmar Schnee, Chairman of the Board ​ 23,236 — 23,236 ​ (23,236) ​ — Thomas Eklund, Board member (until June, 2020) ​ 2,816 — 2,816 ​ (2,816) ​ — Hilde Furberg, Board member ​ 8,449 — 8,449 ​ (8,449) ​ — Lennart Hansson, Board member (until May, 2022) ​ 8,449 — 8,449 ​ (8,449) ​ — Diane Parks, Board member ​ 8,449 — 8,449 ​ (8,449) ​ — Total ​ 51,399 — 51,399 (51,399) — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board LTIP 2020 Share Awards Outstanding as of Holder January 1, 2021 Change December 31, 2021 Change December 31, 2022 Elmar Schnee, Chairman of the Board ​ 14,063 — 14,063 ​ — ​ 14,063 Hilde Furberg, Board member ​ 4,327 — 4,327 ​ — ​ 4,327 Lennart Hansson, Board member (until May, 2022) ​ 4,327 — 4,327 ​ (1,443) ​ 2,884 Diane Parks, Board member ​ 4,327 — 4,327 ​ — ​ 4,327 Molly Hendersson, Board member ​ 4,327 ​ — ​ 4,327 ​ — ​ 4,327 Total ​ 31,371 — 31,371 (1,443) 29,928 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board LTIP 2021 Share Awards Outstanding as of Holder January 1, 2021 Change December 31, 2021 Change December 31, 2022 Elmar Schnee, Chairman of the Board ​ — 10,624 10,624 ​ — ​ 10,624 Hilde Furberg, Board member ​ — 4,086 4,086 ​ — ​ 4,086 Lennart Hansson, Board member (until May, 2022) ​ — 4,086 4,086 ​ (2,724) ​ 1,362 Diane Parks, Board member ​ — 4,086 4,086 ​ — ​ 4,086 Molly Henderson, Board member ​ — ​ 4,086 ​ 4,086 ​ — ​ 4,086 Total ​ — 26,968 26,968 (2,724) 24,244 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board LTIP 2022 Share Awards Outstanding as of Holder January 1, 2021 Change December 31, 2021 Change December 31, 2022 Elmar Schnee, Chairman of the Board ​ — — — ​ 13,926 ​ 13,926 Hilde Furberg, Board member ​ — — — ​ 5,356 ​ 5,356 Diane Parks, Board member ​ — — — ​ 5,356 ​ 5,356 Molly Hendersson, Board member ​ — ​ — ​ — ​ 5,356 ​ 5,356 Henrik Stenqvist, Board member ​ — ​ — ​ — ​ 5,356 ​ 5,356 Elisabeth Björk, Board member ​ — ​ — ​ — ​ 5,356 ​ 5,356 Total ​ — — — 40,706 40,706 ​ For each share award program, calculation of fair value of share-based payments (Board LTIP) Fair value at grant day has been measured using a Monte Carlo simulation of future share price developments. The simulated share price trend has been used to both calculate the outcome of the program and the value of each share at the time of acquisition (present value adjusted to the grant date). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Number ​ ​ Exercised ​ at Grant ​ of Share ​ ​ Date ​ Date ​ Awards Board LTIP 2019 ​ June 1, 2022 ​ 22.49 ​ 51,399 Board LTIP 2020 ​ July 1, 2023 ​ 33.97 ​ 29,928 Board LTIP 2021 ​ July 1, 2024 ​ 62.95 ​ 24,244 Board LTIP 2022 July 1, 2025 51.54 40,706 ​ The total cost of the outstanding share-based payments is presented below. These total costs do not affect the Groups consolidated statement of cash flows. The Group has in total 72,000 warrants, which are set aside to secure the delivery of shares in connection with the exercise of the share award programs. For additional information see Note 25 Equity. ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 ​ 2021 2020 Share-based payments ​ 1,531 ​ 876 267 Provisions attributable to changes in social security costs (Share-based payments) ​ (1,614) ​ 297 207 Total ​ (83) ​ 1,173 474 ​ Warrants Calliditas has implemented warrant programs for employees and key consultants in Calliditas. When warrant is exercised, the holder pays a subscription price and then receives one common share in the Parent Company. The warrants have been valued according to the Black & Scholes model, which means the value of the warrant depends on factors including the value of the underlying share, which in this case is the common share. ​ For the programs initiated in 2018 and 2019, the observation period was short for the underlying share and the volatility was then based on the observation period with a discount as it normally decreases as the share’s history becomes longer. The risk-free interest rate is at the same level as Swedish government bonds with a corresponding term. Dividends are assumed to amount to zero during the period until the date of expiration. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Outstanding as of Inputs used for the Black & Scholes valuation ​ ​ December 31, ​ December 31, ​ Exercise Price, ​ Price per ​ Value per ​ ​ ​ ​ ​ ​ Outstanding Warrants per Year 2021 2022 SEK Warrant in SEK Share in SEK Risk-Free Rate Volatility Expiration Date Warrant program 2018/2022 ​ 856,586 ​ — ​ 74.30 ​ 3.29 ​ 46.50 ​ (0.28%) ​ 33 % 2022-03-31 Warrant program 2019/2022 ​ 422,500 — ​ 74.50 6.69 * 54.39 * (0.55%) * 36 %* 2022-12-31 Total ​ 1,279,086 — ​ ​ * Average value ​ Changes and holdings of warrants for the Board, CEO, other executive management and other employees and consultants on the opening and closing balance are presented below; ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Outstanding as of Holder ​ January 1, 2021 Change December 31, 2021 Change December 31, 2022 CEO Renée Lucander 545,000 — 545,000 (545,000) — ​ Other executive management 437,500 — 437,500 (437,500) — ​ Other employees, consultants and external parties 296,586 — 296,586 (296,586) ​ — ​ Total 1,279,086 — 1,279,086 (1,279,086) — ​ ​ Summary of Granted Warrants, Options and Share Awards ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options ​ Share Awards Warrants ​ ​ Weighted Average ​ Weighted Average ​ Weighted Average ​ ​ Number of Shares ​ Exercise Prices ​ Number of Shares ​ Exercise Prices ​ Number of Shares ​ Exercise Prices Outstanding as of January 1, 2021 1,089,000 120.94 82,770 — ​ 1,279,086 74.37 Granted 1,331,000 133.48 26,968 — ​ — — Forfeited (131,000) 121.78 — — ​ — — Outstanding as of December 31, 2021 2,289,000 128.18 109,738 — ​ 1,279,086 74.37 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding as of January 1, 2022 2,289,000 128.18 109,738 — ​ 1,279,086 74.37 Granted 1,751,000 94.33 40,706 — ​ — — Forfeited (87,834) 133.33 (4,167) — ​ — — Exercised — — (51,399) — ​ (1,279,086) 74.37 Outstanding as of December 31, 2022 3,952,166 113.07 94,878 — ​ — — Weighted average share price at the date of exercise — — 102.06 — ​ 91.45 — ​

Financial Income

Financial Income	12 Months Ended
	Dec. 31, 2022
Financial Income
Financial Income	Note 11 Financial Income ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Interest income under the effective interest method ​ 3,553 ​ 102 547 Exchange rate differences ​ 46,642 ​ 20,234 — Total ​ 50,195 ​ 20,336 547 ​

Financial Expenses

Financial Expenses	12 Months Ended
	Dec. 31, 2022
Financial Expenses
Financial Expenses	Note 12 Financial Expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Interest on lease liabilities ​ (1,604) ​ (590) (388) Other interest expenses under the effective interest method ​ (31,191) ​ (6,518) (5) Exchange rate differences ​ — ​ — (53,267) Changes in FX options measured at fair value ​ — ​ — (3,318) Other financial expenses ​ (4,874) ​ (2,145) ​ — Total ​ (37,669) ​ (9,253) (56,978) ​

Income Tax Expense

Income Tax Expense	12 Months Ended
	Dec. 31, 2022
Income Tax Expense
Income Tax Expense	Note 13 Income Tax Expense ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 ​ 2021 2020 Current income taxes ​ (11,539) ​ (4,581) (1,035) Deferred tax ​ 8,688 ​ 8,417 675 Income tax expense recognized in the consolidated statements of income ​ (2,851) ​ 3,836 (360) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Reconciliation of effective tax rate 2022 2021 2020 Accounting loss before income tax ​ (409,417) ​ (513,373) (436,151) Tax in accordance with applicable tax rate in Sweden 20.6% ( 20.6% , 21.4 )% ​ 84,340 ​ 105,755 93,336 ​ ​ ​ ​ ​ ​ ​ Tax effect of: ​ ​ ​ ​ ​ ​ Effect of other tax rates for foreign subsidiaries ​ (11,857) ​ 11,481 680 Tax attributable to unrecognized deferred tax assets for tax losses carried forward ​ (64,150) ​ (101,785) (91,725) Non-deductible expenses ​ (11,184) ​ (11,615) (2,652) Non-taxable income ​ — ​ — 1 Income tax expense recognized in the consolidated statements of income ​ (2,851) ​ 3,836 (360) ​ ​ ​ ​ ​ ​ ​ At the effective income tax rate ​ (1) % 1 % — ​ The Group has costs attributable to new share issue amounted to SEK - The Group has SEK 3,562,440 and SEK 3,200,911 of tax losses carried forward for which deferred tax assets have not been recognized in the statement of financial position as of December 31, 2022 and 2021, respectively. The tax losses carried forward are allocated between Sweden of SEK 1,597,989, France of SEK 1,194,206 and Switzerland of SEK 770,245, where the tax losses carried forward in Sweden and France may be carried forward indefinitely, but in Switzerland there is a time limit of seven years. Deferred tax assets will be recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized.

Earnings per Share

Earnings per Share	12 Months Ended
	Dec. 31, 2022
Earnings per Share
Earnings per Share	Note 14 Earnings per Share ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Loss per share before and after dilution 2022 2021 2020 Net loss for the year attributable to equity holders of the Parent Company ​ (412,268) ​ (500,293) (433,494) Weighted-average number of common shares outstanding ​ 53,022,550 ​ 50,829,255 44,873,448 Loss per share before and after dilution ​ (7.78) ​ (9.84) (9.66) ​ For calculation of earnings per share after dilution, the weighted-average number of outstanding ordinary shares is adjusted for the dilution effect of all potential ordinary shares, with the exception of treasury shares held by Calliditas. The Parent Company has a category of potential common stock with dilution effect: stock options. These potential common shares are attributable to the options and performance shares granted during the years 2020 – 2022. For additional information see Note 10 Share-Based Payments. If the profit for the year is negative, the options are not considered dilutive. The options also do not impact the numerator in the earnings per share calculation, including the addition of the value of remaining future services to report during the vesting period, exceeding the average market price for the period. There is no dilution effect for issued options with entitlement to subscribe to 3,952,166 shares and for issued share awards with entitlement to receive 94,878 shares, since the Group is in a loss position in 2022, 2021 and 2020, respectively. For disclosures regarding the number of outstanding shares, refer to Note 25 Equity.

Intangible Assets and Impairmen

Intangible Assets and Impairment Testing	12 Months Ended
	Dec. 31, 2022
Intangible Assets and Impairment Testing
Intangible Assets and Impairment Testing	Note 15 Intangible Assets and Impairment Testing ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Licenses and similar rights ​ Cost at opening balance ​ 390,166 380,836 Acquisition for the year ​ — ​ 16,066 Exchange differences on translation ​ 78,545 (6,736) Cost at closing balance ​ 468,711 390,166 ​ ​ ​ ​ ​ Impairment ​ ​ ​ ​ Cost at opening balance ​ (27,975) ​ — Impairment ​ — ​ (27,975) Exchange differences on translation ​ (2,679) ​ — Accumulated impairment at closing balance ​ (30,654) ​ (27,975) ​ ​ ​ ​ ​ Goodwill ​ ​ ​ ​ Cost at opening balance ​ 37,227 ​ 37,989 Exchange differences on translation ​ 8,557 ​ (762) Cost at closing balance ​ 45,784 37,227 ​ ​ ​ ​ ​ Net book value ​ 483,841 399,418 ​ Intangible assets consist of licenses and similar rights of SEK 438,057 and goodwill of SEK 45,784 as of December 31, 2022. Intangible assets are mainly from the acquisition of the NOX platform and associated goodwill. The net book value of the NOX platform amounts to SEK 405,925 as of December 31, 2022. The NOX platform constitutes a technology, including the lead compound setanaxib, enables the identification of orally available small molecules which selectively inhibit specific NOX enzymes that amplify multiple disease processes such as fibrosis and inflammation. The estimated fair value of the NOX platform was determined using the discounted cash flow (DCF) method, adjusted for the likelihood of occurrence. Impairment Testing of Intangible Assets Goodwill The assessment of the value of the Group’s goodwill is based on the fair value less cost of disposals for the smallest cash-generating unit, which for Calliditas is deemed to be the full Group. The impairment measurement is based on a probability-adjusted cash flow model, measured at Level 3 of the fair value hierarchy, where the most critical assumptions mainly consist of assumptions about the timing of potential commercialization, market size, market share and probability of reaching the market. The period for the forecast cash flow extends to 2035, where no terminal growth rate has been taken into account. As of December 31, 2022, the Group’s goodwill amounted to SEK 45,784. There is no impairment for the year ended December 31, 2022. The following table shows the discount rate used before tax: ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Parameter, % 2022 2021 Discount rate 12.0 11.0 ​ Intangible assets, not yet available for use These significantly consist of the NOX platform and Budenofalk 3 mg oral capsule, which are tested, at least, annually for impairment requirement. The technology and the rights were reviewed for impairment individually. The assessment of the value of the technology and the rights is based on the fair value less cost of disposals of each individual asset. The fair value less cost of disposals is based on cash flows that are expected to be generated over the remaining life of the asset. The following table shows the discount rate used before tax: ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Parameter, % 2022 2021 Discount rate NOX platform 12.0 17.7 Discount rate Budenofalk 3 mg oral capsule 12.0 12.4 ​ When the technology and the rights are tested for impairment requirement, a number of assumptions are made, where the most critical assumptions mainly consist of the timing of potential commercialization, market size, market share, probability of reaching the market and the discount rate. The earlier in the chain of development the project is, the higher the risk. As it passes through the defined phases of development, the likelihood of reaching the market increases. The review of the technology and the rights showed no impairment.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2022
Equipment.
Equipment	Note 16 Equipment ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 ​ Cost at opening balance ​ 7,073 214 ​ Acquisition for the year ​ 2,512 ​ 6,588 ​ Disposal for the year ​ — ​ (118) ​ Exchange differences ​ 1,582 389 ​ Cost at closing balance ​ 11,167 7,073 ​ ​ ​ ​ ​ ​ ​ Depreciation at opening balance ​ (764) (51) ​ Depreciation for the year ​ (2,106) (465) ​ Disposal for the year ​ — 51 ​ Exchange differences ​ (830) ​ (299) ​ Depreciation at closing balance ​ (3,700) (764) ​ ​ ​ ​ ​ ​ ​ Net book value ​ 7,468 6,309 ​ ​ Depreciation on equipment is included in the consolidated statement of income under Research and development expenses amounted to SEK 579, SEK 59 and SEK – in 2022, 2021 and 2020, respectively, under Marketing and selling expenses amounted to SEK 806, SEK 176 and SEK – in 2022, 2021 and 2020, respectively and under Administrative expenses amounted to SEK 721, SEK 230 and SEK 37 in 2022, 2021 and 2020, respectively.

Non-Current Financial Assets

Non-Current Financial Assets	12 Months Ended
	Dec. 31, 2022
Non-Current Financial Assets
Non-Current Financial Assets	Note 17 Non-Current Financial Assets ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Cost at opening balance ​ 3,915 2,225 ​ Additional acquisition ​ 7,064 1,686 ​ Exchange differences ​ 231 4 ​ Net book value ​ 11,210 3,915 ​ ​ Non-current financial assets comprise of bank guarantees/deposits amounted to SEK 6,851 and SEK 3,915 as of December 31, 2022 and 2021, respectively and other non-current receivables amounted to SEK 4,359 as of December 31, 2022, and no other non-current receivables were recognized as of December 31, 2021.

Deferred Tax Assets and Deferre

Deferred Tax Assets and Deferred Tax Liabilities	12 Months Ended
	Dec. 31, 2022
Deferred Tax Assets and Deferred Tax Liabilities
Deferred Tax Assets and Deferred Tax Liabilities	Note 18 Deferred Tax Assets and Deferred Tax Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred Tax Deferred Tax ​ Deferred tax assets and liabilities as of December 31, 2022 Assets Liabilities Net Intangible assets — (56,789) (56,789) Tangible assets ​ — ​ (766) ​ (766) Lease items net value ​ 382 ​ — ​ 382 Liabilities ​ 3,218 ​ — ​ 3,218 Personnel-related items 10,654 — 10,654 Tax loss carried forward 17,037 — 17,037 Other items 311 — 311 Total 31,601 (57,555) (25,953) Offsetting (17,803) 17,803 — Tax assets/liabilities, net 13,799 (39,752) (25,953) ​ Tax losses carried forward of SEK 17,037 have been recognized as deferred tax assets in the statement of financial position as of December 31, 2022 due to future temporary differences that such asset can be used to offset. ​ For information regarding recognition of deferred tax losses, see Note 13 Income Tax Expense. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change in deferred tax, 2022 Cost at Opening Balance Recognized in Profit or Loss Exchange Differences Cost at Closing Balance Intangible assets (46,175) — (10,614) (56,789) Tangible assets ​ (238) ​ (477) ​ (51) ​ (766) Lease items net value ​ 270 ​ 68 ​ 44 ​ 382 Liabilities ​ — ​ 3,122 ​ 96 ​ 3,218 Personnel-related items 4,140 5,699 814 10,653 Tax loss carried forward 15,319 — 1,718 17,037 Other items 23 276 12 311 Total (26,661) 8,688 (7,981) (25,953) ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred Tax Deferred Tax ​ Deferred tax assets and liabilities as of December 31, 2021 ​ Assets ​ Liabilities ​ Net Intangible assets — (46,175) (46,175) Tangible assets — (238) (238) Lease items net value ​ 270 ​ — ​ 270 Personnel-related items ​ 4,141 ​ — ​ 4,141 Tax loss carried forward 15,319 — 15,319 Other items 23 — 23 Total 19,753 (46,413) (26,661) Offsetting (15,557) 15,557 — Tax assets/liabilities, net 4,196 (30,856) (26,661) ​ Tax losses carried forward of SEK 15,319 have been recognized as deferred tax assets in the statement of financial position as of December 31, 2021 due to future temporary differences that such asset can be used to offset. For information regarding recognition of deferred tax losses, see Note 13 Income Tax Expense. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change in deferred tax, 2021 ​ Cost at Opening Balance ​ Recognized in Profit or Loss ​ Exchange Differences ​ Cost at Closing Balance Intangible assets (47,120) — 945 (46,175) Tangible assets ​ — ​ (226) ​ (12) ​ (238) Lease items net value ​ — ​ 256 ​ 14 ​ 270 Personnel-related items 596 3,304 240 4,140 Tax loss carried forward 9,666 5,065 588 15,319 Other items 4 18 1 23 Total (36,854) 8,417 1,776 (26,661) ​

Financial and Non-Financial Ass

Financial and Non-Financial Assets and Liabilities	12 Months Ended
	Dec. 31, 2022
Financial and Non-Financial Assets and Liabilities
Financial and Non-Financial Assets and Liabilities	Note 19 Financial and Non-Financial Assets and Liabilities Financial and non-financial assets and liabilities as of December 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financial Assets ​ Financial Assets ​ ​ ​ ​ ​ ​ Measured at ​ Measured ​ Non- ​ Total ​ ​ Fair Value through ​ at Amortized ​ Financial ​ Carrying ​ ​ Profit or Loss ​ Cost ​ Assets ​ Amount Assets Non-current financial assets — 11,210 — 11,210 Accounts receivable — 78,703 — 78,703 Prepaid expenses and accrued income — 2,287 — 2,287 Cash — 1,249,094 — 1,249,094 ​ — 1,341,295 — 1,341,295 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financial Liabilities ​ ​ ​ ​ ​ ​ ​ Measured at Financial Liabilities Non- Total ​ ​ Fair Value through ​ Measured at ​ Financial ​ Carrying ​ ​ Profit or Loss ​ Amortized Cost ​ Liabilities ​ Amount Liabilities Contingent consideration 75,880 — — 75,880 Non-current interest-bearing liabilities ​ — ​ 713,030 ​ — ​ 713,030 Non-current lease liabilities — 15,792 — 15,792 Other non-current liabilities ​ — ​ 1,363 ​ 2,987 ​ 4,350 Accounts payable — 160,404 — 160,404 Other current liabilities — 10,374 12,323 22,697 Accrued expenses and deferred revenue — 75,754 60,692 136,446 ​ 75,880 976,717 76,002 1,128,598 ​ Financial and non-financial assets and liabilities as of December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financial Assets ​ Financial Assets ​ ​ ​ ​ ​ Measured at Measured at Non- Total ​ ​ Fair Value through ​ at Amortized ​ Financial ​ Carrying ​ ​ Profit or Loss ​ Cost ​ Assets ​ Amount Assets ​ ​ ​ ​ ​ ​ ​ ​ Non-current financial assets — 3,915 — 3,915 Cash — 955,507 — 955,507 ​ — 959,422 — 959,422 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financial Liabilities ​ ​ ​ ​ ​ ​ ​ Measured at Financial Liabilities Non- Total ​ Fair Value through Measured at Financial Carrying ​ Profit or Loss Amortized Cost Liabilities Amount Liabilities ​ Contingent consideration ​ 54,399 ​ — ​ — ​ 54,399 Non-current interest-bearing liabilities ​ — ​ 189,164 ​ — ​ 189,164 Non-current lease liabilities ​ — ​ 24,052 ​ — ​ 24,052 Accounts payable — 67,971 — 67,971 Other current liabilities — 9,591 3,111 12,702 Accrued expenses and deferred revenue — 25,168 28,385 53,553 ​ 54,399 315,946 31,496 401,841 ​ Financial liabilities valued through profit or loss constitutes of contingent consideration of SEK 75,880 and SEK 54,399 as of December 31, 2022 and 2021, respectively. The fair value of contingent consideration is measured at Level 3 of the fair value hierarchy. ​ The carrying amount for other items above is an approximation of the fair value, which is why these items are not separated into levels according to the fair value hierarchy.

Financial Risks

Financial Risks	12 Months Ended
	Dec. 31, 2022
Financial Risks
Financial Risks	Note 20 Financial Risks Through its operations, the Group is exposed to a variety of financial risks: credit risk, market risk (currency risk, interest rate risk and other price risk), refinancing risk and liquidity risk. The Group’s overall risk management focuses on the unpredictability of the financial markets and it endeavors to minimize potentially unfavorable effects on the Group’s financial results. The Group’s financial transactions and risks are managed centrally through the Group’s CFO and CEO. The overall objective for financial risks is to provide cost-efficient financing and liquidity management and to ensure that all payment commitments are managed in a timely manner. The Board prepares written policies for both the overall risk management and for specific areas, such as credit risks, currency risks, interest rate risks, refinancing risks, liquidity risks and the use of derivative instruments and investment of surplus liquidity. Credit Risk Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument, leading to a financial loss for the Group. The Group’s exposure to credit risk, except for accounts receivable as described below, is limited to deposits with banks with high credit ratings, which means the Group is of the opinion that there is no material credit risk related to deposits with bank. Credit risk accounts receivable The payment terms amount to 30-45 days depending on the counterparty. Days past due, but not impaired, receivables on the closing balance is given below. Of accounts receivable net, SEK 71,825 is to an individual major customer as of December 31, 2022. ​ ​ ​ ​ ​ ​ ​ ​ December 31, Accounts receivable 2022 2021 Gross accounts receivable ​ 79,873 — ​ Provisions, expected credit losses ​ (1,170) — ​ Net accounts receivable ​ 78,703 — ​ ​ ​ ​ ​ ​ ​ Maturity structure accounts receivable ​ ​ Accounts receivable, not yet due ​ 79,873 — ​ Provisions, expected credit losses ​ (1,170) — ​ Net book value ​ 78,703 — ​ ​ ​ ​ ​ ​ ​ Provisions for expected credit losses ​ ​ Opening balance, expected credit loss provisions ​ — — ​ This years provisions ​ (1,170) — ​ Closing balance, expected credit loss provisions ​ (1,170) — ​ ​ The credit quality of receivables that are not past due or written down is deemed to be good. See Note 3 Revenue from Contracts with Customers for further information. Market Risks Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The type of market risk that impacts the Group is currency risk. Interest Rate Risk Interest rate risk is the risk that would be adversely impacted by changes in interest rates resulting from increased interest costs. Calliditas exposure to interest rate risk mainly occurs through external loans and cash. Calliditas financing sources primarily consist of equity and borrowings. In the case of interest-bearing liabilities, the Group is exposed to interest rate risk. The Group does not currently have any variable interest rate and as of December 31, 2022 the carrying amount of Non-current interest-bearing liabilities are in all material respect an approximation of the present value. Foreign Currency Risk Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The primary exposure derives from the Group’s sales and purchases in foreign currencies. This exposure is known as transaction exposure. Currency risk is also found in the translation of the assets and liabilities of foreign operations to the Parent Company’s functional currency, known as translation exposure. Transaction Exposure Transaction exposure from contracted payment flows in foreign currency is limited in the Group. Refer to the table below for exposure in each currency. ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Currency exposure 2022 (%) ​ Revenue ​ expenses USD 68 % 20 % EUR 32 % 48 % GBP — 4 % SEK ​ — ​ 27 % Other currencies — 1 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Currency exposure 2021 (%) ​ Revenue ​ expenses USD 14 % 43 % EUR 86 % 36 % GBP — 3 % SEK — 18 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating ​ Currency exposure 2020 (%) Revenue expenses USD 100 % 35 % EUR — 36 % GBP — 6 % SEK — 23 % ​ As presented in the table above, the Group’s primary transaction exposure is in Euro and U.S. dollar. A 10% stronger Euro against the Swedish Krona would have a negative impact on profit after tax and equity of approximately SEK 23,132, SEK 909 and SEK 10,247 in 2022, 2021 and 2020, respectively. A 10% stronger U.S. dollar against the Swedish Krona would have a negative impact on profit after tax and equity of approximately SEK 9 624, SEK 22,402 and pos. SEK 9,979 in 2022, 2021 and 2020, respectively. Translation Exposure The Group also has translation exposure that arises on the translation of earnings and net assets of foreign subsidiaries to the Swedish Kronor. Translation against U.S. dollar amounted to SEK 48,771 and SEK 18,270 as of December 31, 2022 and 2021, respectively. A 10% stronger Swedish Krona against the U.S. dollar would have a positive impact on equity of approximately SEK 4,877 and SEK 1,827 as of December 31, 2022 and 2021, respectively. Translation against Euros amounted to SEK -322,135 and SEK -93,814 as of December 31, 2022 and 2021, respectively. A 10% stronger Swedish Krona against Euros would have a negative impact on equity of approximately SEK 32,214 and SEK 9,381 as of December 31, 2022 and 2021, respectively. The Group also has a translation exposure arising from the translation of foreign accounts payable to the Swedish Kronor. This exposure amounted to SEK 19,377 and SEK 29,236 as of December 31, 2022 and 2021, respectively, and in U.S. dollars SEK 80,655 and SEK 10,707 in Euros as of December 31, 2022 and 2021, respectively. A 10% stronger U.S. dollar against the Swedish Krona would have a negative impact on profit after tax and equity of approximately SEK 1,938 and SEK 2,924 as of December 31, 2022 and 2021, respectively. A 10% stronger Euro against the Swedish Krona would have a negative impact on profit after tax and equity of approximately SEK 8,065 and SEK 1,071 as of December 31, 2022 and 2021. respectively. Refinancing Risk Refinancing risk refers to the risk that cash are not available and the risk that financing cannot be secured at a reasonable cost or at all. The Group is financed with equity, external loan financing and income from operations. The main risks relate to not receiving further contributions from shareholders, external loans or in the event of continued negative cash flow from operations. Liquidity Risk Liquidity risk is the risk that the Group encounters difficulties in meeting its obligations associated with financial liabilities. The Board manages liquidity risks by continuously monitoring cash flow so that it can reduce liquidity risk and ensure its solvency. Given that the Parent Company currently does not have its own earning ability, the Board carries out long-term work with owners and independent investors to ensure that liquidity is available to the Parent Company when a need arises. The Group’s contractual and undiscounted interest payments and repayments of financial liabilities are presented in the table below. Amounts in foreign currency were translated to SEK at the closing balance rate. Financial instruments with variable interest rates were measured at the rate on the closing balance. Liabilities were included in the earliest period when repayment is required. For future lease payments see Note 8 Leases. ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 Maturity analysis <6 months 6-12 months 2-5 years Contingent consideration ​ — — 75,880 Non-current interest-bearing liabilities ​ — ​ — ​ 713,030 Non-current lease liabilities ​ — ​ — ​ 15,792 Other non-current liabilities ​ — ​ — ​ 4,350 Accounts payable ​ 160,404 — — Other current liabilities ​ 13,288 9,409 — Accrued expenses ​ 121,865 ​ 14,581 ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 Maturity analysis <6 months 6-12 months 2-5 years Contingent consideration ​ — — 54,399 Non-current interest-bearing liabilities ​ — ​ — ​ 189,164 Non-current lease liabilities ​ — ​ — ​ 24,052 Accounts payable ​ 67,971 ​ — ​ — Other current liabilities ​ 7,906 4,796 — Accrued expenses ​ 47,753 5,800 — ​ Non-current interest-bearing liabilities ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Opening balance ​ 189,164 — ​ New borrowings, net ​ 491,745 ​ 199,524 ​ Transaction costs paid ​ (1,260) (14,858) ​ Interest expense ​ 4,874 ​ 2,145 ​ Exchange difference on translation ​ 28,507 2,353 ​ Closing balance ​ 713,030 189,164 ​ ​ In July 2021, Calliditas signed a loan agreement of up to the euro equivalent of USD 75 million with Kreos Capital. The loan facility is divided into three tranches of USD 25 million each. Draw down of the first USD 25 million tranche was made in 2021. Draw down of the second tranche of USD 25 million was made in June 2022 and draw down of the third and final USD 25 million tranche was made December 2022. The interest rate on the loan is 9 % per annum with a maturity to December 2025, which is recognized in Financial expenses. The loan has no financial covenants.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2022
Inventories
Inventories	Note 21 Inventories ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ 2022 ​ 2021 Raw materials 1,855 889 Work in progress 937 — Finished goods 855 — Total 3,647 889 ​ Inventories recognized as cost of sales amounted to SEK 3,179 in 2022. No inventories were recognized as cost of sales in 2021 and 2020, respectively. No write-downs of inventories have occurred.

Prepaid Expenses and Accrued In

Prepaid Expenses and Accrued Income	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses and Accrued Income
Prepaid Expenses and Accrued Income	Note 22 Prepaid Expenses and Accrued Income ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Accrued royalties ​ 2,287 — Prepaid insurance premiums ​ 9,148 ​ 10,813 Prepaid interest costs ​ 3,693 ​ — Prepaid expenses for research and development ​ 45,454 ​ 27,888 Prepaid expenses for marketing and selling ​ 8,194 — Other prepaid expenses ​ 1,964 6,331 Total ​ 70,741 45,032 ​

Cash

Cash	12 Months Ended
	Dec. 31, 2022
Cash
Cash	Note 23 Cash ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Cash at Banks ​ 1,249,094 955,507 Total ​ 1,249,094 955,507 ​ Cash and Banks balances are primarily in SEK, EUR and USD. Adjustments for non-cash items in the consolidated statements of cash flows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Depreciations and impairments ​ 12,913 34,433 ​ 2,823 Chage in Provisions ​ (3,346) 5,856 ​ 6,634 Share-based payments ​ 35,791 21,960 ​ 6,012 Cange in Contingent consideration ​ 15,941 ​ 4,470 ​ — Other items ​ (39) (43) ​ (4) Total ​ 61,260 66,676 ​ 15,465 ​ Reconciliation of liabilities from financing activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ Non-Cash December 31, ​ ​ 2022 ​ Cash-Flow Items ​ 2022 Non- current interest-bearing liabilities ​ 189,164 490,485 33,381 713,030 Lease liabilities 33,642 (9,615) 2,138 26,165 ​ 222,806 480,870 35,519 739,195 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ Non-Cash December 31, ​ ​ 2021 ​ Cash-Flow Items ​ 2021 Non-current interest-bearing liabilities ​ — ​ 184,667 ​ 4,497 ​ 189,164 Lease liabilities 4,786 (5,575) 34,431 33,642 ​ 4,786 179,092 38,928 222,806 ​

Group Companies

Group Companies	12 Months Ended
	Dec. 31, 2022
Group Companies
Group Companies	Note 24 Group Companies ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Country of % Equity Interest Company Principal Activities Incorporation 2022 ​ 2021 2020 Parent Company ​ ​ ​ Calliditas Therapeutics AB Research and development of pharmaceuticals Sweden — ​ — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Subsidiaries ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nefecon AB ​ Administration of incentive programs issued by the Parent Company ​ Sweden ​ 100 % 100 % 100 % Calliditas NA Enterprises Inc ​ Market access activities in the United States ​ United States ​ 100 % 100 % 100 % Calliditas Therapeutics US Inc Commercial activities in the United States United States 100 % 100 % — ​ Calliditas Therapeutics France SAS ​ Research and development of pharmaceuticals ​ France ​ 100 % 100 % 86.2 % Calliditas Therapeutics Suisse SA ​ Research and development of pharmaceuticals ​ Switzerland ​ 100 % 100 % 86.2 % ​

Equity

Equity	12 Months Ended
	Dec. 31, 2022
Equity
Equity	Note 25 Equity ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 ​ 2021 ​ 2020 Total registered shares at the beginning of the year 52,341,584 49,941,584 38,707,638 New share issue* — 2,400,000 9,937,446 Exercise of warrants 1,322,985 — 1,296,500 Issuance of treasury shares 5,908,018 — — Shares subscribed but not registered during the year** 7,500 — — Total registered and subscribed but not registered shares at the end of the year ​ 59,580,087 52,341,584 49,941,584 ​ ​ ​ ​ ​ ​ ​ Shares ​ ​ ​ ​ ​ ​ Ordinary shares ​ 59,580,087 ​ 52,341,584 ​ 49,941,584 Total 59,580,087 52,341,584 49,941,584 - of which shares are held by Calliditas ​ 5,908,018 ​ — ​ — Total registered and subscribed but not registered shares at the end of the year, net of shares held by Calliditas ​ 53,672,069 ​ 52,341,584 ​ 49,941,584 ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, Share Capital ​ 2022 ​ 2021 ​ 2020 Opening balance 2,094 1,998 1,548 New share issue* — 96 397 Exercise of warrants 53 — 52 Issuance of treasury shares 236 — — Closing balance 2,383 2,094 1,998 ​ * Initial public offering on The Nasdaq Global Select Market in the United States in June 2020 and the following exercise of the partial over-allotment option from the IPO in July 2020. * New share issue in August 2021 ** As of December 31, 2022, there was an on-going issue of 7,500 shares under registration related to the exercise under the Warrant Program 2019/2022. These shares have been included in the weighted-average number of shares outstanding for the period. Share Capital All shares have been fully paid and no shares are reserved for sale. All shares are common shares, confer the same entitlement to capital, and carry one vote, with the exception of treasury shares held by Calliditas. The quotient value is SEK 0.04 per share. Transactions in Treasury Shares Since 2020, Calliditas has had ordinary shares, in the form of American Depositary Shares (“ADSs”), listed in the United States on The Nasdaq Global Select Market. In 2022 Calliditas has implemented and launched an At-The-Market program (“ATM Program”). The purpose of the ATM Program is to efficiently and cost-effectively raise capital, if necessary, in the U.S. market and to ensure delivery of shares to be sold under the company’s ATM Program. In 2022, 5,908,018 series C shares were issued, which were repurchased and converted to ordinary shares by Calliditas. These transactions are in accordance with the granting mandate. In 2022, no shares were sold in the ATM Program. Translation Reserve The reserves pertain in their entirety to translation reserves. The translation reserve includes all exchange rate differences arising on the translation of the financial statements from foreign operations. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 2020 Opening balance (26,979) ​ (6,090) (45) Change of the year 36,286 ​ (20,889) (6,045) Closing balance 9,307 ​ (26,979) (6,090) ​

Provisions

Provisions	12 Months Ended
	Dec. 31, 2022
Provisions
Provisions	Note 26 Provisions ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Social Security Costs on ​ ​ ​ ​ Provisions as of December 31, 2022 Share-Based Payment Other Provisions Provisions, net Opening balance 13,084 1,446 14,530 Provisions for the year ​ 1,027 ​ — ​ 1,027 Amounts claimed for the year ​ (204) ​ — ​ (204) Reversal of unused amounts ​ (2,666) ​ (1,573) ​ (4,239) Exchange differences 551 127 678 Total 11,792 — 11,792 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Social Security Costs on ​ ​ ​ ​ Provisions as of December 31, 2021 Share-Based Payment Other Provisions Provisions, net Opening balance 4,972 1,419 6,391 Provisions for the year 8,112 — 8,112 Exchange differences — 27 27 Total 13,084 1,446 14,530 ​ Social Security Costs on Share-Based Payment There is uncertainty as to when social security costs for share-based payments will be paid in the future, and what amount they will ultimately be adjusted to as it is dependent on market values at the time when share awards are used.

Contingent Consideration

Contingent Consideration	12 Months Ended
	Dec. 31, 2022
Contingent Consideration
Contingent Consideration	Note 27 Contingent Consideration ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ 2022 ​ 2021 Opening balance 54,399 48,969 Change for the year 15,942 4,470 Exchange differences 5,539 960 Net book value 75,880 54,399 ​ Contingent Consideration In connection with the business combination of Genkyotex SA, the Group has undertaken to make potential future milestone payments relating to contingent consideration, provided that future regulatory approvals or marketing authorizations regarding setanaxib are obtained. The transaction stipulates the following contingent consideration: Milestone 1: Milestone 2: Milestone 3: The fair value of contingent consideration is measured at Level 3 of the fair value hierarchy. Contingent consideration is recognized as a financial liability in the consolidated statements of financial position, which is revalued at fair value each reporting period. Any revaluation gains and losses are recognized in the consolidated statements of income. The contingent consideration has been computed in accordance with the present value method and the probability has been taken into account if and when the various milestones will occur. The calculations are based on a discount rate of 12.0 percent. The most significant input affecting the valuation of the contingent consideration is the company’s estimate of the probability of the milestones being reached and the change of the year was primarily derived from the assumptions regarding the probability of success in the clinical trials. ​ The Group has assessed the weighted average probability of outcome at 20.8% and 15.21% as of December 31, 2022 and 2021, respectively. A 10% higher probability of success in the clinical trials would have a negative impact on profit after tax of approximately SEK 7,588 and SEK 5,440 as of December 31, 2022 and 2021, respectively. A higher probability of success in the clinical trials will increase the fair value of the liability and a lower probability will decrease the fair value. There are no interrelationships between unobservable inputs used in the fair value measurement.

Pension Liabilities

Pension Liabilities	12 Months Ended
	Dec. 31, 2022
Pension Liabilities
Pension Liabilities	Note 28 Pension Liabilities Defined-Benefit Pension Plan The defined-benefit pension obligations are based on actuarial principles. Calliditas has defined-benefit pension plans for the subsidiaries in France and Switzerland for retirement, death and disability. The present value of the obligation includes special payroll tax, in accordance with IAS 19, for the Swiss pension plans. Pension expenses are recognized under research and development expenses and administrative expenses in the consolidated statements of income. ​ ​ ​ ​ ​ ​ ​ December 31, Net obligation per country 2022 2021 Switzerland (789) ​ (3,071) France (94) ​ (111) Total (884) ​ (3,182) ​ Changes in the defined-benefit pension obligations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Defined Benefit Defined Benefit Fair Value Employee ​ Plan Obligation Plan Obligation of Plan Assets Benefit ​ (Switzerland) (France) (Switzerland) Obligations January 1, 2022 (7,942) (111) 4,871 (3,182) ​ ​ ​ ​ ​ ​ ​ ​ ​ Service costs (1,530) (26) — (1,556) Interest expense (27) (1) 18 (10) Employee contribution — — 887 887 Subtotal included in the statement of consolidated operations (1,558) (27) 906 (679) ​ ​ ​ ​ ​ ​ ​ ​ ​ Amounts paid/received 2,140 — (2,140) — ​ ​ ​ ​ ​ ​ ​ ​ ​ Return on assets (excluding interest expenses) — — 34 34 Actuarial gains/(losses) related to changes in demographic assumptions — 54 — 54 Actuarial gains/(losses) related to changes in financial assumptions 2,846 — — 2,846 Other actuarial gains/(losses) ​ (454) ​ — ​ — ​ (454) Subtotal included in other items of comprehensive income 2,392 54 34 2,480 ​ ​ ​ ​ ​ ​ ​ ​ ​ Employer contributions — — 887 887 Currency translation effect (1,059) (9) 679 (390) December 31, 2022 (6,027) (94) 5,238 (884) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Defined ​ Defined ​ ​ ​ ​ ​ ​ Benefit Plan ​ Benefit Plan ​ Fair Value ​ Employee ​ ​ Obligation ​ Obligation ​ of Plan Assets ​ Benefit ​ (Switzerland) (France) (Switzerland) Obligations January 1, 2021 (19,193) (172) 11,069 (8,296) ​ ​ ​ ​ ​ ​ ​ ​ ​ Service costs (2,165) (13) — (2,178) Interest expense (17) — 10 (7) Curtailment* 12,011 — (7,805) 4,206 Employee contribution — — 704 704 Subtotal included in the statement of consolidated operations 9,829 (13) (7,091) 2,725 ​ ​ ​ ​ ​ ​ ​ ​ ​ Amounts paid/received 291 — (291) — ​ ​ ​ ​ ​ ​ ​ ​ ​ Return on assets (excluding interest expenses) — — 64 64 Actuarial gains/(losses) related to changes in demographic assumptions 349 77 — 426 Actuarial gains/(losses) related to changes in financial assumptions 1,120 — — 1,120 Other actuarial gains/(losses) 360 — — 360 Subtotal included in other items of comprehensive income 1,829 77 64 1,970 ​ ​ ​ ​ ​ ​ ​ ​ ​ Employer contributions — — 704 704 Currency translation effect (698) (3) 416 (285) December 31, 2021 (7,942) (111) 4,871 (3,182) ​ *The change in the Curtailment refer to retirement obligation settlement connected to the departure of senior management member of Switzerland employees. ​ ​ ​ ​ ​ ​ ​ December 31, Distribution by Plan Assets (Switzerland) 2022 ​ 2021 Cash 137 ​ 205 Bonds 3,048 ​ 2,801 Mortgage loans 655 ​ 667 Shares 126 ​ 92 Real estate 901 ​ 760 Other investments 372 ​ 346 Total 5,238 ​ 4,871 ​ Of the plan assets above, SEK 3,048 and SEK 2,801 as of December 31, 2022 and 2021, respectively, has a quoted price in an active market. For pension obligations in France, there are no plan assets. Risks connected to defined-benefit pension plans Through its defined-benefit pension plans for post-employment benefits, the Group is exposed to a number of risks. The most significant risks are: Life expectancy assumption: particularly significant in the Swiss plan, in which inflation increases result in higher sensitivity to changes in life expectancy assumptions. Inflation risk: Discount rate: The French pension plan is covered by the labor law and the collective bargaining agreement of the pharmaceutical industry. The Swiss and French plans are based on final salary. ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, Actuarial Assumptions on the Closing Balance 2022 ​ 2021 Swiss pension plan ​ ​ ​ Discount rate 2.30 % 0.35 % Mortality table LPP 2020 generation ​ LPP 2020 generation ​ Salary revaluation rate 1.00 % 1.00 % Retirement pension inflation rate 0.50 % 0.50 % Deposit rate on savings accounts 1.00 % 1.00 % Turnover rate 10.00 % 10.00 % Remaining life expectancy after retirement 18.6 years 22.3 years Retirement age ​ 65 years 65 years ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, Sensitivity Analysis 2022 2021 Pension commitments under current assumptions for Swiss pension plans 6,027 ​ 7,942 Discount rate , -0,5% ​ 6,615 ​ 8,904 Discount rate , +0,5% ​ 5,518 ​ 7,130 Retirement pension inflation rate, -0,5% ​ 5,797 ​ 7,575 Retirement pension inflation rate, +0,5% ​ 6,281 ​ 8,353 Salary revaluation rate, -0,5% ​ 5,927 ​ 7,792 Salary revaluation rate, +0,5% ​ 6,131 ​ 8,100 ​ The amounts above show what the value of the pension obligation would have been assuming the change in the individual assumption. The sensitivity analyses are based on a change in one assumption, with all other assumptions remaining constant. In practice, this is highly unlikely to occur and some of the changes in the assumptions may be correlated. When calculating the sensitivity of the defined-benefit obligations to significant actuarial assumptions, the same method (present value of the defined-benefit obligation applying the projected unit credit method at the end of the reporting period) has been applied as when calculating the pension liability recognized in the consolidated statements of financial position. As the defined benefit pension plans in France are deemed to be insignificant for the Group, no further information has been provided. Contributions to plans for post-employment benefits are expected to be SEK 813 and SEK 555 in 2022 and 2021, respectively. The weighted average maturity of the obligation is an estimated 18.6 22.3

Other Non-Current Liabilities

Other Non-Current Liabilities	12 Months Ended
	Dec. 31, 2022
Other Non-Current Liabilities
Other Non-Current Liabilities	Note 29 Other Non-Current Liabilities ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ 2022 ​ 2021 Opening balance — — Additional liabilities 4,350 — Closing balance 4,350 — ​ Additional liabilities are related to advance payments from customers.

Accrued Expenses and Deferred R

Accrued Expenses and Deferred Revenue	12 Months Ended
	Dec. 31, 2022
Accrued Expenses and Deferred Revenue
Accrued Expenses and Deferred Revenue	Note 30 Accrued Expenses and Deferred Revenue ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Vacation pay liabilities 8,310 6,107 Accrued salaries and Board fees 28,186 16,786 Social security costs 7,065 5,492 Deferred revenue ​ — ​ 3,387 Accrued rebates on sales 15,849 — Accrued expenses for royalty 12,023 — Accrued expenses for research and development ​ 34,637 ​ 4,230 Accrued expenses for marketing and selling ​ 21,543 ​ 1,242 Accrued expenses for administration 8,832 16,309 Total 136,446 53,553 ​

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2022
Related-Party Transactions
Related-Party Transactions	Note 31 Related-Party Transactions For information regarding remuneration of executive management, refer to Note 9 Employees and Personnel Costs and Note 10 Share-Based Payments. There are no additional agreements or transactions with related parties, other than those described in Notes 9 Employees and Personnel Costs and 10 Share-Based Payments.

Change of presentation of expen

Change of presentation of expenses	12 Months Ended
	Dec. 31, 2022
Change of presentation of expenses
Change of presentation of expenses	Note 32 Change of presentation of expenses ​ From January 1, 2022, Calliditas has switched to presenting marketing and selling expenses separately from administrative expenses. The purpose of the change is to provide more relevant information about the Group’s and the Parent Company’s financial results and follow the practice in the industry for a company in commercial stage. The change constitutes a voluntary change and is applied with full retroactivity. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Year Ended December 31, ​ ​ 2021 ​ Re-classification ​ 2021 ​ 2020 ​ Re-classification ​ 2020 Net sales 229,347 — 229,347 874 — 874 Operating expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development expenses (357,485) — (357,485) (241,371) — (241,371) Marketing and selling expenses — (179,603) (179,603) — (38,964) (38,964) Administrative expenses (390,232) 179,603 (210,629) (141,724) 38,964 (102,760) Other operating income/expenses (6,085) — (6,085) 2,501 — 2,501 Operating loss (524,456) — (524,456) (379,720) — (379,720) Net financial income/(expenses) 11,083 — 11,083 (56,431) — (56,431) Loss before income tax (513,373) — (513,373) (436,151) — (436,151) Income tax 3,836 — 3,836 (360) — (360) Loss for the year (509,537) — (509,537) (436,511) — (436,511) ​

Pledged Assets, Contingent Liab

Pledged Assets, Contingent Liabilities and Other Obligations	12 Months Ended
	Dec. 31, 2022
Pledged Assets, Contingent Liabilities and Other Obligations
Pledged Assets, Contingent Liabilities and Other Obligations	Note 33 Pledged Assets, Contingent Liabilities and Other Obligations The Group is required to pay Kyowa Kirin Services Ltd., f/k/a Archimedes Development Ltd (“Archimedes”) a fixed royalty of 3% of net sales of Nefecon/Tarpeyo covered by the license in according to the Group’s agreement with Archimedes pursuant to which Calliditas were granted (i) an exclusive license to joint intellectual property developed with Archimedes and (ii) a non-exclusive license to certain of Archimedes’ know-how as necessary or useful to develop and commercialize Nefecon or other product candidates. The Group has exclusive rights to use, develop and market the formulation under the license agreement with Archimedes, and Archimedes only has rights to royalties when the product is sold in the future. The Group will then have an obligation to pay a low single digit percentage of royalties based on net sales until the exclusive license for the patent covering the formulation of Nefecon expires in 2029. The Group has pledged assets amounted to SEK 6,859 and SEK 3,915 as of December 31, 2022 and 2021, respectively, which consist of restricted bank accounts and lease deposits. The assets are pledged for the benefit of certain lessors and other suppliers. The Group has no other obligations.

Events After the Reporting Peri

Events After the Reporting Period	12 Months Ended
	Dec. 31, 2022
Events After the Reporting Period
Events After the Reporting Period	Note 34 Events After the Reporting Period In March 2023, Calliditas announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO ® ®

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Basis for Preparation	Basis for Preparation These consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) published by the International Accounting Standards Board (IASB). The accounting policies stated below have, unless otherwise stated, been applied consistently over all periods presented in the consolidated financial statements. The Group’s accounting policies have been applied consistently by the Group’s companies. The consolidated financial statements provide comparative information in respect of the previous period and an additional comparative period.
Functional Currency and Reporting Currency	Functional Currency and Reporting Currency The Parent Company’s functional currency is Swedish Kronor (SEK), which is also the presentation currency of the Group. This means that the financial statements are presented in Swedish kronor (SEK) and all amounts, unless otherwise stated, are rounded to the nearest thousand (SEK 000s).
Basis for Valuation and Current versus Non-Current Classification	Basis for Valuation and Current versus Non-Current Classification The consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets (including derivative financial instrument) and contingent consideration that have been measured at fair value through profit or loss. The Group presents assets and liabilities in the statement of financial position based on current/non-current classification. An asset is current when it is expected to be realized within twelve months after the reporting period. All other assets are classified as non-current. A liability is current when it is due to be settled within twelve months after the reporting period. The Group classifies all other liabilities as non-current.
Basis for Consolidation	Basis for Consolidation The consolidated financial statements comprise the financial statements of the Parent Company and its subsidiaries as of December 31, 2022. Control is achieved when the Parent Company has control over the investee, the Parent Company is exposed to or has rights to variable returns from its involvement in the investee, and the Parent Company has the ability to use its power over the investee to affect the amount of the investor’s returns, which normally means that the Parent Company owns more than half of the number of votes for all of the shares and participations. The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes of the control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary. All subsidiaries are consolidated using the acquisition method. The cost of an acquisition is measured as the fair value of assets that have been provided as payment along with any liabilities taken over or which have arisen at the acquisition date. With the acquisition method, the fair value of acquired identifiable assets, assumed liabilities and contingent liabilities in a business combination, regardless of the scope of any non-controlling interest, are measured at fair value as of the acquisition date. Any surplus arising from the difference between cost and fair value of identifiable acquired assets, liabilities and contingent liabilities is recognized as goodwill. If the cost amount is less than the fair value of the acquired net assets, it is recognized in the consolidated statements of income. Subsidiaries that were acquired during the financial year are included in the consolidated financial statements as soon as the controlling interest has been transferred to the Group. Subsidiaries that were disposed during the financial year are included in the consolidated financial statements up until the date when the controlling interest no longer exists. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree’s identifiable net assets. Acquisition-related costs are expensed as incurred and included in administrative and selling expenses in the consolidated statements of income. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.
New and Amended Standards and Interpretations	New and Amended Standards and Interpretations Updated standards and interpretations from IASB and IFRIC interpretations that came into effect for the year ended December 31, 2022 have had no material impact on the Group. The Group has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective.
Future Standards and New Interpretations	Future Standards and New Interpretations Other future or altered standards or interpretations that the IASB has published are not expected to have any significant impact on the financial statements for the Group.
Revenue	Revenue The Group is in the business of identifying, developing and commercializing novel treatments in orphan indications. Operating revenue mainly comprises of product sales, outlicensing of Nefecon to our partnerships in Europe, China and Japan and royalty revenue. Revenue is recognized as follows: ​ Product Sales Revenue from product sales is recognized at the transaction price of goods sold excluding sales tax, rebates and returns. At the time of delivery, when the control of the goods passes to the customer, the revenue is recognized in full, as this represents the single performance obligation in the transaction. The customer is defined as the specialty pharmacy who dispenses the good to the end user. As the final price is related to the rebate paid to the patients’ insurance company or government payer, the transaction price is not known upon delivery. This is accounted for by an accrued estimated rebate deduction in the Group based on calculation models considering statistical data, actual amounts incurred and/or historical trends. These liabilities for expected returns and rebates are based on estimates of the amounts received or to be claimed on the related sales. Furthermore, the Group estimates the liability for expected returns of obsolete medicines. Outlicensing of Product Revenue attributable to outlicensing Nefecon consisted of the agreement with STADA for Europe, the expansion of Everest Medicines to South Korea and the agreement with Viatris for Japan. Revenue for outlicensing is recognized at a point in time, which occurs when control over the intangible asset is transferred to the counterparty, which was at the time when the agreements with the parties were signed. These contracts with customers consist of fixed remuneration as well as variable remuneration in the form of regulatory and commercial milestones, and sales-based royalties. Variable remuneration (for example, attributable to future regulatory milestones) are initially considered constrained, as there is significant uncertainty as to whether these will occur. Compensation attributable to sales-based milestones or royalties are not recognized until the sale that results in the right to milestones or royalties arises. Royalty Revenue Calliditas is entitled to royalties on sold goods, as per agreement. Revenue recognition is based on royalty reports received, which are based on actual net sales statistics of the licensee. Accrued royalty revenue is recognized on the balance sheet under prepaid expenses and accrued income.
Financial Income	Financial Income Financial income consists of interest income and foreign exchange gains. Interest income is recognized in accordance with the effective interest method. Effective interest is the interest that discounts estimated future receipts and payments during a financial instrument’s anticipated duration to the financial assets or liability’s recognized net value. The calculation contains all costs included in the effective interest paid by the parties to the contract, transaction costs and all other premiums and discounts. Dividends received are recognized when the right to receive a dividend has been established. Foreign exchange gains and losses are netted.
Cost of Sales	Cost of Sales Cost of sales includes the cost of inventory sold, labor costs, manufacturing overhead expenses and reserves for expected scrap, as well as shipping and freight costs. Cost of sales also includes royalty costs related to in-license agreements.
Research and Development	Research and Development Research and development expenses consist primarily of costs incurred for the Group’s development activities, including the development of the Group’s product candidates. The Group expenses research and development costs as incurred. The Group recognizes external development costs based on an evaluation of the progress to completion of specific tasks using information provided by Calliditas’ service providers. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as a prepaid expense or accrued expense. Research and development tax credits are recognized in Sweden and in France. In Sweden tax credits are recognized on social security costs and in France tax credits are recognized on accredited suppliers. These research and development tax credits are recognized as an offset to research and development expenses in the consolidated statements of income.
Administrative and Selling	Marketing and Selling Expenses Marketing and selling expenses consist of salaries and other related costs for personnel in the Group and market access, commercialization and business development. Administrative Expenses Administrative expenses consist of salaries and other related costs for personnel in the Group, finance, corporate and administrative functions. Administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, related travel expenses and facility-related expenses, which include allocated expenses for rent and maintenance of facilities and other operating costs.
Employee Benefits	Employee Benefits Short-term benefits Current employee benefits such as salaries, social security costs, vacation pay and bonuses are expensed during the period in which employees perform the service. Pensions The Group has both defined-contribution and defined-benefit pension plans, and most employees are covered by and recognized in the defined-contribution pension plans. Employees in France and Switzerland are covered by defined-benefit pension plans. All other employees were covered by defined-contribution pension plans. See Note 27 Pension Liabilities for more information. Defined-contribution pension plans A defined-contribution pension plan is a pension plan according to which the Group pays fixed premiums to a separate legal entity. The Group does not have any legal or informal obligation to pay further premiums if this legal entity does not have sufficient assets to pay the full remuneration to employees corresponding to their service during the current or previous periods. The Group therefore has no further risk. The Group’s obligations relating to fees for defined-contribution plans are expensed in profit or loss as they are accrued due to the employee performing services for the Group over a period. Defined-benefit pension plans In defined-benefit plans, the pension is determined as a percentage of the pensionable final salary, based on the employee’s length of service and average final salary. The Group is responsible for ensuring that the established benefits are paid out. The defined-benefit pension obligations are recognized in the consolidated statements of financial position as the net total of the estimated present value of the obligations and the fair value of the plan assets, which are recognized as a provision or a non-current financial receivable. For defined-benefit plans, pension expense and commitments are calculated using the applicable principles of IAS 19. This calculation is performed at least annually by independent actuaries. The Group’s obligations are measured at the present value of expected future payments. Actuarial gains and losses may arise in connection with the determination of the present value of the obligations and the fair value of plan assets. These arise either because the fair value differs from the previous assumption, or the assumptions change. Actuarial gains and losses are recognized in the consolidated statements of comprehensive income in the period in which they arise. Interest expense, less the estimated return on plan assets, is classified as a financial expense. Other cost items in the pension expense are charged to operating profit. Severance pay An expense for remuneration in connection with termination of employment of personnel is recognized only if the Group is committed, without any realistic possibility of withdrawal, by a formal detailed plan to eliminate a position in advance of when that position would normally expire. When remuneration is paid as an offer to encourage voluntary termination of employment, the cost is recognized if it is probable that the offer will be accepted and the number of employees that will accept the offer can be reliably estimated. ​ Share-based payments Share-based payments in the Group refers to option programs and performance-based share award programs, which are regulated by equity instruments. In cases where the fair value of the instrument exceeds what the employee paid, the difference is recognized as a personnel cost. The fair value of options is determined at the grant date using the Black-Scholes model for pricing of options. The valuation of the performance share awards is based on a discounted model with Monte Carlo simulation of the share price’s development for the share-related parts and with estimated probabilities for the outcome of the market conditions. The cost is recognized, together with a corresponding increase in equity, during the period in which the service conditions are met, up to and including, the date on which the employees concerned are fully eligible for compensation. Social security costs attributable to equity-related instruments to employees as remuneration for purchased services shall be expensed over the periods during which the services are performed. The cost should then be measured using the same valuation model used when the options were issued. The provision recognized must be revalued at each reporting period on the basis of a calculation of the social security costs that may be paid when the instruments are resolved.
Leases	Leases Lessee The Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities for future remaining lease payments and right-of-use assets representing the right to use the underlying assets. Right-of-use assets The Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the estimated lease term, which currently is two to four years for the Group’s leases. Lease liabilities At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments less any lease incentives receivable and variable lease payments that depend on an index or a rate. In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the commencement date, because the interest rate implicit in the lease is not readily determinable. Following the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, or a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments). The Group’s lease liabilities are included in Non-current lease liabilities and other current liabilities in the consolidated statements of financial position (see Note 8 Leases and 19 Financial and Non-Financial Assets and Liabilities). Short-term leases and leases of low-value assets The Group applies the short-term lease recognition exemption to its short-term leases of equipment (i.e., those leases that have a lease term of twelve months or less from the commencement date). It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered to be low value. Lease payments on short-term leases and leases of low value assets are recognized as an expense on a straight-line basis over the lease term.
Financial Expenses	Financial Expenses Financial expenses mainly consist of interest expenses, realized and unrealized losses on foreign exchange derivative instruments and unrealized foreign exchange losses. Foreign exchange gains and losses are netted.
Taxes	Taxes Income tax comprises current tax and deferred tax. Income tax is recognized in net profit for the year, except when the underlying transaction is recognized in other comprehensive income or equity with the related tax effect recognized in other comprehensive income and in equity. Current tax is the tax that is to be paid or received in the current year, with the application of the tax rates that have been enacted or substantively enacted by the end of the reporting period. Current tax also includes adjustments of current tax attributable to prior periods. Deferred tax is recognized on all temporary differences that arise between the tax value of assets and liabilities and their carrying amounts. Temporary differences attributable to participations in Group companies is not recognized, since it is unlikely that such a reversal will take place in the foreseeable future. The valuation of deferred tax is based on how the underlying assets or liabilities are expected to be realized or settled. Deferred tax is measured with the application of the tax rates and tax rules decided or announced on the closing date, and that are expected to apply when the deferred tax asset in question is realized or the deferred tax liability is settled. Deferred tax liabilities and deferred tax assets are offset as far as possible within the framework of local laws and regulations on taxation. Deferred tax assets on deductible temporary differences and loss carryforwards are recognized only to the extent that it is probable that it will be possible to utilize these, or to the extent that there are temporary differences which these can be utilized to offset. A provision for deferred tax assets will be recognized when it is no longer deemed probable that they can be utilized.
Intangible Assets	Intangible Assets Intangible assets in the Group consist of licenses and similar rights and goodwill. Licenses and similar rights Intangible assets with a finite useful life are recognized at initial recognition at cost less accumulated amortization and any accumulated impairment losses. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. When determining the amortized amount of the assets, the residual value of the asset is taken into account, when applicable. Goodwill Goodwill arising in a business combination comprises the difference between the cost of the business combination and the fair value of identifiable assets acquired, liabilities assumed, and any contingent liabilities recognized at the acquisition date. Goodwill on business combinations is included in intangible assets and measured at cost less any accumulated impairment losses. Goodwill is allocated to the cash-generating units, which is the full Group, and tested annually for impairment requirement, or whenever there is any indication of impairment. There is no amortization of goodwill and impairment of goodwill is not reversed. Research and development expenses Development expenditures are recognized as an intangible asset when related development projects meet the criteria for capitalization. The most important criteria for capitalization are that the final product of the development process will generate future economic benefits or the ability of cost-savings capacity, including the technical feasibility of completing the intangible asset. Research and development expense are otherwise recognized as operating expenses. Full market approval has not yet been obtained for the Group’s products and, accordingly, the Group deems that the conditions for capitalizing development expenditures are not met. Amortization Amortization of the intangible assets begins when the asset can be used, that is, when it is in the place and in the condition required to be able to use it in the manner intended by the Group’s management. The Group’s expected finite useful life is: – Licenses and similar rights – 6-15 years Until full market approval from regulatory authorities has been granted, amortization of “Licenses and Similar Rights” will not commence. As market approval has not yet been obtained, no other costs have been capitalized. Following market approval from regulatory authorities, “Licenses and Similar Rights” will be amortized on a straight-line basis over the expected useful life. Until a market approval of the product has been obtained, the asset is assessed for impairment at least once a year, and when there is an indication that the asset may be impaired.
Equipment	Equipment Equipment is recognized in the consolidated statement of financial position at cost less accumulated depreciation and impairment. Such cost includes the cost price and expenses directly attributable to the asset. Repairs and maintenance costs are expensed as incurred, while expenses for improvements are recognized as investments and added to the cost of the assets. An item of equipment and any significant part initially recognized is derecognized upon disposal (i.e., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of income when the asset is derecognized. Depreciation Equipment is depreciated on a straight-line basis over the expected useful life. The Group’s expected useful life is: – Equipment – 5 years – Computers – 5 years The residual values, useful lives, and methods of depreciation of equipment are reviewed at each financial year and adjusted prospectively, if appropriate. If there is an indication that an asset needs to be impaired, the asset is written down to its recoverable amount if this is lower than the carrying amount. The recoverable amount corresponds to the highest of net realizable value and value in use.
Impairment of Non-Financial Assets	Impairment of Non-Financial Assets Goodwill and intangible assets not yet available for use, are not amortized but the Group assesses for impairment at each reporting date, and when there is an indication that an asset may be impaired. Equipment that is depreciated is assessed for impairment whenever events or changes in circumstances indicate that the carrying amount is not recoverable. An impairment loss is made by the amount by which the asset’s carrying amount exceeds its recoverable amount. An asset’s recoverable amount is the higher of an asset’s or cash generating units’ (“CGU”) fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators. ​ The Group bases its impairment measurement on intangible assets on a probability-adjusted cash flow model. The value of licenses is measured by estimating the expected future cash flows and present value adjustments to take into account the development risk. The valuation takes into account cash flow from potential commercialization during the expected useful life and does not include calculation of any residual value thereafter. The most critical assumptions mainly consist of assumptions about the timing of potential commercialization, market size, market share and probability of reaching the market. When assessing the impairment requirement for goodwill, this is grouped at the lowest levels for which there are separately identifiable cash flows. Calliditas has made the assessment that the Group’s operations as a whole comprise a cash-generating unit. Impairment losses of continuing operations are recognized in the statement of income in expense categories consistent with the function of the impaired asset. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset’s recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years.
Financial Assets and Financial Liabilities	Financial Assets and Financial Liabilities A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial instruments are classified at initial recognition, including on the basis of the purpose for which the instrument was acquired and managed. This classification determines the valuation of the instruments. Initial recognition and measurement of financial assets The Group’s financial assets consist of non-current financial assets, accounts receivable and cash, which are recognized at amortized cost. The instruments are classified into: – Amortized cost, or – Fair value through profit or loss Financial assets at amortized cost are initially measured at fair value with the addition of transaction costs. Following the initial recognition, the assets are measured at amortized cost less a provision for losses on expected credit losses. Assets classified at amortized cost are held according to the business model to collect contractual cash flows that are only payments of capital amount and interest on the outstanding capital amount. Initial recognition and measurement of financial liabilities The Group’s financial liabilities consist of contingent consideration, non-current interest-bearing liabilities, other non-current liabilities, lease liabilities, accounts payable and other current liabilities, all of which, except contingent consideration, are recognized as amortized cost. Contingent consideration is recognized at fair value through profit or loss. The instruments are classified into: – Amortized cost, or – Fair value through profit or loss Financial liabilities at amortized costs are initially measured at fair value, net of transaction costs. Subsequently periods are measured at amortized cost using the effective interest (EIR) method. Financial liabilities classified at fair value are measured both initially and in subsequent periods at fair value in the Group’s consolidated statements of financial position, where changes in fair value are recognized in the Group’s consolidated statements of income. The components of the change in fair value relating to exchange rate effects are recognized in net financial items and other changes in fair value are recognized in operating profit or loss. Recognition and derecognition A financial asset or financial liability is recognized in the consolidated statement of financial position when the Group becomes a party in accordance with the contractual terms of the instrument. Debt is recognized when the counterparty has performed and a contractual obligation exists to pay, even if an invoice has not yet been received. A financial asset is derecognized from the consolidated statement of financial position when the rights in the agreement are realized, expire or the Group loses control of them. A financial liability is derecognized from the consolidated statement of financial position when the contractual obligation is fulfilled or otherwise extinguished. The same applies to part of a financial asset or financial liability. Gains and losses from derecognition from the consolidated statement of financial position are recorded in the consolidated statement of income. A financial asset and financial liability are offset and recognized with a net amount in the consolidated statement of financial position only when there is a legal right to set off the amounts and that there is an intention to settle the items with a net amount or to simultaneously realize the asset and settle the debt. Impairment of financial assets The Group’s impairment model is based on expected credit losses and takes into account forward-looking information. The valuation of expected credit losses takes into account any collateral and other credit enhancements in the form of guarantees. See Note 20 Financial Risks for information on considerations relating to accounts receivable and deposits.
Inventory	Inventory Inventory is recognized as the lower of the acquisition cost and the net realizable value. The acquisition cost for completed goods and goods being manufactured comprises raw materials and other direct costs and applicable indirect manufacturing costs. The net realizable value is the estimated sale price in operating activities. By continuously monitoring inventory, we ensure that it is dispatched based on its shelf life and moving average basis. When necessary, impairment of inventory is performed within the frame of normal business operations and is recognized in costs of goods sold.
Accounts Receivable	Accounts Receivable Accounts receivable are reported at amortized cost. A provision for expected credit losses is recorded based on the Group’s forward looking expected credit losses (ECL). An analysis of expected credit losses is performed, taking into account historical, current and forward looking factors. The effect of recognition of the provision amount is reported in the statement of income.
Cash	Cash Cash is entirely comprised of cash at banks.
Equity	Equity Common shares, other contributed capital and retained earnings are classified as equity. Financial instruments that meet the criteria for classification as equity are recognized as equity even if the financial instrument is legally structured as a liability. Transaction costs that are directly attributable to the issue of new shares or options are recognized net after tax in equity as a deduction from the issue proceeds. When Calliditas shares are repurchased, the amount of the consideration paid is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are presented as a deduction from total equity. When treasury shares are sold or subsequently reissued, the amount received is recognized as an increase in equity and the resulting surplus or deficit on the transaction is transferred to or from Additional Paid-in Capital.
Option Program	​ Option Program The Group has issued an option program which constitutes share-based payments. The cost for the remuneration that is recognized in a period is dependent on the original valuation that was made on the date on which the contracts with the participants in the incentive programs were concluded, the number of months of service required for vesting of their options (accruals are made over this period), the number of options that are expected to be vested under the terms of the plans and a continuous reassessment of the value of the tax benefits for the participants under the plans (for determining provisions for social security expenses). Those estimates which affect the cost in a period and the corresponding increase in equity mainly refer to inputs for the valuation of the options. All the options are classified as equity-settled, as vested options are settled in equity. When the options are exercised, the company issues new shares.
Provisions	Provisions A provision differs from other liabilities in that there is uncertainty about the time of payment or the amount of the amount to settle the provision. A provision is recognized in the statement of financial position when there is an existing legal or informal obligation arising from past events, and it is likely that an outflow of financial resources will be required to settle the obligation and a reliable estimate of the amount can be made. The amount recognized is the best estimate of what is required to settle the existing obligation on the balance sheet date. Where the effect of when payment is made in time is significant, provisions are calculated by discounting the expected future cash flow.
Contingent Liabilities	Contingent Liabilities A contingent liability is disclosed when there is a possible commitment originating from events that have occurred and whose occurrence is confirmed by one or several uncertain future events. An obligation arising from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events is not recognized as a liability or provision.
Foreign Currency	Foreign Currency Transactions in foreign currency Transactions in foreign currency are translated to the functional currency at the exchange rate on the date of the transaction. Monetary assets and liabilities in foreign currency are translated to the functional currency at the exchange rate that applies on the closing date. Exchange rate differences arising on translation are recognized in net profit for the year. Foreign exchange gains and losses on operating receivables and liabilities are recognized in operating profit, while foreign exchange gains and losses on financial receivables and liabilities are recognized as financial items. Translation from foreign operations Assets and liabilities in foreign operations are translated from the functional currency of the operations to the Group’s presentation currency at the exchange rate applicable on the closing date. Income and expenses in a foreign operation are translated to SEK at the average exchange rate which corresponds to an approximation of the exchange rates prevailing on each individual transaction date. Translation differences arising in the translation of foreign operations’ functional currencies are recognized in the consolidated statements of comprehensive income.
Earnings per Share	Earnings per Share The calculation of earnings per share is based on the Group’s net loss for the year and on the weighted-average number of common shares outstanding during the year. In calculating earnings per share after dilution, earnings and the average number of shares are adjusted for the dilutive effects of potential common shares. Earnings per share is not adjusted for any dilution that results in a profit per share after dilution that is higher than profit per share before dilution, or loss per share that is lower than loss per share before dilution.
Cash Flow	Cash Flow The consolidated statement of cash flows is prepared in accordance with the indirect method. The recognized cash flow includes only transactions that involve inflows and outflows, divided into operating activities, investing activities and financing activities. Cash flows from inflows and outflows are recognized at gross amounts, except for transactions comprising large inflows and outflows that pertain to items that are traded quickly and have short terms.
Segment Information	Segment Information An operating segment is a part of the Group that conducts business activities from which it can generate revenue and incur costs, and for which independent financial information is available. Identification of segments is based on internal reporting to the chief operating decision maker (“CODM”). The CODM for the Group is the Chief Executive Officer (“CEO”). The Group does not divide its operations into different segments and the CODM operates and manages the Group’s entire operations as one segment, which is consistent with the Group’s internal organization and reporting system. The Group’s revenue is attributable to the Parent Company in Sweden and to the U.S. subsidiary Calliditas NA Enterprises Inc. The non-current assets are located in Sweden, the U.S.,France and Switzerland.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue from Contracts with Customers
Schedule of revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Type of goods or service ​ 2022 ​ 2021 ​ 2020 Product sales 375,515 — — Outlicensing of product 421,689 225,252 — Royalty income ​ 2,287 ​ — ​ — Performance of certain regulatory services ​ 3,387 ​ 4,095 ​ — Provision of drugs ​ — ​ — ​ 874 Total 802,879 229,347 874 ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Geographical markets ​ 2022 ​ 2021 ​ 2020 USA ​ 372,247 ​ — ​ — Europe* 143,955 201,878 — Asia ​ 286,677 ​ 27,469 ​ 874 Total 802,879 229,347 874 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Revenue from major customers 2022 2021 2020 Customer A ​ 372,247 — — Customer B ​ 80,643 27,469 874 Customer C ​ 143,955 201,879 — Customer D ​ 206,034 — — Total ​ 802,879 229,348 874 ​

Other Operating Income (Tables)

Other Operating Income (Tables)	12 Months Ended
	Dec. 31, 2022
Other Operating Income
Components of other operating income	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Exchange rate differences — 149 2,501 Pass through costs ​ 439 ​ — ​ — Net gains on disposal of equipment ​ — ​ 110 ​ — Other income ​ 2,423 ​ — ​ — Total 2,862 259 2,501

Other Operating Expenses (Table

Other Operating Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Other Operating Expenses
Components of other operating expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Exchange rate differences 7,133 1,807 — Net loss on disposal of equipment — 67 — Change in value of the contingent consideration at fair value 15,941 4,470 — Total 23,074 6,344 —

Auditors Fee (Tables)

Auditors Fee (Tables)	12 Months Ended
	Dec. 31, 2022
Auditors' Fee
Auditors fees expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 EY ​ Audit services 13,369 6,235 4,449 Other audit activities ​ 3,370 ​ 2,105 ​ 3,774 Tax advice — 73 — Total ​ 16,739 ​ 8,413 ​ 8,223 ​ ​ ​ ​ ​ ​ ​ KPMG ​ ​ ​ ​ ​ ​ Audit services ​ — ​ 472 ​ 102 Other audit activities ​ — ​ 1,178 ​ 2,552 Total ​ — ​ 1,650 ​ 2,654 ​ ​ ​ ​ ​ ​ ​ Other auditors ​ ​ ​ ​ ​ ​ Audit services ​ — ​ 471 ​ 102 Other audit activities ​ — ​ 79 ​ — Total ​ — ​ 550 ​ 102 ​ ​ ​ ​ ​ ​ ​ Total Audit Fee ​ 16,739 ​ 10,613 ​ 10,979 ​

Costs according to Type of Co_2

Costs according to Type of Cost (Tables)	12 Months Ended
	Dec. 31, 2022
Costs according to Type of Cost
Schedule of operating expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Raw materials and consumables ​ 3,179 ​ — ​ — Other external expenses 939,566 549,079 ​ 311,329 Personnel costs 248,952 164,206 ​ 68,943 Depreciation on equipment’s and right-of-use assets 12,913 34,433 ​ 2,823 Other operating expenses 23,074 6,344 ​ — Total 1,227,684 754,062 ​ 383,095

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases
Schedule of Right-of-use assets	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Right-of-use assets ​ ​ ​ ​ Opening balance ​ 37,198 ​ 9,595 Additional agreements ​ — ​ 34,944 Revaluation agreements ​ (474) ​ — Termination of agreement ​ — ​ (7,625) Exchange differences ​ 3,485 ​ 284 Closing balance ​ 40,209 ​ 37,198 ​ ​ ​ ​ ​ Depreciation ​ ​ Opening balance ​ (3,898) ​ (4,351) Depreciation ​ (10,807) ​ (5,711) Revaluation agreements ​ 47 ​ — Termination of agreement ​ — ​ 6,456 Exchange differences ​ (1,099) ​ (292) Closing balance ​ (15,757) ​ (3,898) ​ ​ ​ ​ ​ Net book value ​ 24,452 ​ 33,300 ​
Schedule of Lease liabilities	​ ​ ​ ​ ​ ​ ​ December 31, Lease liabilities 2022 2021 Non-current lease liabilities ​ 15,792 ​ 24,052 Current lease liabilities ​ 10,374 ​ 9,591 Total 26,165 ​ 33,642 ​
Maturity analysis on future lease liabilities	​ ​ ​ ​ ​ ​ ​ ​ December 31, Maturity analysis on future lease liabilities 2022 2021 <12 months ​ 16,467 11,909 1-2 years ​ 12,613 11,231 >2 years ​ 10,053 16,256 ​ ​ 39,133 39,396 ​
Schedule of lease payments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 ​ 2021 2020 Interest expenses attributable to lease liabilities ​ 1,604 ​ 590 388 Expenses attributable to short-term lease ​ — ​ 633 731 Expenses attributable to leasing agreements with low value ​ 214 ​ 146 103 Expenses attributable to variable lease payments that are not included in lease liabilities ​ 303 ​ 446 344 Expenses attributable to lease depreciation ​ 10,807 ​ 5,711 ​ 2,786 Total expensed during the year ​ 12,928 ​ 7,526 ​ 4,352 ​ ​ ​ ​ ​ ​ ​ This year’s lease payments in the Group ​ 13,231 ​ 6,659 4,930

Employees and Personnel Costs (

Employees and Personnel Costs (Tables)	12 Months Ended
	Dec. 31, 2022
Employees and Personnel Costs
Schedule of Average Number of Employees	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 ​ 2021 ​ 2020 ​ Number % of Male Number % of Male Number % of Male ​ ​ of Empl. ​ Empl. ​ of Empl. ​ Empl. ​ of Empl. ​ Empl. Parent Company ​ ​ ​ ​ ​ Sweden 45 33 % 29 40 % 16 ​ 44 % ​ 45 33 % 29 40 % 16 ​ 44 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Subsidiaries ​ ​ ​ ​ ​ France ​ 2 ​ — ​ 3 ​ 26 % — ​ — ​ Switzerland ​ 6 ​ 53 % 6 ​ 47 % 2 ​ 50 % United States 33 52 % 18 62 % 5 ​ 100 % ​ 41 51 % 27 55 % 7 ​ 86 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total for the Group 86 41 % 56 47 % 23 ​ 57 % ​
Schedule of Wages and Salaries	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Wages and Salaries 2022 2021 2020 Parent Company ​ ​ ​ ​ Board and Executive Management 1) 33,471 ​ 27,792 19,211 Other employees 52,126 ​ 33,370 15,598 ​ ​ ​ ​ ​ ​ ​ Subsidiaries ​ ​ ​ Board and Executive Management 14,493 ​ 4,983 3,184 Other employees ​ 90,055 ​ 57,452 ​ 11,615 Total 190,145 ​ 123,597 49,608 ​ 1) Executive Management includes the Board, CEO and other executive management.
Schedule of Social Security Costs and Pension Costs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Social Security Costs and Pension Costs 2022 2021 2020 Parent Company ​ ​ ​ Pension costs for the Board and Executive Management 2,167 1,785 ​ 1,748 Pension costs to other employees 6,582 4,084 ​ 1,666 Social security costs 17,393 17,088 ​ 12,330 ​ ​ ​ ​ ​ ​ ​ Subsidiaries ​ Pension costs for the Board and Executive Management ​ 616 ​ 167 ​ 129 Pension costs to other employees ​ 2,647 ​ 928 ​ 506 Social security costs 6,484 8,596 ​ 225 Total 35,889 32,648 ​ 16,604 ​
Schedule of Gender Distribution Among the Board and Senior Executives	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 2020 ​ Percentage of women on the Board ​ 67 % 60 % 60 % Percentage of men on the Board 33 % 40 % 40 % Percentage of women among other executive management 38 % 33 % 33 % Percentage of men among other executive management 62 % 67 % 67 % ​
Schedule of Disclosures Regarding Total Remuneration of The Board and Senior Executives	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2022 ​ Base Salary, ​ Variable Other Share-Based ​ ​ ​ Board Fee ​ Pension Costs ​ Remuneration ​ Remuneration ​ Payments ​ Total Chairman of the Board Elmar Schnee 975 — — — 647 1,622 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board members Hilde Furberg 413 — — — 239 651 Diane Parks 490 — — — 239 729 Lennart Hansson (until May, 2022) 200 — — — 33 233 Molly Henderson 590 — — — 227 817 Henrik Stenqvist (from May, 2022) 275 — — — 74 349 Elisabeth Björk (from May, 2022) 188 — — — 74 261 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Executive Management CEO, Renée Aguiar-Lucander 5,938 760 2,293 — 4,056 13,048 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other executive management (7 people) 17,784 2,023 5,146 — 8,083 33,037 of which relates to subsidiaries 7,516 616 3,152 — 3,824 15,109 Total 26,853 2,783 7,440 — 13,671 50,747 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2021 ​ Base Salary, ​ Variable Other Share-Based ​ ​ ​ Board Fee ​ Pension Costs ​ Remuneration ​ Remuneration ​ Payments ​ Total Chairman of the Board Elmar Schnee 898 — — — 465 1,363 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board members Hilde Furberg 336 — — — 162 498 Lennart Hansson 360 — — — 162 522 Diane Parks ​ 421 ​ — ​ — ​ — ​ 162 ​ 583 Molly Henderson 539 — — — 124 663 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Executive Management ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CEO, Renée Aguiar-Lucander ​ 4,860 ​ 760 ​ 1,840 ​ — ​ 3,270 ​ 10,730 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other executive management (5 people) ​ 11,279 ​ 1,193 ​ 2,335 ​ — ​ 5,561 ​ 20,368 of which relates to subsidiaries 2,775 167 694 — 1,515 5,151 Total 18,693 1,953 4,175 — 9,906 34,727 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2020 ​ Base Salary, ​ Variable Other Share-Based ​ ​ ​ Board Fee ​ Pension Costs ​ Remuneration ​ Remuneration ​ Payments ​ Total Chairman of the Board Elmar Schnee 834 — — — 310 1,144 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board members Thomas Eklund (until June, 2022) 72 — — — 43 115 Hilde Furberg ​ 273 ​ — ​ — ​ — ​ 106 ​ 379 Lennart Hansson 281 — — — 106 387 Bengt Julander (until June, 2022) ​ 58 ​ — ​ — ​ — ​ — ​ 58 Diane Parks ​ 379 ​ — ​ — ​ — ​ 106 ​ 485 Molly Henderson (from June, 2022) ​ 345 ​ — ​ — ​ — ​ 37 ​ 382 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Executive Management ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CEO, Renée Aguiar-Lucander ​ 3,401 ​ 678 ​ 1,357 ​ — ​ 1,094 ​ 6,530 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other executive management (5 people) ​ 9,816 ​ 1,198 ​ 1,760 ​ 472 ​ 2,018 ​ 15,264 of which relates to subsidiaries 2,547 129 636 — — 3,312 Total 15,459 1,876 3,117 472 3,820 24,744 ​

Share-Based Payments - Incentiv

Share-Based Payments - Incentive Programs (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of calculation of fair value of option program	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value Upon ​ ​ No. of Shares ​ ​ ​ ​ ​ Issue of the Options, Exercise ​ ​ Covered by ​ Grant Date Exercised Date SEK Price, SEK Volatility Options ESOP 2020:1 July 1, 2020 July 1, 2023 22.14 121.43 39.60 % 836,500 ESOP 2020:2 September 17,2020 September 17,2023 22.50 116.78 41.60 % 104,000 ESOP 2020:3 ​ February 4, 2021 February 4, 2024 ​ 30.41 ​ 145.05 ​ 44.30 % 37,000 ESOP 2020:4 ​ March 9, 2021 ​ March 9, 2024 ​ 30.41 ​ 141.26 ​ 45.20 % 394,166 ESOP 2021:1 ​ June 14, 2021 ​ June 14, 2024 ​ 35.88 ​ 140.71 ​ 46.00 % 500,000 ESOP 2021:2 ​ September 29, 2021 ​ September 29, 2024 ​ 25.72 ​ 109.38 ​ 47.50 % 329,500 ESOP 2021:3 ​ March 17, 2022 ​ March 17, 2025 ​ 27.64 ​ 93.77 ​ 43.84 % 650,000 ESOP 2022:1 ​ September 27, 2022 ​ September 27, 2025 ​ 26.57 ​ 94.66 ​ 45.14 % 1,101,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 3,952,166 ​
Summary of warrants outstanding and inputs used for the black and scholes valuation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Outstanding as of Inputs used for the Black & Scholes valuation ​ ​ December 31, ​ December 31, ​ Exercise Price, ​ Price per ​ Value per ​ ​ ​ ​ ​ ​ Outstanding Warrants per Year 2021 2022 SEK Warrant in SEK Share in SEK Risk-Free Rate Volatility Expiration Date Warrant program 2018/2022 ​ 856,586 ​ — ​ 74.30 ​ 3.29 ​ 46.50 ​ (0.28%) ​ 33 % 2022-03-31 Warrant program 2019/2022 ​ 422,500 — ​ 74.50 6.69 * 54.39 * (0.55%) * 36 %* 2022-12-31 Total ​ 1,279,086 — ​
Summary of changes and holding of warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Outstanding as of Holder ​ January 1, 2021 Change December 31, 2021 Change December 31, 2022 CEO Renée Lucander 545,000 — 545,000 (545,000) — ​ Other executive management 437,500 — 437,500 (437,500) — ​ Other employees, consultants and external parties 296,586 — 296,586 (296,586) ​ — ​ Total 1,279,086 — 1,279,086 (1,279,086) — ​ ​
Summary of Granted Warrants, Options and Share Awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options ​ Share Awards Warrants ​ ​ Weighted Average ​ Weighted Average ​ Weighted Average ​ ​ Number of Shares ​ Exercise Prices ​ Number of Shares ​ Exercise Prices ​ Number of Shares ​ Exercise Prices Outstanding as of January 1, 2021 1,089,000 120.94 82,770 — ​ 1,279,086 74.37 Granted 1,331,000 133.48 26,968 — ​ — — Forfeited (131,000) 121.78 — — ​ — — Outstanding as of December 31, 2021 2,289,000 128.18 109,738 — ​ 1,279,086 74.37 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding as of January 1, 2022 2,289,000 128.18 109,738 — ​ 1,279,086 74.37 Granted 1,751,000 94.33 40,706 — ​ — — Forfeited (87,834) 133.33 (4,167) — ​ — — Exercised — — (51,399) — ​ (1,279,086) 74.37 Outstanding as of December 31, 2022 3,952,166 113.07 94,878 — ​ — — Weighted average share price at the date of exercise — — 102.06 — ​ 91.45 —
Esop 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of changes and holdings of awards by grantees	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding as of Holder January 1, 2021 Change December 31, 2021 Change ​ December 31, 2022 Renée Aguiar-Lucander, CEO 225,000 71,000 296,000 295,000 591,000 Other executive management 415,000 120,000 535,000 ​ 520,000 ​ 1,055,000 Other employees and consultants 449,000 1,009,000 1,458,000 ​ 848,166 ​ 2,306,166 Total 1,089,000 1,200,000 2,289,000 ​ 1,663,166 ​ 3,952,166 ​
Schedule of effect of share-based payments on entity's profit or loss	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Share-based payments ​ 34,549 ​ 24,737 ​ 5,304 Provisions attributable to changes in social security costs (Share-based payments) 234 9,992 ​ 3,164 Total 34,783 34,729 ​ 8,468 ​
Board LTIP 2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of changes and holdings of awards by grantees	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board LTIP 2019 Share Awards Outstanding as of Holder January 1, 2021 Change December 31, 2021 Change December 31, 2022 Elmar Schnee, Chairman of the Board ​ 23,236 — 23,236 ​ (23,236) ​ — Thomas Eklund, Board member (until June, 2020) ​ 2,816 — 2,816 ​ (2,816) ​ — Hilde Furberg, Board member ​ 8,449 — 8,449 ​ (8,449) ​ — Lennart Hansson, Board member (until May, 2022) ​ 8,449 — 8,449 ​ (8,449) ​ — Diane Parks, Board member ​ 8,449 — 8,449 ​ (8,449) ​ — Total ​ 51,399 — 51,399 (51,399) — ​
Schedule of effect of share-based payments on entity's profit or loss	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 ​ 2021 2020 Share-based payments ​ 1,531 ​ 876 267 Provisions attributable to changes in social security costs (Share-based payments) ​ (1,614) ​ 297 207 Total ​ (83) ​ 1,173 474 ​
Schedule of effect of share-based payments on entity's financial position	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Number ​ ​ Exercised ​ at Grant ​ of Share ​ ​ Date ​ Date ​ Awards Board LTIP 2019 ​ June 1, 2022 ​ 22.49 ​ 51,399 Board LTIP 2020 ​ July 1, 2023 ​ 33.97 ​ 29,928 Board LTIP 2021 ​ July 1, 2024 ​ 62.95 ​ 24,244 Board LTIP 2022 July 1, 2025 51.54 40,706 ​
Board LTIP 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of changes and holdings of awards by grantees	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board LTIP 2020 Share Awards Outstanding as of Holder January 1, 2021 Change December 31, 2021 Change December 31, 2022 Elmar Schnee, Chairman of the Board ​ 14,063 — 14,063 ​ — ​ 14,063 Hilde Furberg, Board member ​ 4,327 — 4,327 ​ — ​ 4,327 Lennart Hansson, Board member (until May, 2022) ​ 4,327 — 4,327 ​ (1,443) ​ 2,884 Diane Parks, Board member ​ 4,327 — 4,327 ​ — ​ 4,327 Molly Hendersson, Board member ​ 4,327 ​ — ​ 4,327 ​ — ​ 4,327 Total ​ 31,371 — 31,371 (1,443) 29,928 ​
Board LTIP 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of changes and holdings of awards by grantees	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board LTIP 2021 Share Awards Outstanding as of Holder January 1, 2021 Change December 31, 2021 Change December 31, 2022 Elmar Schnee, Chairman of the Board ​ — 10,624 10,624 ​ — ​ 10,624 Hilde Furberg, Board member ​ — 4,086 4,086 ​ — ​ 4,086 Lennart Hansson, Board member (until May, 2022) ​ — 4,086 4,086 ​ (2,724) ​ 1,362 Diane Parks, Board member ​ — 4,086 4,086 ​ — ​ 4,086 Molly Henderson, Board member ​ — ​ 4,086 ​ 4,086 ​ — ​ 4,086 Total ​ — 26,968 26,968 (2,724) 24,244 ​
Board LTIP 2022 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of changes and holdings of awards by grantees	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Board LTIP 2022 Share Awards Outstanding as of Holder January 1, 2021 Change December 31, 2021 Change December 31, 2022 Elmar Schnee, Chairman of the Board ​ — — — ​ 13,926 ​ 13,926 Hilde Furberg, Board member ​ — — — ​ 5,356 ​ 5,356 Diane Parks, Board member ​ — — — ​ 5,356 ​ 5,356 Molly Hendersson, Board member ​ — ​ — ​ — ​ 5,356 ​ 5,356 Henrik Stenqvist, Board member ​ — ​ — ​ — ​ 5,356 ​ 5,356 Elisabeth Björk, Board member ​ — ​ — ​ — ​ 5,356 ​ 5,356 Total ​ — — — 40,706 40,706 ​

Financial Income (Tables)

Financial Income (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Income
Schedule of Financial income	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Interest income under the effective interest method ​ 3,553 ​ 102 547 Exchange rate differences ​ 46,642 ​ 20,234 — Total ​ 50,195 ​ 20,336 547

Financial Expenses (Tables)

Financial Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Expenses
Schedule of Financial expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Interest on lease liabilities ​ (1,604) ​ (590) (388) Other interest expenses under the effective interest method ​ (31,191) ​ (6,518) (5) Exchange rate differences ​ — ​ — (53,267) Changes in FX options measured at fair value ​ — ​ — (3,318) Other financial expenses ​ (4,874) ​ (2,145) ​ — Total ​ (37,669) ​ (9,253) (56,978)

Income Tax Expense (Tables)

Income Tax Expense (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Expense
Schedule of reconciliation of effective tax rate	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 ​ 2021 2020 Current income taxes ​ (11,539) ​ (4,581) (1,035) Deferred tax ​ 8,688 ​ 8,417 675 Income tax expense recognized in the consolidated statements of income ​ (2,851) ​ 3,836 (360) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Reconciliation of effective tax rate 2022 2021 2020 Accounting loss before income tax ​ (409,417) ​ (513,373) (436,151) Tax in accordance with applicable tax rate in Sweden 20.6% ( 20.6% , 21.4 )% ​ 84,340 ​ 105,755 93,336 ​ ​ ​ ​ ​ ​ ​ Tax effect of: ​ ​ ​ ​ ​ ​ Effect of other tax rates for foreign subsidiaries ​ (11,857) ​ 11,481 680 Tax attributable to unrecognized deferred tax assets for tax losses carried forward ​ (64,150) ​ (101,785) (91,725) Non-deductible expenses ​ (11,184) ​ (11,615) (2,652) Non-taxable income ​ — ​ — 1 Income tax expense recognized in the consolidated statements of income ​ (2,851) ​ 3,836 (360) ​ ​ ​ ​ ​ ​ ​ At the effective income tax rate ​ (1) % 1 % — ​

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings per Share
Schedule of Earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Loss per share before and after dilution 2022 2021 2020 Net loss for the year attributable to equity holders of the Parent Company ​ (412,268) ​ (500,293) (433,494) Weighted-average number of common shares outstanding ​ 53,022,550 ​ 50,829,255 44,873,448 Loss per share before and after dilution ​ (7.78) ​ (9.84) (9.66) ​

Intangible Assets and Impairm_2

Intangible Assets and Impairment Testing (Tables)	12 Months Ended
	Dec. 31, 2022
Intangible Assets and Impairment Testing
Schedule of intangible assets and impairment testing	​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Licenses and similar rights ​ Cost at opening balance ​ 390,166 380,836 Acquisition for the year ​ — ​ 16,066 Exchange differences on translation ​ 78,545 (6,736) Cost at closing balance ​ 468,711 390,166 ​ ​ ​ ​ ​ Impairment ​ ​ ​ ​ Cost at opening balance ​ (27,975) ​ — Impairment ​ — ​ (27,975) Exchange differences on translation ​ (2,679) ​ — Accumulated impairment at closing balance ​ (30,654) ​ (27,975) ​ ​ ​ ​ ​ Goodwill ​ ​ ​ ​ Cost at opening balance ​ 37,227 ​ 37,989 Exchange differences on translation ​ 8,557 ​ (762) Cost at closing balance ​ 45,784 37,227 ​ ​ ​ ​ ​ Net book value ​ 483,841 399,418 ​
Schedule of impairment testing of intangible assets discount rate	​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Parameter, % 2022 2021 Discount rate 12.0 11.0 ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Parameter, % 2022 2021 Discount rate NOX platform 12.0 17.7 Discount rate Budenofalk 3 mg oral capsule 12.0 12.4 ​

Equipment (Tables)

Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Equipment.
Schedule of depreciation and amortisation expense	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 ​ Cost at opening balance ​ 7,073 214 ​ Acquisition for the year ​ 2,512 ​ 6,588 ​ Disposal for the year ​ — ​ (118) ​ Exchange differences ​ 1,582 389 ​ Cost at closing balance ​ 11,167 7,073 ​ ​ ​ ​ ​ ​ ​ Depreciation at opening balance ​ (764) (51) ​ Depreciation for the year ​ (2,106) (465) ​ Disposal for the year ​ — 51 ​ Exchange differences ​ (830) ​ (299) ​ Depreciation at closing balance ​ (3,700) (764) ​ ​ ​ ​ ​ ​ ​ Net book value ​ 7,468 6,309 ​ ​

Non-Current Financial Assets (T

Non-Current Financial Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Non-Current Financial Assets
Schedule of non-current financial assets	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Cost at opening balance ​ 3,915 2,225 ​ Additional acquisition ​ 7,064 1,686 ​ Exchange differences ​ 231 4 ​ Net book value ​ 11,210 3,915 ​ ​

Deferred Tax Assets and Defer_2

Deferred Tax Assets and Deferred Tax Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Deferred Tax Assets and Deferred Tax Liabilities
Schedule of deferred tax assets and liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred Tax Deferred Tax ​ Deferred tax assets and liabilities as of December 31, 2022 Assets Liabilities Net Intangible assets — (56,789) (56,789) Tangible assets ​ — ​ (766) ​ (766) Lease items net value ​ 382 ​ — ​ 382 Liabilities ​ 3,218 ​ — ​ 3,218 Personnel-related items 10,654 — 10,654 Tax loss carried forward 17,037 — 17,037 Other items 311 — 311 Total 31,601 (57,555) (25,953) Offsetting (17,803) 17,803 — Tax assets/liabilities, net 13,799 (39,752) (25,953) ​ ​
Schedule of change in deferred tax	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change in deferred tax, 2022 Cost at Opening Balance Recognized in Profit or Loss Exchange Differences Cost at Closing Balance Intangible assets (46,175) — (10,614) (56,789) Tangible assets ​ (238) ​ (477) ​ (51) ​ (766) Lease items net value ​ 270 ​ 68 ​ 44 ​ 382 Liabilities ​ — ​ 3,122 ​ 96 ​ 3,218 Personnel-related items 4,140 5,699 814 10,653 Tax loss carried forward 15,319 — 1,718 17,037 Other items 23 276 12 311 Total (26,661) 8,688 (7,981) (25,953) ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred Tax Deferred Tax ​ Deferred tax assets and liabilities as of December 31, 2021 ​ Assets ​ Liabilities ​ Net Intangible assets — (46,175) (46,175) Tangible assets — (238) (238) Lease items net value ​ 270 ​ — ​ 270 Personnel-related items ​ 4,141 ​ — ​ 4,141 Tax loss carried forward 15,319 — 15,319 Other items 23 — 23 Total 19,753 (46,413) (26,661) Offsetting (15,557) 15,557 — Tax assets/liabilities, net 4,196 (30,856) (26,661) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change in deferred tax, 2021 ​ Cost at Opening Balance ​ Recognized in Profit or Loss ​ Exchange Differences ​ Cost at Closing Balance Intangible assets (47,120) — 945 (46,175) Tangible assets ​ — ​ (226) ​ (12) ​ (238) Lease items net value ​ — ​ 256 ​ 14 ​ 270 Personnel-related items 596 3,304 240 4,140 Tax loss carried forward 9,666 5,065 588 15,319 Other items 4 18 1 23 Total (36,854) 8,417 1,776 (26,661)

Financial and Non-Financial A_2

Financial and Non-Financial Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Financial and Non-Financial Assets and Liabilities
Schedule of financial and non-financial assets and liabilities	Financial and non-financial assets and liabilities as of December 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financial Assets ​ Financial Assets ​ ​ ​ ​ ​ ​ Measured at ​ Measured ​ Non- ​ Total ​ ​ Fair Value through ​ at Amortized ​ Financial ​ Carrying ​ ​ Profit or Loss ​ Cost ​ Assets ​ Amount Assets Non-current financial assets — 11,210 — 11,210 Accounts receivable — 78,703 — 78,703 Prepaid expenses and accrued income — 2,287 — 2,287 Cash — 1,249,094 — 1,249,094 ​ — 1,341,295 — 1,341,295 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financial Liabilities ​ ​ ​ ​ ​ ​ ​ Measured at Financial Liabilities Non- Total ​ ​ Fair Value through ​ Measured at ​ Financial ​ Carrying ​ ​ Profit or Loss ​ Amortized Cost ​ Liabilities ​ Amount Liabilities Contingent consideration 75,880 — — 75,880 Non-current interest-bearing liabilities ​ — ​ 713,030 ​ — ​ 713,030 Non-current lease liabilities — 15,792 — 15,792 Other non-current liabilities ​ — ​ 1,363 ​ 2,987 ​ 4,350 Accounts payable — 160,404 — 160,404 Other current liabilities — 10,374 12,323 22,697 Accrued expenses and deferred revenue — 75,754 60,692 136,446 ​ 75,880 976,717 76,002 1,128,598 ​ Financial and non-financial assets and liabilities as of December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financial Assets ​ Financial Assets ​ ​ ​ ​ ​ Measured at Measured at Non- Total ​ ​ Fair Value through ​ at Amortized ​ Financial ​ Carrying ​ ​ Profit or Loss ​ Cost ​ Assets ​ Amount Assets ​ ​ ​ ​ ​ ​ ​ ​ Non-current financial assets — 3,915 — 3,915 Cash — 955,507 — 955,507 ​ — 959,422 — 959,422 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Financial Liabilities ​ ​ ​ ​ ​ ​ ​ Measured at Financial Liabilities Non- Total ​ Fair Value through Measured at Financial Carrying ​ Profit or Loss Amortized Cost Liabilities Amount Liabilities ​ Contingent consideration ​ 54,399 ​ — ​ — ​ 54,399 Non-current interest-bearing liabilities ​ — ​ 189,164 ​ — ​ 189,164 Non-current lease liabilities ​ — ​ 24,052 ​ — ​ 24,052 Accounts payable — 67,971 — 67,971 Other current liabilities — 9,591 3,111 12,702 Accrued expenses and deferred revenue — 25,168 28,385 53,553 ​ 54,399 315,946 31,496 401,841 ​

Financial Risks (Tables)

Financial Risks (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Risks
Schedule of credit risk accounts receivable	​ ​ ​ ​ ​ ​ ​ ​ December 31, Accounts receivable 2022 2021 Gross accounts receivable ​ 79,873 — ​ Provisions, expected credit losses ​ (1,170) — ​ Net accounts receivable ​ 78,703 — ​ ​ ​ ​ ​ ​ ​ Maturity structure accounts receivable ​ ​ Accounts receivable, not yet due ​ 79,873 — ​ Provisions, expected credit losses ​ (1,170) — ​ Net book value ​ 78,703 — ​ ​ ​ ​ ​ ​ ​ Provisions for expected credit losses ​ ​ Opening balance, expected credit loss provisions ​ — — ​ This years provisions ​ (1,170) — ​ Closing balance, expected credit loss provisions ​ (1,170) — ​ ​
Schedule of transaction exposure from contracted payment flows in foreign currency	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Currency exposure 2022 (%) ​ Revenue ​ expenses USD 68 % 20 % EUR 32 % 48 % GBP — 4 % SEK ​ — ​ 27 % Other currencies — 1 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Currency exposure 2021 (%) ​ Revenue ​ expenses USD 14 % 43 % EUR 86 % 36 % GBP — 3 % SEK — 18 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating ​ Currency exposure 2020 (%) Revenue expenses USD 100 % 35 % EUR — 36 % GBP — 6 % SEK — 23 % ​
Schedule of maturity analysis	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 Maturity analysis <6 months 6-12 months 2-5 years Contingent consideration ​ — — 75,880 Non-current interest-bearing liabilities ​ — ​ — ​ 713,030 Non-current lease liabilities ​ — ​ — ​ 15,792 Other non-current liabilities ​ — ​ — ​ 4,350 Accounts payable ​ 160,404 — — Other current liabilities ​ 13,288 9,409 — Accrued expenses ​ 121,865 ​ 14,581 ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 Maturity analysis <6 months 6-12 months 2-5 years Contingent consideration ​ — — 54,399 Non-current interest-bearing liabilities ​ — ​ — ​ 189,164 Non-current lease liabilities ​ — ​ — ​ 24,052 Accounts payable ​ 67,971 ​ — ​ — Other current liabilities ​ 7,906 4,796 — Accrued expenses ​ 47,753 5,800 — ​
Schedule of non-current interesting-bearing liabilities	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Opening balance ​ 189,164 — ​ New borrowings, net ​ 491,745 ​ 199,524 ​ Transaction costs paid ​ (1,260) (14,858) ​ Interest expense ​ 4,874 ​ 2,145 ​ Exchange difference on translation ​ 28,507 2,353 ​ Closing balance ​ 713,030 189,164 ​ ​

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2022
Inventories
Schedule of inventories	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ 2022 ​ 2021 Raw materials 1,855 889 Work in progress 937 — Finished goods 855 — Total 3,647 889 ​

Prepaid Expenses and Accrued _2

Prepaid Expenses and Accrued Income (Tables)	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses and Accrued Income
Schedule of prepaid expenses and accrued income	​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Accrued royalties ​ 2,287 — Prepaid insurance premiums ​ 9,148 ​ 10,813 Prepaid interest costs ​ 3,693 ​ — Prepaid expenses for research and development ​ 45,454 ​ 27,888 Prepaid expenses for marketing and selling ​ 8,194 — Other prepaid expenses ​ 1,964 6,331 Total ​ 70,741 45,032

Cash (Tables)

Cash (Tables)	12 Months Ended
	Dec. 31, 2022
Cash
Schedule of cash	​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Cash at Banks ​ 1,249,094 955,507 Total ​ 1,249,094 955,507 ​
Schedule of adjustments for non cash items	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Depreciations and impairments ​ 12,913 34,433 ​ 2,823 Chage in Provisions ​ (3,346) 5,856 ​ 6,634 Share-based payments ​ 35,791 21,960 ​ 6,012 Cange in Contingent consideration ​ 15,941 ​ 4,470 ​ — Other items ​ (39) (43) ​ (4) Total ​ 61,260 66,676 ​ 15,465 ​
Schedule of reconciliation of liabilities from financing activities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ Non-Cash December 31, ​ ​ 2022 ​ Cash-Flow Items ​ 2022 Non- current interest-bearing liabilities ​ 189,164 490,485 33,381 713,030 Lease liabilities 33,642 (9,615) 2,138 26,165 ​ 222,806 480,870 35,519 739,195 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ Non-Cash December 31, ​ ​ 2021 ​ Cash-Flow Items ​ 2021 Non-current interest-bearing liabilities ​ — ​ 184,667 ​ 4,497 ​ 189,164 Lease liabilities 4,786 (5,575) 34,431 33,642 ​ 4,786 179,092 38,928 222,806

Group Companies (Tables)

Group Companies (Tables)	12 Months Ended
	Dec. 31, 2022
Group Companies
Schedule of group companies	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Country of % Equity Interest Company Principal Activities Incorporation 2022 ​ 2021 2020 Parent Company ​ ​ ​ Calliditas Therapeutics AB Research and development of pharmaceuticals Sweden — ​ — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Subsidiaries ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nefecon AB ​ Administration of incentive programs issued by the Parent Company ​ Sweden ​ 100 % 100 % 100 % Calliditas NA Enterprises Inc ​ Market access activities in the United States ​ United States ​ 100 % 100 % 100 % Calliditas Therapeutics US Inc Commercial activities in the United States United States 100 % 100 % — ​ Calliditas Therapeutics France SAS ​ Research and development of pharmaceuticals ​ France ​ 100 % 100 % 86.2 % Calliditas Therapeutics Suisse SA ​ Research and development of pharmaceuticals ​ Switzerland ​ 100 % 100 % 86.2 %

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Equity
Schedule of Share capital and other contributed capital	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 ​ 2021 ​ 2020 Total registered shares at the beginning of the year 52,341,584 49,941,584 38,707,638 New share issue* — 2,400,000 9,937,446 Exercise of warrants 1,322,985 — 1,296,500 Issuance of treasury shares 5,908,018 — — Shares subscribed but not registered during the year** 7,500 — — Total registered and subscribed but not registered shares at the end of the year ​ 59,580,087 52,341,584 49,941,584 ​ ​ ​ ​ ​ ​ ​ Shares ​ ​ ​ ​ ​ ​ Ordinary shares ​ 59,580,087 ​ 52,341,584 ​ 49,941,584 Total 59,580,087 52,341,584 49,941,584 - of which shares are held by Calliditas ​ 5,908,018 ​ — ​ — Total registered and subscribed but not registered shares at the end of the year, net of shares held by Calliditas ​ 53,672,069 ​ 52,341,584 ​ 49,941,584 ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, Share Capital ​ 2022 ​ 2021 ​ 2020 Opening balance 2,094 1,998 1,548 New share issue* — 96 397 Exercise of warrants 53 — 52 Issuance of treasury shares 236 — — Closing balance 2,383 2,094 1,998 ​ * Initial public offering on The Nasdaq Global Select Market in the United States in June 2020 and the following exercise of the partial over-allotment option from the IPO in July 2020. * New share issue in August 2021 ** As of December 31, 2022, there was an on-going issue of 7,500 shares under registration related to the exercise under the Warrant Program 2019/2022. These shares have been included in the weighted-average number of shares outstanding for the period.
Schedule of changes in translation reserve	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 2020 Opening balance (26,979) ​ (6,090) (45) Change of the year 36,286 ​ (20,889) (6,045) Closing balance 9,307 ​ (26,979) (6,090)

Provisions (Tables)

Provisions (Tables)	12 Months Ended
	Dec. 31, 2022
Provisions
Summary of provisions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Social Security Costs on ​ ​ ​ ​ Provisions as of December 31, 2022 Share-Based Payment Other Provisions Provisions, net Opening balance 13,084 1,446 14,530 Provisions for the year ​ 1,027 ​ — ​ 1,027 Amounts claimed for the year ​ (204) ​ — ​ (204) Reversal of unused amounts ​ (2,666) ​ (1,573) ​ (4,239) Exchange differences 551 127 678 Total 11,792 — 11,792 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Social Security Costs on ​ ​ ​ ​ Provisions as of December 31, 2021 Share-Based Payment Other Provisions Provisions, net Opening balance 4,972 1,419 6,391 Provisions for the year 8,112 — 8,112 Exchange differences — 27 27 Total 13,084 1,446 14,530 ​

Contingent Consideration (Table

Contingent Consideration (Tables)	12 Months Ended
	Dec. 31, 2022
Contingent Consideration
Schedule of contingent consideration	​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ 2022 ​ 2021 Opening balance 54,399 48,969 Change for the year 15,942 4,470 Exchange differences 5,539 960 Net book value 75,880 54,399 ​

Pension Liabilities (Tables)

Pension Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Pension Liabilities
Summary of net pension obligation per country	​ ​ ​ ​ ​ ​ ​ December 31, Net obligation per country 2022 2021 Switzerland (789) ​ (3,071) France (94) ​ (111) Total (884) ​ (3,182) ​
Summary of changes in the defined-benefit pension obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Defined Benefit Defined Benefit Fair Value Employee ​ Plan Obligation Plan Obligation of Plan Assets Benefit ​ (Switzerland) (France) (Switzerland) Obligations January 1, 2022 (7,942) (111) 4,871 (3,182) ​ ​ ​ ​ ​ ​ ​ ​ ​ Service costs (1,530) (26) — (1,556) Interest expense (27) (1) 18 (10) Employee contribution — — 887 887 Subtotal included in the statement of consolidated operations (1,558) (27) 906 (679) ​ ​ ​ ​ ​ ​ ​ ​ ​ Amounts paid/received 2,140 — (2,140) — ​ ​ ​ ​ ​ ​ ​ ​ ​ Return on assets (excluding interest expenses) — — 34 34 Actuarial gains/(losses) related to changes in demographic assumptions — 54 — 54 Actuarial gains/(losses) related to changes in financial assumptions 2,846 — — 2,846 Other actuarial gains/(losses) ​ (454) ​ — ​ — ​ (454) Subtotal included in other items of comprehensive income 2,392 54 34 2,480 ​ ​ ​ ​ ​ ​ ​ ​ ​ Employer contributions — — 887 887 Currency translation effect (1,059) (9) 679 (390) December 31, 2022 (6,027) (94) 5,238 (884) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Defined ​ Defined ​ ​ ​ ​ ​ ​ Benefit Plan ​ Benefit Plan ​ Fair Value ​ Employee ​ ​ Obligation ​ Obligation ​ of Plan Assets ​ Benefit ​ (Switzerland) (France) (Switzerland) Obligations January 1, 2021 (19,193) (172) 11,069 (8,296) ​ ​ ​ ​ ​ ​ ​ ​ ​ Service costs (2,165) (13) — (2,178) Interest expense (17) — 10 (7) Curtailment* 12,011 — (7,805) 4,206 Employee contribution — — 704 704 Subtotal included in the statement of consolidated operations 9,829 (13) (7,091) 2,725 ​ ​ ​ ​ ​ ​ ​ ​ ​ Amounts paid/received 291 — (291) — ​ ​ ​ ​ ​ ​ ​ ​ ​ Return on assets (excluding interest expenses) — — 64 64 Actuarial gains/(losses) related to changes in demographic assumptions 349 77 — 426 Actuarial gains/(losses) related to changes in financial assumptions 1,120 — — 1,120 Other actuarial gains/(losses) 360 — — 360 Subtotal included in other items of comprehensive income 1,829 77 64 1,970 ​ ​ ​ ​ ​ ​ ​ ​ ​ Employer contributions — — 704 704 Currency translation effect (698) (3) 416 (285) December 31, 2021 (7,942) (111) 4,871 (3,182) ​ *The change in the Curtailment refer to retirement obligation settlement connected to the departure of senior management member of Switzerland employees.
Summary of distribution by plan assets	​ ​ ​ ​ ​ ​ ​ December 31, Distribution by Plan Assets (Switzerland) 2022 ​ 2021 Cash 137 ​ 205 Bonds 3,048 ​ 2,801 Mortgage loans 655 ​ 667 Shares 126 ​ 92 Real estate 901 ​ 760 Other investments 372 ​ 346 Total 5,238 ​ 4,871 ​
Summary of actuarial assumptions on the balance sheet date	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, Actuarial Assumptions on the Closing Balance 2022 ​ 2021 Swiss pension plan ​ ​ ​ Discount rate 2.30 % 0.35 % Mortality table LPP 2020 generation ​ LPP 2020 generation ​ Salary revaluation rate 1.00 % 1.00 % Retirement pension inflation rate 0.50 % 0.50 % Deposit rate on savings accounts 1.00 % 1.00 % Turnover rate 10.00 % 10.00 % Remaining life expectancy after retirement 18.6 years 22.3 years Retirement age ​ 65 years 65 years ​
Summary of sensitivity analysis	​ ​ ​ ​ ​ ​ ​ ​ December 31, Sensitivity Analysis 2022 2021 Pension commitments under current assumptions for Swiss pension plans 6,027 ​ 7,942 Discount rate , -0,5% ​ 6,615 ​ 8,904 Discount rate , +0,5% ​ 5,518 ​ 7,130 Retirement pension inflation rate, -0,5% ​ 5,797 ​ 7,575 Retirement pension inflation rate, +0,5% ​ 6,281 ​ 8,353 Salary revaluation rate, -0,5% ​ 5,927 ​ 7,792 Salary revaluation rate, +0,5% ​ 6,131 ​ 8,100 ​

Other Non-Current Liabilities (

Other Non-Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Other Non-Current Liabilities
Schedule of other non-current liabilities	​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ 2022 ​ 2021 Opening balance — — Additional liabilities 4,350 — Closing balance 4,350 — ​

Accrued Expenses and Deferred_2

Accrued Expenses and Deferred Revenue (Tables)	12 Months Ended
	Dec. 31, 2022
Accrued Expenses and Deferred Revenue
Schedule of accrued expenses and deferred revenue	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Vacation pay liabilities 8,310 6,107 Accrued salaries and Board fees 28,186 16,786 Social security costs 7,065 5,492 Deferred revenue ​ — ​ 3,387 Accrued rebates on sales 15,849 — Accrued expenses for royalty 12,023 — Accrued expenses for research and development ​ 34,637 ​ 4,230 Accrued expenses for marketing and selling ​ 21,543 ​ 1,242 Accrued expenses for administration 8,832 16,309 Total 136,446 53,553

Change of presentation of exp_2

Change of presentation of expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Change of presentation of expenses
Schedule of effects of the change in the statement of income	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Year Ended December 31, ​ ​ 2021 ​ Re-classification ​ 2021 ​ 2020 ​ Re-classification ​ 2020 Net sales 229,347 — 229,347 874 — 874 Operating expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development expenses (357,485) — (357,485) (241,371) — (241,371) Marketing and selling expenses — (179,603) (179,603) — (38,964) (38,964) Administrative expenses (390,232) 179,603 (210,629) (141,724) 38,964 (102,760) Other operating income/expenses (6,085) — (6,085) 2,501 — 2,501 Operating loss (524,456) — (524,456) (379,720) — (379,720) Net financial income/(expenses) 11,083 — 11,083 (56,431) — (56,431) Loss before income tax (513,373) — (513,373) (436,151) — (436,151) Income tax 3,836 — 3,836 (360) — (360) Loss for the year (509,537) — (509,537) (436,511) — (436,511)

Description of Business (Detail

Description of Business (Details)	Dec. 31, 2022 subsidiary
Description of Business
Number of subsidiaries	4

Significant Accounting Polici_3

Significant Accounting Policies - Leases (Details)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Estimated lease term	12 months

Significant Accounting Polici_4

Significant Accounting Policies - Intangible assets (Details) kr in Thousands	12 Months Ended
	Dec. 31, 2022 SEK (kr)
Intangible Assets and Impairment Testing
Reversal of impairment of goodwill	kr 0
Licenses and similar rights | Minimum
Intangible Assets and Impairment Testing
Expected finite useful life	6 years
Licenses and similar rights | Maximum
Intangible Assets and Impairment Testing
Expected finite useful life	15 years

Significant Accounting Polici_5

Significant Accounting Policies - Equipment (Details)	12 Months Ended
	Dec. 31, 2022
Office Equipment
Equipment
Expected useful life	5 years
Computer equipment
Equipment
Expected useful life	5 years

Significant Accounting Polici_6

Significant Accounting Policies - Impairment of Non-Financial Assets (Details) kr in Thousands	12 Months Ended
	Dec. 31, 2022 SEK (kr)
Significant Accounting Policies
Impairment loss	kr 0

Significant Accounting Judgem_2

Significant Accounting Judgements, Estimates and Assumptions (Details) kr in Thousands	12 Months Ended
	Dec. 31, 2022 SEK (kr)
Intangible Assets and Impairment Testing
Goodwill	kr 45,784
Intangible assets	438,057
Impairment loss	kr 0
Minimum
Intangible Assets and Impairment Testing
Invoices payment term	30 days
Maximum
Intangible Assets and Impairment Testing
Invoices payment term	45 days

Revenue from Contracts with C_3

Revenue from Contracts with Customers (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue from Contracts with Customers
Net sales	kr 802,879		kr 874
Total liability for expected returns and rebates	24,294
Expected return of liability for returns and rebates	0
Performance obligation	0
Accrued rebates on sales	15,849
Deferred revenue		kr 3,387
Customer A
Revenue from Contracts with Customers
Net sales	372,247
Customer B
Revenue from Contracts with Customers
Net sales	80,643	27,469	874
Customer C
Revenue from Contracts with Customers
Net sales	143,955	201,879
Customer D
Revenue from Contracts with Customers
Net sales	206,034
USA
Revenue from Contracts with Customers
Net sales	372,247
Europe
Revenue from Contracts with Customers
Net sales	143,955	201,878
Asia
Revenue from Contracts with Customers
Net sales	286,677	27,469	874
Sweden
Revenue from Contracts with Customers
Net sales	0	0	0
Product sales
Revenue from Contracts with Customers
Net sales	375,515
Outlicensing of product
Revenue from Contracts with Customers
Net sales	421,689	225,252
Royalty income
Revenue from Contracts with Customers
Net sales	2,287	0
Performance of certain regulatory services
Revenue from Contracts with Customers
Net sales	kr 3,387	kr 4,095
Provision of drugs
Revenue from Contracts with Customers
Net sales			kr 874

Other Operating Income (Details

Other Operating Income (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Operating Income
Exchange rate differences		kr 149	kr 2,501
Pass through costs	kr 439
Net gains on disposal of equipment		110
Other income	2,423
Total	kr 2,862	kr 259	kr 2,501

Other Operating Expenses (Detai

Other Operating Expenses (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Other Operating Expenses
Exchange rate differences	kr 7,133	kr 1,807
Net loss on disposal of equipment		67
Change in value of the contingent consideration at fair value	15,941	4,470
Total	kr 23,074	kr 6,344

Auditor's Fee (Details)

Auditor's Fee (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Auditors' Fee
Total audit fee	kr 16,739	kr 10,613	kr 10,979
EY
Auditors' Fee
Audit services	13,369	6,235	4,449
Other audit activities	3,370	2,105	3,774
Tax advice		73
Total audit fee	kr 16,739	8,413	8,223
KPMG
Auditors' Fee
Audit services		472	102
Other audit activities		1,178	2,552
Total audit fee		1,650	2,654
Other auditors
Auditors' Fee
Audit services		471	102
Other audit activities		79
Total audit fee		kr 550	kr 102

Costs according to Type of Co_3

Costs according to Type of Cost (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Costs according to Type of Cost
Raw materials and consumables	kr 3,179
Other external expenses	939,566	kr 549,079	kr 311,329
Personnel costs	248,952	164,206	68,943
Depreciation on equipment's and right-of-use assets	12,913	34,433	2,823
Other operating expenses	23,074	6,344
Total	kr 1,227,684	kr 754,062	kr 383,095

Leases - Right-of-Use Assets (D

Leases - Right-of-Use Assets (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases
Balance at beginning of period	kr 33,300
Depreciation	12,913	kr 34,433	kr 2,823
Balance at end of period	24,452	33,300
Research and Development Expenses [Member]
Leases
Depreciation on right of use assets	1,073	997	165
Marketing and Selling Expenses [Member]
Leases
Depreciation on right of use assets	3,743	1,522
Administrative expenses
Leases
Depreciation on right of use assets	5,991	3,192	2,621
Cost at closing balance
Leases
Balance at beginning of period	37,198	9,595
Additional agreements		34,944
Revaluation agreements	(474)
Termination of agreement		(7,625)
Exchange differences	3,485	284
Balance at end of period	40,209	37,198	9,595
Depreciation
Leases
Balance at beginning of period	(3,898)	(4,351)
Revaluation agreements	47
Depreciation	(10,807)	(5,711)
Termination of agreement		6,456
Exchange differences	(1,099)	(292)
Balance at end of period	kr (15,757)	kr (3,898)	kr (4,351)

Leases - Lease Liabilities (Det

Leases - Lease Liabilities (Details) - SEK (kr) kr in Thousands	Dec. 31, 2022	Dec. 31, 2021
Leases
Non-current lease liabilities	kr 15,792	kr 24,052
Current lease liabilities	10,374	9,591
Total	kr 26,165	kr 33,642

Leases - Maturity Analysis on F

Leases - Maturity Analysis on Future Lease Liabilities (Details) - SEK (kr) kr in Thousands	Dec. 31, 2022	Dec. 31, 2021
Leases
Future lease liabilities	kr 39,133	kr 39,396
Less than 12 months
Leases
Future lease liabilities	16,467	11,909
1-2 years
Leases
Future lease liabilities	12,613	11,231
>2 years
Leases
Future lease liabilities	kr 10,053	kr 16,256

Leases - Lease of Low-value ass

Leases - Lease of Low-value assets (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases
Interest expenses attributable to lease liabilities	kr 1,604	kr 590	kr 388
Expenses attributable to short-term lease		633	731
Expenses attributable to leasing agreements with low value	214	146	103
Expenses attributable to variable lease payments that are not included in lease liabilities	303	446	344
Expenses attributable to lease depreciation	10,807	5,711	2,786
Total expensed during the year	12,928	7,526	4,352
This year's lease payments in the Group	kr 13,231	kr 6,659	kr 4,930

Employees and Personnel Costs -

Employees and Personnel Costs - Average Number of Employees (Details) - employee	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2020
Employees and Personnel Costs
Average number of employees	86	41	56	47	23	57
Parent Company
Employees and Personnel Costs
Average number of employees	45		29		16
Percentage of male employees		33%		40%		44%
Parent Company | Sweden
Employees and Personnel Costs
Average number of employees	45		29		16
Percentage of male employees		33%		40%		44%
Subsidiaries
Employees and Personnel Costs
Average number of employees	41		27		7
Percentage of male employees		51%		55%		86%
Subsidiaries | France
Employees and Personnel Costs
Average number of employees	2		3
Percentage of male employees				26%
Subsidiaries | Switzerland
Employees and Personnel Costs
Average number of employees	6		6		2
Percentage of male employees		53%		47%		50%
Subsidiaries | USA
Employees and Personnel Costs
Average number of employees	33		18		5
Percentage of male employees		52%		62%		100%

Employees and Personnel Costs_2

Employees and Personnel Costs - Wages and Salaries (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employees and Personnel Costs
Wages and Salaries	kr 190,145	kr 123,597	kr 49,608
Parent Company | Board and executive management
Employees and Personnel Costs
Wages and Salaries	33,471	27,792	19,211
Parent Company | Other employees
Employees and Personnel Costs
Wages and Salaries	52,126	33,370	15,598
Subsidiaries | Board and executive management
Employees and Personnel Costs
Wages and Salaries	14,493	4,983	3,184
Subsidiaries | Other employees
Employees and Personnel Costs
Wages and Salaries	kr 90,055	kr 57,452	kr 11,615

Employees and Personnel Costs_3

Employees and Personnel Costs - Social Security Costs and Pension Costs (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employees and Personnel Costs
Pension costs	kr 2,783	kr 1,953	kr 1,876
Social security costs and pension costs	35,889	32,648	16,604
Parent Company
Employees and Personnel Costs
Social security costs	17,393	17,088	12,330
Parent Company | Board and executive management
Employees and Personnel Costs
Pension costs	2,167	1,785	1,748
Parent Company | Other employees
Employees and Personnel Costs
Pension costs	6,582	4,084	1,666
Subsidiaries
Employees and Personnel Costs
Social security costs	6,484	8,596	225
Subsidiaries | Board and executive management
Employees and Personnel Costs
Pension costs	616	167	129
Subsidiaries | Other employees
Employees and Personnel Costs
Pension costs	kr 2,647	kr 928	kr 506

Employees and Personnel Costs_4

Employees and Personnel Costs - Gender Distribution (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Board
Employees and Personnel Costs
Percentage of women	67%	60%	60%
Percentage of men	33%	40%	40%
Executive management
Employees and Personnel Costs
Percentage of women	38%	33%	33%
Percentage of men	62%	67%	67%

Employees and Personnel Costs_5

Employees and Personnel Costs - Disclosures Regarding Total Remuneration of The Board and Senior Executives (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employees and Personnel Costs
Base salary, foard fee	kr 26,853	kr 18,693	kr 15,459
Pension costs	2,783	1,953	1,876
Variable remuneration	7,440	4,175	3,117
Other remuneration			472
Share-based payments	13,671	9,906	3,820
Reimbursement received	50,747	34,727	24,744
Elmar Schnee
Employees and Personnel Costs
Base salary, foard fee	975	898	834
Share-based payments	647	465	310
Reimbursement received	1,622	1,363	1,144
Thomas Eklund
Employees and Personnel Costs
Base salary, foard fee			72
Share-based payments			43
Reimbursement received			115
Hilde Furberg
Employees and Personnel Costs
Base salary, foard fee	413	336	273
Share-based payments	239	162	106
Reimbursement received	651	498	379
Lennart Hansson
Employees and Personnel Costs
Base salary, foard fee	200	360	281
Share-based payments	33	162	106
Reimbursement received	233	522	387
Bengt Julander
Employees and Personnel Costs
Base salary, foard fee			58
Reimbursement received			58
Diane Parks
Employees and Personnel Costs
Base salary, foard fee	490	421	379
Share-based payments	239	162	106
Reimbursement received	729	583	485
Molly Henderson
Employees and Personnel Costs
Base salary, foard fee	590	539	345
Share-based payments	227	124	37
Reimbursement received	817	663	382
Henrik Stenqvist
Employees and Personnel Costs
Base salary, foard fee	275
Share-based payments	74
Reimbursement received	349
Elisabeth Bjrk
Employees and Personnel Costs
Base salary, foard fee	188
Share-based payments	74
Reimbursement received	261
CEO
Employees and Personnel Costs
Base salary, foard fee	5,938	4,860	3,401
Pension costs	760	760	678
Variable remuneration	2,293	1,840	1,357
Share-based payments	4,056	3,270	1,094
Reimbursement received	13,048	10,730	6,530
Other executive management
Employees and Personnel Costs
Base salary, foard fee	17,784	11,279	9,816
Pension costs	2,023	1,193	1,198
Variable remuneration	5,146	2,335	1,760
Other remuneration			472
Share-based payments	8,083	5,561	2,018
Reimbursement received	33,037	20,368	15,264
Other executive management | Subsidiaries
Employees and Personnel Costs
Base salary, foard fee	7,516	2,775	2,547
Pension costs	616	167	129
Variable remuneration	3,152	694	636
Share-based payments	3,824	1,515
Reimbursement received	kr 15,109	kr 5,151	kr 3,312

Employees and Personnel Costs_6

Employees and Personnel Costs - Other Remuneration (Details) kr in Thousands	12 Months Ended
	Dec. 31, 2022 SEK (kr) age	Dec. 31, 2020 SEK (kr)
Employees and Personnel Costs
Pension obligations	kr 0
Vesting period	1 year
Board
Employees and Personnel Costs
Severance payment	kr 0
Previous payments of executive remuneration that have not been due	kr 0
Other executive management
Employees and Personnel Costs
Age of retirement | age	65
Minimum | Executive management
Employees and Personnel Costs
Mutual notice period	3 months
Minimum | Other executive management | Sweden
Employees and Personnel Costs
Percentage of pension commitments	15%
Maximum | Board
Employees and Personnel Costs
Annual fixed remuneration	60%
Maximum | Executive management
Employees and Personnel Costs
Mutual notice period	12 months
Maximum | CEO
Employees and Personnel Costs
Annual fixed remuneration	60%
Maximum | Other executive management | Sweden
Employees and Personnel Costs
Percentage of pension commitments	20%
Parent Company | CEO
Employees and Personnel Costs
Age of retirement | age	65
Percentage of pension premium based on salary	20%
Notice period	6 months
Parent Company | Cordcom Consultants KB | Other executive management
Employees and Personnel Costs
Fees for services rendered		kr 472

Share-Based Payments - Option P

Share-Based Payments - Option Program (Details)	12 Months Ended
	Dec. 31, 2022 EquityInstruments Option shares	Dec. 31, 2021 EquityInstruments Option shares
Share-Based Payments
Beginning balance	2,289,000	1,089,000
Change | shares	1,663,166	1,200,000
End balance	3,952,166	2,289,000
Share Awards [Member]
Share-Based Payments
Beginning balance | Option	109,738	82,770
End balance | Option	94,878	109,738
CEO [Member]
Share-Based Payments
Beginning balance	296,000	225,000
Change | shares	295,000	71,000
End balance	591,000	296,000
Other Executive Management [Member]
Share-Based Payments
Beginning balance	535,000	415,000
Change | shares	520,000	120,000
End balance	1,055,000	535,000
Other employees, consultants and external parties [Member]
Share-Based Payments
Beginning balance	1,458,000	449,000
Change | shares	848,166	1,009,000
End balance	2,306,166	1,458,000

Share-Based Payments - Calculat

Share-Based Payments - Calculation of fair value of option program (Details)	12 Months Ended
	Dec. 31, 2022 SEK (kr) shares	Dec. 31, 2022 SEK (kr) $ / shares shares	Dec. 31, 2021 SEK (kr)	Dec. 31, 2020 SEK (kr)
Share-Based Payments
Number of Shares covered by Options | shares	3,952,166	3,952,166
Number of warrants set aside to secure the delivery of shares in connection with the utilization of the award program | shares	5,000,000	5,000,000
Share-based payments	kr 34,549,000		kr 24,737,000	kr 5,304,000
Provisions attributable to changes in social security costs (Share-based payments)	234,000	kr 234,000	9,992,000	3,164,000
Total cost	kr 34,783,000		kr 34,729,000	kr 8,468,000
ESOP 2020
Share-Based Payments
Percentage of weighted average share price	115%
ESOP 2020:1
Share-Based Payments
Fair Value upon Issue of the Options	kr 22.14	kr 22.14
Exercise price | $ / shares		kr 121.43
Volatility	39.60%
Number of Shares covered by Options | shares	836,500	836,500
ESOP 2020:2
Share-Based Payments
Fair Value upon Issue of the Options	kr 22.50	kr 22.50
Exercise price | $ / shares		kr 116.78
Volatility	41.60%
Number of Shares covered by Options | shares	104,000	104,000
ESOP 2020:3
Share-Based Payments
Fair Value upon Issue of the Options	kr 30.41	kr 30.41
Exercise price | $ / shares		kr 145.05
Volatility	44.30%
Number of Shares covered by Options | shares	37,000	37,000
ESOP 2020:4
Share-Based Payments
Fair Value upon Issue of the Options	kr 30.41	kr 30.41
Exercise price | $ / shares		kr 141.26
Volatility	45.20%
Number of Shares covered by Options | shares	394,166	394,166
ESOP 2021:1
Share-Based Payments
Fair Value upon Issue of the Options	kr 35.88	kr 35.88
Exercise price | $ / shares		kr 140.71
Volatility	46%
Number of Shares covered by Options | shares	500,000	500,000
ESOP 2021:2
Share-Based Payments
Fair Value upon Issue of the Options	kr 25.72	kr 25.72
Exercise price | $ / shares		kr 109.38
Volatility	47.50%
Number of Shares covered by Options | shares	329,500	329,500
ESOP 2021:3
Share-Based Payments
Fair Value upon Issue of the Options	kr 27.64	kr 27.64
Exercise price | $ / shares		kr 93.77
Volatility	43.84%
Number of Shares covered by Options | shares	650,000	650,000
ESOP 2022:1
Share-Based Payments
Fair Value upon Issue of the Options	kr 26.57	kr 26.57
Exercise price | $ / shares		kr 94.66
Volatility	45.14%
Number of Shares covered by Options | shares	1,101,000	1,101,000

Share-Based Payments - Board LT

Share-Based Payments - Board LTIP 2019 - Additional information (Details)	12 Months Ended
	Dec. 31, 2022 shares
Share-Based Payments
Number of shares holder receives when warrant is exercised	1
Board LTIP 2019 | Scenario One [Member]
Share-Based Payments
Percentage of share price increases as the condition for share awards to be earned	60%
Percentage of the share awards earned based on the price increase condition	100%
Board LTIP 2019 | Scenario Two [Member]
Share-Based Payments
Percentage of share price increases as the condition for share awards to be earned	20%
Percentage of the share awards earned based on the price increase condition	33%
Board LTIP 2019 | Scenario Three [Member] | Minimum
Share-Based Payments
Percentage of the share awards earned based on the price increase condition	20%
Board LTIP 2019 | Scenario Three [Member] | Maximum
Share-Based Payments
Percentage of share price increases as the condition for share awards to be earned	60%
Board LTIP 2019 | Scenario four
Share-Based Payments
Percentage of share price increases as the condition for share awards to be earned	20%
Board LTIP 2019 | Scenario four | Maximum
Share-Based Payments
Percentage of the share awards earned based on the price increase condition	0%

Share-Based Payments - Board's

Share-Based Payments - Board's Holding of Share Awards 2019(Details) - Board LTIP 2019 - EquityInstruments	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payments
Beginning balance	51,399	51,399
Change	(51,399)	0
End balance		51,399
Elmar Schnee, Chairman of the Board
Share-Based Payments
Beginning balance	23,236	23,236
Change	(23,236)	0
End balance	0	23,236
Thomas Eklund, Board Member
Share-Based Payments
Beginning balance	2,816	2,816
Change	(2,816)	0
End balance	0	2,816
Hilde Furberg, Board Member
Share-Based Payments
Beginning balance	8,449	8,449
Change	(8,449)	0
End balance	0	8,449
Lennart Hansson, Board Member
Share-Based Payments
Beginning balance	8,449	8,449
Change	(8,449)	0
End balance	0	8,449
Diane Parks, Board Member
Share-Based Payments
Beginning balance	8,449	8,449
Change	(8,449)	0
End balance	0	8,449

Share-based Payments - Board _2

Share-based Payments - Board LTIP share awards 2020 (Details) - Board LTIP 2020 [Member] - EquityInstruments	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payments
Beginning balance	31,371	31,371
Change	(1,443)	0
End balance	29,928	31,371
Elmar Schnee
Share-Based Payments
Beginning balance	14,063	14,063
Change		0
End balance	14,063	14,063
Hilde Furberg
Share-Based Payments
Beginning balance	4,327	4,327
Change		0
End balance	4,327	4,327
Lennart Hansson
Share-Based Payments
Beginning balance	4,327	4,327
Change	(1,443)	0
End balance	2,884	4,327
Diane Parks
Share-Based Payments
Beginning balance	4,327	4,327
Change		0
End balance	4,327	4,327
Molly Henderson
Share-Based Payments
Beginning balance	4,327	4,327
Change		0
End balance	4,327	4,327

Share-based Payments - Board _3

Share-based Payments - Board LTIP share awards 2021 (Details) - Board LTIP 2021 - EquityInstruments	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payments
Beginning balance	26,968	0
Change	(2,724)	26,968
End balance	24,244	26,968
Accumulated number of outstanding	24,244	26,968
Elmar Schnee [Member]
Share-Based Payments
Beginning balance	10,624	0
Change		10,624
End balance	10,624	10,624
Accumulated number of outstanding	10,624	10,624
Hilde Furberg [Member]
Share-Based Payments
Beginning balance	4,086	0
Change		4,086
End balance	4,086	4,086
Accumulated number of outstanding	4,086	4,086
Lennart Hansson [Member]
Share-Based Payments
Beginning balance	4,086	0
Change	(2,724)	4,086
End balance	1,362	4,086
Accumulated number of outstanding	1,362	4,086
Diane Parks [Member]
Share-Based Payments
Beginning balance	4,086	0
Change		4,086
End balance	4,086	4,086
Accumulated number of outstanding	4,086	4,086
Molly Henderson [Member]
Share-Based Payments
Beginning balance	4,086	0
Change		4,086
End balance	4,086	4,086
Accumulated number of outstanding	4,086	4,086

Share-based Payments - Board _4

Share-based Payments - Board LTIP share awards 2022 (Details) - Board LTIP 2022 [Member] - EquityInstruments	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payments
Beginning balance	0	0
Change	40,706	0
End balance	40,706	0
Accumulated number of outstanding	40,706	0
Elmar Schnee [Member]
Share-Based Payments
Beginning balance	0	0
Change	13,926	0
End balance	13,926	0
Accumulated number of outstanding	13,926	0
Hilde Furberg [Member]
Share-Based Payments
Beginning balance	0	0
Change	5,356	0
End balance	5,356	0
Accumulated number of outstanding	5,356	0
Diane Parks [Member]
Share-Based Payments
Beginning balance	0	0
Change	5,356	0
End balance	5,356	0
Accumulated number of outstanding	5,356	0
Molly Henderson [Member]
Share-Based Payments
Beginning balance	0	0
Change	5,356	0
End balance	5,356	0
Accumulated number of outstanding	5,356	0
Henrik Stenqvist, Board member
Share-Based Payments
Beginning balance	0	0
Change	5,356	0
End balance	5,356	0
Accumulated number of outstanding	5,356	0
Elisabeth Bjrk, Board member
Share-Based Payments
Beginning balance	0	0
Change	5,356	0
End balance	5,356	0
Accumulated number of outstanding	5,356	0

Share-Based Payments - Fair Val

Share-Based Payments - Fair Value of Share-Based Payments (Details)	Dec. 31, 2022 EquityInstruments $ / shares shares	Dec. 31, 2021 EquityInstruments	Dec. 31, 2020 EquityInstruments
Share-Based Payments
Number of warrants set aside to secure the delivery of shares in connection with the utilization of the award program | shares	5,000,000
Board LTIP 2019
Share-Based Payments
Fair value of stock awards | $ / shares	$ 22.49
Number of other equity instruments outstanding in share-based payment arrangement | EquityInstruments		51,399	51,399
Number of warrants set aside to secure the delivery of shares in connection with the utilization of the award program | shares	72,000
Board LTIP 2020
Share-Based Payments
Fair value of stock awards | $ / shares	$ 33.97
Number of other equity instruments outstanding in share-based payment arrangement | EquityInstruments	29,928	31,371	31,371
Board LTIP 2021
Share-Based Payments
Fair value of stock awards | $ / shares	$ 62.95
Number of other equity instruments outstanding in share-based payment arrangement | EquityInstruments	24,244	26,968	0
Board LTIP 2022
Share-Based Payments
Fair value of stock awards | $ / shares	$ 51.54
Number of other equity instruments outstanding in share-based payment arrangement | EquityInstruments	40,706	0	0

Share-Based Payments - Total Co

Share-Based Payments - Total Cost of the Outstanding Share-Based Payments (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payments
Share-based payments	kr 1,531	kr 876	kr 267
Provisions attributable to changes in social security costs (Share-based payments)	(1,614)	297	207
Total	kr (83)	kr 1,173	kr 474

Share-Based Payments - Warrants

Share-Based Payments - Warrants Outstanding and Inputs used for the Black and Scholes valuation (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares kr / shares shares	Dec. 31, 2021 shares	Dec. 31, 2020 shares
Share-Based Payments
Warrants Outstanding | shares	0	1,279,086	1,279,086
Warrant program 2018/2022
Share-Based Payments
Warrants Outstanding | shares	0	856,586
Exercise Price, SEK	kr 74.30
Value per Share in SEK | $ / shares	46.50
Price per Share in SEK	kr 3.29
Risk-Free Rate	(0.28%)
Volatility	33%
Expiration Date	Mar. 31, 2022
Warrant program 2019/2022
Share-Based Payments
Warrants Outstanding | shares	0	422,500
Exercise Price, SEK	kr 74.50
Value per Share in SEK | $ / shares	54.39
Price per Share in SEK	kr 6.69
Risk-Free Rate	(0.55%)
Volatility	36%
Expiration Date	Dec. 31, 2022

Share-Based Payments - Changes

Share-Based Payments - Changes and holdings of warrants (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payments
Warrants Outstanding, Beginning Balance	1,279,086	1,279,086
Change	(1,279,086)	0
Warrants Outstanding, End Balance	0	1,279,086
CEO Rene Lucander
Share-Based Payments
Warrants Outstanding, Beginning Balance	545,000	545,000
Change	(545,000)	0
Warrants Outstanding, End Balance	0	545,000
Other executive management
Share-Based Payments
Warrants Outstanding, Beginning Balance	437,500	437,500
Change	(437,500)	0
Warrants Outstanding, End Balance	0	437,500
Other employees, consultants and external parties
Share-Based Payments
Warrants Outstanding, Beginning Balance	296,586	296,586
Change	(296,586)	0
Warrants Outstanding, End Balance	0	296,586

Share-Based Payments - Summary

Share-Based Payments - Summary of Granted Warrants, Options and Share Awards (Details)	12 Months Ended
	Dec. 31, 2022 Option EquityInstruments kr / shares	Dec. 31, 2021 Option EquityInstruments kr / shares	Dec. 31, 2020 EquityInstruments Option
Number of Shares
Options Outstanding | EquityInstruments	3,952,166	2,289,000	1,089,000
End balance | EquityInstruments	3,952,166	2,289,000
Options
Number of Shares
Options Outstanding | Option	3,952,166	2,289,000	1,089,000
Granted | Option	1,751,000	1,331,000
Forfeited | Option	(87,834)	(131,000)
End balance | Option	3,952,166	2,289,000
Weighted Average Exercise Prices
Beginning balance	kr 128.18	kr 120.94
Granted	94.33	133.48
Forfeited	133.33	121.78
End balance	kr 113.07	kr 128.18
Share Awards
Number of Shares
Options Outstanding | Option	94,878	109,738	82,770
Granted | Option	40,706	26,968
Forfeited | Option	(4,167)
Exercised | Option	(51,399)
End balance | Option	94,878	109,738
Weighted average share price at the date of exercise	102.06
Weighted Average Exercise Prices
Beginning balance	kr 0	kr 0
Granted	0	0
Forfeited	0	0
Exercised	0
End balance	0	kr 0
Weighted average share price at the date of exercise	kr 0
Warrants
Number of Shares
Options Outstanding | Option		1,279,086	1,279,086
Exercised | Option	(1,279,086)
End balance | Option		1,279,086
Weighted average share price at the date of exercise	91.45
Weighted Average Exercise Prices
Beginning balance	kr 74.37	kr 74.37
Granted	0	0
Forfeited	0	0
Exercised	74.37
End balance	0	kr 74.37
Weighted average share price at the date of exercise	kr 0

Financial Income (Details)

Financial Income (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial Income
Interest income under the effective interest method	kr 3,553	kr 102	kr 547
Exchange rate differences	46,642	20,234
Total	kr 50,195	kr 20,336	kr 547

Financial Expenses (Details)

Financial Expenses (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial Expenses
Interest on lease liabilities	kr (1,604)	kr (590)	kr (388)
Other interest expenses under the effective interest method	(31,191)	(6,518)	(5)
Exchange rate differences			(53,267)
Changes in FX options measured at fair value			(3,318)
Other financial expenses	(4,874)	(2,145)
Total	kr (37,669)	kr (9,253)	kr (56,978)

Income Tax Expense (Details)

Income Tax Expense (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Expense
Current income taxes	kr (11,539)	kr (4,581)	kr (1,035)
Deferred tax	8,688	8,417	675
Income tax expense recognized in the consolidated statements of income	(2,851)	3,836	(360)
Reconciliation of effective tax rate
Accounting loss before income tax	(409,417)	(513,373)	(436,151)
Tax in accordance with applicable tax rate in Sweden 20,6% (21,4% ,21,4%)	84,340	105,755	93,336
Effect of other tax rates for foreign subsidiaries	(11,857)	11,481	680
Tax attributable to non-deductible tax losses carried forward and unrecognized deferred tax assets	(64,150)	(101,785)	(91,725)
Non-deductible expenses	(11,184)	(11,615)	(2,652)
Non-taxable income			1
Income tax expense recognized in the consolidated statements of income	kr (2,851)	kr 3,836	kr (360)
At the effective income tax rate	(1.00%)	1%
Applicable tax rate	20.60%	20.60%	21.40%

Income Tax Expense - Additional

Income Tax Expense - Additional information (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Expense
Cost attributable to new share issue	kr 0	kr 20,909	kr 97,686
Tax losses carried forward for which deferred tax assets have not been recognized	kr 3,562,440		kr 3,200,911
Expiry period of unused tax losses	7 years
Sweden
Income Tax Expense
Tax losses carried forward for which deferred tax assets have not been recognized	kr 1,597,989
France
Income Tax Expense
Tax losses carried forward for which deferred tax assets have not been recognized	1,194,206
Switzerland
Income Tax Expense
Tax losses carried forward for which deferred tax assets have not been recognized	kr 770,245

Earnings per Share (Details)

Earnings per Share (Details) kr in Thousands	12 Months Ended
	Dec. 31, 2022 SEK (kr) shares	Dec. 31, 2022 $ / shares	Dec. 31, 2021 SEK (kr) shares	Dec. 31, 2021 $ / shares	Dec. 31, 2020 SEK (kr) shares	Dec. 31, 2020 $ / shares
Loss per share before and after dilution
Loss for the period | kr	kr (412,268)		kr (500,293)		kr (433,494)
Weighted-average number of common shares outstanding	53,022,550		50,829,255		44,873,448
Loss per share before and after dilution | $ / shares		$ (7.78)		$ (9.84)		$ (9.66)
Warrants and options
Loss per share before and after dilution
Number of potential dilutive instruments	3,952,166		3,952,166		3,952,166
Share Awards
Loss per share before and after dilution
Number of potential dilutive instruments	94,878		94,878		94,878

Intangible Assets and Impairm_3

Intangible Assets and Impairment Testing (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Intangible Assets and Impairment Testing
Cost at opening balance	kr 399,418
Impairment	0
Cost at closing balance	483,841	kr 399,418
Licenses and similar rights
Intangible Assets and Impairment Testing
Cost at opening balance	390,166	380,836
Acquisition license	0	16,066
Exchange difference on translation	78,545	(6,736)
Cost at closing balance		390,166
Goodwill
Intangible Assets and Impairment Testing
Cost at opening balance	37,227	37,989
Exchange difference on translation	8,557	(762)
Cost at closing balance	45,784	37,227
Nox Platforms
Intangible Assets and Impairment Testing
Cost at closing balance	405,925
Accumulated impairment [member]
Intangible Assets and Impairment Testing
Cost at opening balance	(27,975)
Impairment		(27,975)
Exchange difference on translation	(2,679)
Cost at closing balance	kr (30,654)	kr (27,975)

Intangible Assets and Impairm_4

Intangible Assets and Impairment Testing - Discount rate used before tax (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Intangible Assets and Impairment Testing
Discount rate	12%	11%
Impairment loss	kr 0
NOX platform
Intangible Assets and Impairment Testing
Discount rate	12%	17.70%
Budenofalk 3 mg oral capsule
Intangible Assets and Impairment Testing
Discount rate	12%	12.40%
Goodwill [member]
Intangible Assets and Impairment Testing
Impairment loss	kr 0

Equipment (Details)

Equipment (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equipment
Property, plant and equipment at beginning of period	kr 6,309
Exchange differences	(830)	kr (299)
Property, plant and equipment at end of period	7,468	6,309
Research And Development Expenses
Equipment
Depreciation for the year	(579)	(59)
Marketing and selling expenses
Equipment
Depreciation for the year	(806)	(176)
Administrative expenses
Equipment
Depreciation for the year	(721)	(230)	kr (37)
Cost at closing balance
Equipment
Property, plant and equipment at beginning of period	7,073	214
Acquisition for the year	2,512	6,588
Disposal for the year		(118)
Exchange differences	1,582	389
Property, plant and equipment at end of period	11,167	7,073	214
Amortization at closing balance
Equipment
Property, plant and equipment at beginning of period	(764)	(51)
Depreciation for the year	(2,106)	(465)
Disposal for the year		51
Property, plant and equipment at end of period	kr (3,700)	kr (764)	kr (51)

Non-Current Financial Assets (D

Non-Current Financial Assets (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Non-Current Financial Assets
Cost at opening balance	kr 3,915	kr 2,225
Additional acquisition	7,064	1,686
Exchange differences	231	4
Net book value	11,210	3,915
Payment of bank guarantee deposits	6,851	3,915
Other non-current receivables	kr 4,359	kr 0

Deferred Tax Assets and Defer_3

Deferred Tax Assets and Deferred Tax Liabilities (Details) - SEK (kr) kr in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net deferred tax assets and liabilities
Deferred Tax Assets	kr 31,601	kr 19,753
Deferred Tax Liabilities	(57,555)	(46,413)
Tax assets/liabilities, net	(25,953)	(26,661)	kr (36,854)
Offsetting Deferred Tax Assets	(17,803)	(15,557)
Offsetting Deferred Tax Liabilities	17,803	15,557
Net Deferred Tax Assets	13,799	4,196
Net Deferred Tax Liabilities	(39,752)	(30,856)
Intangible assets
Net deferred tax assets and liabilities
Deferred Tax Assets	0
Deferred Tax Liabilities	(56,789)	(46,175)
Tax assets/liabilities, net	(56,789)	(46,175)	(47,120)
Tangible assets
Net deferred tax assets and liabilities
Deferred Tax Assets	0
Deferred Tax Liabilities	(766)	(238)
Tax assets/liabilities, net	(766)	(238)
Lease items net value
Net deferred tax assets and liabilities
Deferred Tax Assets	382	270
Deferred Tax Liabilities	0
Tax assets/liabilities, net	382	270
Liabilities
Net deferred tax assets and liabilities
Deferred Tax Assets	3,218
Deferred Tax Liabilities	0
Tax assets/liabilities, net	3,218	0
Personnel-related items
Net deferred tax assets and liabilities
Deferred Tax Assets	10,654	4,141
Deferred Tax Liabilities	0
Tax assets/liabilities, net			596
Tax loss carried forward
Net deferred tax assets and liabilities
Deferred Tax Assets	17,037	15,319
Deferred Tax Liabilities	0
Tax assets/liabilities, net	17,037	15,319	9,666
Other items
Net deferred tax assets and liabilities
Deferred Tax Assets	311	23
Deferred Tax Liabilities	0
Tax assets/liabilities, net	kr 311	kr 23	kr 4

Deferred Tax Assets and Defer_4

Deferred Tax Assets and Deferred Tax Liabilities - Change in deferred tax (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Change in deferred tax
Cost at Opening Balance	kr (26,661)	kr (36,854)
Recognized in Profit or Loss	8,688	8,417
Exchange Differences	(7,981)	1,776
Cost at Closing Balance	(25,953)	(26,661)
Intangible assets
Change in deferred tax
Cost at Opening Balance	(46,175)	(47,120)
Recognized in Profit or Loss	0
Exchange Differences	(10,614)	945
Cost at Closing Balance	(56,789)	(46,175)
Tangible assets
Change in deferred tax
Cost at Opening Balance	(238)
Recognized in Profit or Loss	(477)	(226)
Exchange Differences	(51)	(12)
Cost at Closing Balance	(766)	(238)
Lease items net value
Change in deferred tax
Cost at Opening Balance	270
Recognized in Profit or Loss	68	256
Exchange Differences	44	14
Cost at Closing Balance	382	270
Liabilities
Change in deferred tax
Cost at Opening Balance	0
Recognized in Profit or Loss	3,122
Exchange Differences	96
Cost at Closing Balance	3,218	0
Personnel-related items
Change in deferred tax
Cost at Opening Balance		596
Recognized in Profit or Loss	5,699	3,304
Exchange Differences	814	240
Tax loss carried forward
Change in deferred tax
Cost at Opening Balance	15,319	9,666
Recognized in Profit or Loss	0	5,065
Exchange Differences	1,718	588
Cost at Closing Balance	17,037	15,319
Other items
Change in deferred tax
Cost at Opening Balance	23	4
Recognized in Profit or Loss	276	18
Exchange Differences	12	1
Cost at Closing Balance	kr 311	kr 23

Financial and Non-Financial A_3

Financial and Non-Financial Assets and Liabilities (Details) - SEK (kr) kr in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financial and Non-Financial Assets and Liabilities
Financial Assets, Carrying Amount	kr 1,341,295	kr 959,422
Financial Liabilities, Carrying Amount	1,128,598	401,841
Non-current interesting-bearing liabilities
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	713,030	189,164
Non-current lease liabilities
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	15,792
Financial Liabilities Measured at Fair Value through Profit or Loss
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Fair Value	75,880	54,399
Contingent consideration	75,880	54,399
Financial Liabilities Measured at Amortized Cost
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	976,717	315,946
Financial Liabilities Measured at Amortized Cost | Non-current interesting-bearing liabilities
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	713,030	189,164
Financial Liabilities Measured at Amortized Cost | Non-current lease liabilities
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	15,792
Non Financial Liabilities
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	76,002	31,496
Contingent Consideration
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Fair Value		54,399
Financial Liabilities, Carrying Amount	75,880	54,399
Contingent Consideration | Financial Liabilities Measured at Fair Value through Profit or Loss
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Fair Value	75,880
Other non-current liabilities
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	4,350	24,052
Other non-current liabilities | Financial Liabilities Measured at Amortized Cost
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	1,363	24,052
Other non-current liabilities | Non Financial Liabilities
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	2,987
Accounts payable
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	160,404	67,971
Accounts payable | Financial Liabilities Measured at Amortized Cost
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	160,404	67,971
Other current liabilities
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	22,697	12,702
Other current liabilities | Financial Liabilities Measured at Amortized Cost
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	10,374	9,591
Other current liabilities | Non Financial Liabilities
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	12,323	3,111
Accrued expenses and deferred revenue
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	136,446	53,553
Accrued expenses and deferred revenue | Financial Liabilities Measured at Amortized Cost
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	75,754	25,168
Accrued expenses and deferred revenue | Non Financial Liabilities
Financial and Non-Financial Assets and Liabilities
Financial Liabilities, Carrying Amount	60,692	28,385
Financial Assets Measured at Amortized Cost
Financial and Non-Financial Assets and Liabilities
Financial Assets, Carrying Amount	1,341,295	959,422
Non-current financial assets
Financial and Non-Financial Assets and Liabilities
Financial Assets, Carrying Amount	11,210	3,915
Non-current financial assets | Financial Assets Measured at Amortized Cost
Financial and Non-Financial Assets and Liabilities
Financial Assets, Carrying Amount	11,210	3,915
Account receivables
Financial and Non-Financial Assets and Liabilities
Financial Assets, Carrying Amount	78,703
Account receivables | Financial Assets Measured at Amortized Cost
Financial and Non-Financial Assets and Liabilities
Financial Assets, Carrying Amount	78,703
Prepaid expenses and accrued income
Financial and Non-Financial Assets and Liabilities
Financial Assets, Carrying Amount	2,287
Prepaid expenses and accrued income | Financial Assets Measured at Amortized Cost
Financial and Non-Financial Assets and Liabilities
Financial Assets, Carrying Amount	2,287
Cash
Financial and Non-Financial Assets and Liabilities
Financial Assets, Carrying Amount	1,249,094	955,507
Cash | Financial Assets Measured at Amortized Cost
Financial and Non-Financial Assets and Liabilities
Financial Assets, Carrying Amount	kr 1,249,094	kr 955,507

Financial Risks - Credit risk a

Financial Risks - Credit risk accounts receivable (Details) kr in Thousands	12 Months Ended
	Dec. 31, 2022 SEK (kr)
Accounts receivable
Net accounts receivable	kr 71,825
Credit risk
Accounts receivable
Gross accounts receivable	79,873
Provisions, expected credit losses	(1,170)
Net accounts receivable	78,703
Maturity structure accounts receivable
Accounts receivable, not yet due	79,873
Provisions, expected credit losses	(1,170)
Net book value	78,703
Provisions for expected credit losses
This years provisions	(1,170)
Closing balance, expected credit loss provisions	kr 1,170

Financial Risks - Transaction E

Financial Risks - Transaction Exposure (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial Risks
Operating Expenses (as a percentage)	1%
USD
Financial Risks
Revenue (as a percentage)	68%	14%	100%
Operating Expenses (as a percentage)	20%	43%	35%
EUR
Financial Risks
Revenue (as a percentage)	32%	86%
Operating Expenses (as a percentage)	48%	36%	36%
GBP
Financial Risks
Operating Expenses (as a percentage)	4%	3%	6%
SEK
Financial Risks
Operating Expenses (as a percentage)	27%	18%	23%

Financial Risks - Translation E

Financial Risks - Translation Exposure (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
USD
Financial Risks
Negative impact on profit after tax and equity of transaction exposure	kr 9,624	kr 22,402	kr 9,979
Translation exposure due to translation of earnings and net assets	kr 48,771	kr 18,270
Translation exposure (as a percent)	10%	10%	10%
Positive impact on equity	kr 4,877	kr 1,827
Translation exposure due to translation of foreign trade debt	19,377	29,236
Negative impact on profit after tax and equity of translation exposure	kr 1,938	kr 2,924
EUR
Financial Risks
Impact of profit after tax and equity (as a percent)	10%	10%	10%
Negative impact on profit after tax and equity of transaction exposure	kr 23,132	kr 909	kr 10,247
Translation exposure due to translation of earnings and net assets	kr (322,135)	kr (93,814)
Translation exposure (as a percent)	10%	10%
Positive impact on equity	kr 32,214	kr 9,381
Translation exposure due to translation of foreign trade debt	80,655	10,707
Negative impact on profit after tax and equity of translation exposure	kr 8,065	kr 1,071

Financial Risks - Maturity Anal

Financial Risks - Maturity Analysis (Details) - SEK (kr) kr in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financial Risks
Non-current lease liabilities	kr 15,792	kr 24,052
Other non-current liabilities	4,350
Other current liabilities	22,697	12,702
Less than 6 months
Financial Risks
Accounts payable	160,404	67,971
Other current liabilities	13,288	7,906
Accrued expenses	121,865	47,753
6 - 12 months
Financial Risks
Other current liabilities	9,409	4,796
Accrued expenses	14,581	5,800
>12 months
Financial Risks
Contingent consideration	75,880	54,399
Non-current interest-bearing liabilities	713,030	189,164
Non-current lease liabilities	15,792	kr 24,052
Other non-current liabilities	kr 4,350

Financial Risks - Non-current i

Financial Risks - Non-current interesting-bearing liabilities (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Opening balance	kr 222,806	kr 4,786
Closing balance	739,195	222,806
Long term Borrowings
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Opening balance	189,164
New borrowings - net	491,745	199,524
Transaction cost paid	(1,260)	(14,858)
Interest expense	4,874	2,145
Exchange difference on translation	28,507	2,353
Closing balance	kr 713,030	kr 189,164

Financial Risks - Non-current_2

Financial Risks - Non-current interesting-bearing liabilities - Additional information (Details) kr in Millions	1 Months Ended
	Sep. 30, 2021 SEK (kr)	Jul. 31, 2021 SEK (kr) tranche
Financial Risks
Interest rate		9%
Kreos Capital
Financial Risks
Amount of loan facility		kr 75
Loan Facility
Financial Risks
Amount of loan facility		kr 25
Number of tranches | tranche		3
Tranche One
Financial Risks
Amount drawn under each tranche	kr 25
Tranche Two
Financial Risks
Amount drawn under each tranche		kr 25
Tranche Three
Financial Risks
Amount drawn under each tranche		kr 25

Inventories (Details)

Inventories (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Inventories
Raw materials	kr 1,855	kr 889
Work in progress	937
Finished goods	855
Total	3,647	889
Inventories recognized as cost of sales	kr 3,179	kr 0	kr 0

Prepaid Expenses and Accrued _3

Prepaid Expenses and Accrued Income (Details) - SEK (kr) kr in Thousands	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expenses and Accrued Income
Accrued royalties	kr 2,287
Prepaid insurance premiums	9,148	kr 10,813
Prepaid interest costs	3,693
Prepaid expenses for research and development	45,454	27,888
Prepaid expenses for marketing and selling	8,194
Other prepaid expenses	1,964	6,331
Total	kr 70,741	kr 45,032

Cash (Details)

Cash (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash
Cash at Banks	kr 1,249,094	kr 955,507
Total	1,249,094	955,507
Depreciation and Impairment	12,913	34,433	kr 2,823
Change in Provisions	(3,346)	5,856	6,634
Share-based payments	35,791	21,960	6,012
Cange in Contingent consideration	15,941	4,470
Other items	(39)	(43)	(4)
Total	kr 61,260	kr 66,676	kr 15,465

Cash - Reconciliation of liabil

Cash - Reconciliation of liabilities (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of liabilities from financing activities
Opening balance	kr 222,806	kr 4,786
Cash - Flow	480,870	179,092
Exchange Differences	35,519	38,928
Closing balance	739,195	222,806
Lease Liabilities
Reconciliation of liabilities from financing activities
Opening balance	33,642	4,786
Cash - Flow	(9,615)	(5,575)
Exchange Differences	2,138	34,431
Closing balance	26,165	33,642
Non-current interesting-bearing liabilities
Reconciliation of liabilities from financing activities
Opening balance	189,164
Cash - Flow	490,485	184,667
Exchange Differences	33,381	4,497
Closing balance	kr 713,030	kr 189,164

Group Companies (Details)

Group Companies (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Nefecon AB
Group Companies
Equity interest	100%	100%	100%
Calliditas NA Enterprises Inc
Group Companies
Equity interest	100%	100%	100%
Calliditas Therapeutics US Inc,
Group Companies
Equity interest	100%	100%
Calliditas Therapeutics France SAS
Group Companies
Equity interest	100%	100%	86.20%
Calliditas Therapeutics Suisse SA
Group Companies
Equity interest	100%	100%	86.20%

Equity - Share Capital and Othe

Equity - Share Capital and Other Contributed Capital (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Changes in equity
Total registered shares at the beginning of the year	52,341,584	49,941,584	38,707,638
New share issue		2,400,000	9,937,446
Exercise of warrants	1,322,985		1,296,500
Issuance of treasury shares	5,908,018
Shares subscribed but not registered during the year	7,500
Total registered and subscribed but not registered shares at the end of the year	59,580,087	52,341,584	49,941,584
Shares
Ordinary shares	59,580,087	52,341,584	49,941,584
Total	59,580,087	52,341,584	49,941,584
of which shares are held by Calliditas	5,908,018
Total registered and subscribed but not registered shares at the end of the year, net of shares held by Calliditas	53,672,069	52,341,584	49,941,584
Share Capital
Opening balance	kr 2,094	kr 1,998	kr 1,548
New share issue		96	397
Exercise of warrant value during the period	53		52
Issuance of treasury shares	236
Closing balance	kr 2,383	kr 2,094	kr 1,998

Equity - Additional information

Equity - Additional information (Details)	12 Months Ended
	Dec. 31, 2022 Vote kr / shares shares
Vote per share | Vote	1
Quotient value (per share) | kr / shares	kr 0.04
Treasury shares issued	5,908,018
ATM Program
Treasury shares issued	0
Series C ordinary shares
Treasury shares issued	5,908,018

Equity - Translation Reserve (D

Equity - Translation Reserve (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity
Opening balance	kr (26,979)	kr (6,090)	kr (45)
Change of the year	36,286	(20,889)	(6,045)
Closing balance	kr 9,307	kr (26,979)	kr (6,090)

Provisions (Details)

Provisions (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of changes in other provisions
Other provisions at beginning of period	kr 14,530	kr 6,391
Provisions for the year	1,027	8,112
Amounts claimed for the year	(204)
Reversal of unused amounts	(4,239)
Exchange differences	678	27
Other provisions at end of period	11,792	14,530
Social Security Costs on Share-Based Payment
Reconciliation of changes in other provisions
Other provisions at beginning of period	13,084	4,972
Provisions for the year	1,027	8,112
Amounts claimed for the year	(204)
Reversal of unused amounts	(2,666)
Exchange differences	551
Other provisions at end of period	11,792	13,084
Other Provision
Reconciliation of changes in other provisions
Other provisions at beginning of period	1,446	1,419
Reversal of unused amounts	(1,573)
Exchange differences	kr 127	27
Other provisions at end of period		kr 1,446

Contingent Consideration (Detai

Contingent Consideration (Details) - Genkyotex SA - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Contingent Consideration
Opening balance	kr 54,399	kr 48,969
Change for the year	15,942	4,470
Exchange differences	5,539	960
Ending balance	kr 75,880	kr 54,399

Contingent Consideration - Addi

Contingent Consideration - Additional information (Details) kr in Thousands, € in Millions	Dec. 31, 2022 SEK (kr)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 SEK (kr)
Contingent Consideration
Discount rate	12%	12%
Weighted average probability	20.80%	20.80%	15.21%
Higher probability (in percent)	10%	10%
Impact on profit after tax | kr	kr 7,588		kr 5,440
Unobservable inputs used in the fair value measurement | kr	kr 0
Genkyotex SA | Milestone 1
Contingent Consideration
Contingent consideration		€ 30
Genkyotex SA | Milestone 2
Contingent Consideration
Contingent consideration		15
Genkyotex SA | Milestone 3
Contingent Consideration
Contingent consideration		€ 10

Pension Liabilities - Net oblig

Pension Liabilities - Net obligation per country (Details) - SEK (kr) kr in Thousands	Dec. 31, 2022	Dec. 31, 2021
Pension Liabilities
Net obligation	kr 884	kr 3,182
Defined-Benefit Pension Plan
Pension Liabilities
Net obligation	884	3,182
Switzerland | Defined-Benefit Pension Plan
Pension Liabilities
Net obligation	789	3,071
France | Defined-Benefit Pension Plan
Pension Liabilities
Net obligation	kr 94	kr 111

Pension Liabilities - Changes i

Pension Liabilities - Changes in the defined-benefit pension obligations (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pension Liabilities
Subtotal included in other items of comprehensive income	kr 2,763	kr 1,993	kr 1,216
Defined-Benefit Pension Plan
Pension Liabilities
Balance at the beginning	(3,182)	(8,296)
Service costs	(1,556)	(2,178)
Interest expense	(10)	(7)
Curtailment		4,206
Employee contribution	887	704
Subtotal included in the statement of consolidated operations	(679)	2,725
Return on assets (excluding interest expenses)	34	64
Actuarial gains/(losses) related to changes in demographic assumptions	54	426
Actuarial gains/(losses) related to changes in financial assumptions	2,846	1,120
Other actuarial gains/(losses)	(454)	360
Subtotal included in other items of comprehensive income	2,480	1,970
Employer contributions	887	704
Currency translation effect	(390)	(285)
Balance at the end	(884)	(3,182)	(8,296)
Defined Benefit Plan Obligation | Defined-Benefit Pension Plan
Pension Liabilities
Balance at the beginning	7,942
Balance at the end	6,027	7,942
Defined Benefit Plan Obligation | Switzerland | Defined-Benefit Pension Plan
Pension Liabilities
Balance at the beginning	(7,942)	(19,193)
Service costs	(1,530)	(2,165)
Interest expense	(27)	(17)
Curtailment		12,011
Subtotal included in the statement of consolidated operations	(1,558)	9,829
Amounts paid/received	2,140	291
Actuarial gains/(losses) related to changes in demographic assumptions		349
Actuarial gains/(losses) related to changes in financial assumptions	2,846	1,120
Other actuarial gains/(losses)	(454)	360
Subtotal included in other items of comprehensive income	2,392	1,829
Currency translation effect	(1,059)	(698)
Balance at the end	(6,027)	(7,942)	(19,193)
Defined Benefit Plan Obligation | France | Defined-Benefit Pension Plan
Pension Liabilities
Balance at the beginning	(111)	(172)
Service costs	(26)	(13)
Interest expense	(1)
Subtotal included in the statement of consolidated operations	(27)	(13)
Actuarial gains/(losses) related to changes in demographic assumptions	54	77
Subtotal included in other items of comprehensive income	54	77
Currency translation effect	(9)	(3)
Balance at the end	(94)	(111)	(172)
Fair Value of Plan Assets | Switzerland | Defined-Benefit Pension Plan
Pension Liabilities
Balance at the beginning	4,871	11,069
Interest expense	18	10
Curtailment		(7,805)
Employee contribution	887	704
Subtotal included in the statement of consolidated operations	906	(7,091)
Amounts paid/received	(2,140)	(291)
Return on assets (excluding interest expenses)	34	64
Subtotal included in other items of comprehensive income	34	64
Employer contributions	887	704
Currency translation effect	679	416
Balance at the end	kr 5,238	kr 4,871	kr 11,069

Pension Liabilities - Distribut

Pension Liabilities - Distribution by plan assets (Details) - Switzerland - Fair Value of Plan Assets - Defined-Benefit Pension Plan - SEK (kr) kr in Thousands	Dec. 31, 2022	Dec. 31, 2021
Distribution by Plan Assets
Cash	kr 137	kr 205
Bonds	3,048	2,801
Mortgage loans	655	667
Shares	126	92
Real estate	901	760
Other investments	372	346
Total	5,238	4,871
Level 1
Distribution by Plan Assets
Bonds	kr 3,048	kr 2,801

Pension Liabilities - Actuarial

Pension Liabilities - Actuarial assumptions on the balance sheet date (Details) - Defined-Benefit Pension Plan	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Pension Liabilities
Discount rate	2.30%	0.35%
Mortality table	2,020	2,020
Salary revaluation rate	1%	1%
Retirement pension inflation rate	0.50%	0.50%
Deposit rate on savings accounts	1%	1%
Turnover rate	10%	10%
Remaining life expectancy after retirement	18 years 7 months 6 days	22 years 3 months 18 days
Retirement age	65 years	65 years

Pension Liabilities - Sensitivi

Pension Liabilities - Sensitivity analysis (Details) - SEK (kr) kr in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined-Benefit Pension Plan
Sensitivity Analysis
Pension commitments under current assumptions for Swiss pension plans	kr (884)	kr (3,182)	kr (8,296)
Defined Benefit Plan Obligation | Defined-Benefit Pension Plan
Sensitivity Analysis
Pension commitments under current assumptions for Swiss pension plans	kr 6,027	7,942
Discount rate | Defined Benefit Plan Obligation
Sensitivity Analysis
Decrease in actuarial assumption (as a percent)	(0.50%)
Increase in actuarial assumption (as a percent)	0.50%
Discount rate | Defined Benefit Plan Obligation | Defined-Benefit Pension Plan
Sensitivity Analysis
Increase(decrease) in defined benefit obligation, assuming decrease in actuarial assumption	kr 6,615	8,904
Increase(decrease) in defined benefit obligation, assuming increase in actuarial assumption	kr 5,518	7,130
Retirement pension inflation rate | Defined Benefit Plan Obligation
Sensitivity Analysis
Decrease in actuarial assumption (as a percent)	(0.50%)
Increase in actuarial assumption (as a percent)	0.50%
Retirement pension inflation rate | Defined Benefit Plan Obligation | Defined-Benefit Pension Plan
Sensitivity Analysis
Increase(decrease) in defined benefit obligation, assuming decrease in actuarial assumption	kr 5,797	7,575
Increase(decrease) in defined benefit obligation, assuming increase in actuarial assumption	kr 6,281	8,353
Salary revaluation rate | Defined Benefit Plan Obligation
Sensitivity Analysis
Decrease in actuarial assumption (as a percent)	(0.50%)
Increase in actuarial assumption (as a percent)	0.50%
Salary revaluation rate | Defined Benefit Plan Obligation | Defined-Benefit Pension Plan
Sensitivity Analysis
Increase(decrease) in defined benefit obligation, assuming decrease in actuarial assumption	kr 5,927	7,792
Increase(decrease) in defined benefit obligation, assuming increase in actuarial assumption	kr 6,131	kr 8,100

Pension Liabilities - Additiona

Pension Liabilities - Additional details (Details) - Not Later Than One Year [Member] - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Pension Liabilities
Estimated contributions to plans for post-employment benefits	kr 813	kr 555
Weighted average maturity	18 years 7 months 6 days	22 years 3 months 18 days

Other Non-Current Liabilities_2

Other Non-Current Liabilities (Details) kr in Thousands	Dec. 31, 2022 SEK (kr)
Other Non-Current Liabilities
Additional liabilities	kr 4,350

Accrued Expenses and Deferred_3

Accrued Expenses and Deferred Revenue (Details) - SEK (kr) kr in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued Expenses and Deferred Revenue
Vacation pay liabilities	kr 8,310	kr 6,107
Accrued salaries and Board fees	28,186	16,786
Social security costs	7,065	5,492
Deferred revenue		3,387
Accrued rebates on sales	15,849
Accrued expenses for royalty	12,023
Accrued expenses for research and development	34,637	4,230
Accrued expenses for marketing and selling	21,543	1,242
Accrued expenses for administration	8,832	16,309
Total	kr 136,446	kr 53,553

Change of presentation of exp_3

Change of presentation of expenses - change in the statement of income (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of voluntary change in accounting policy [line items]
Net sales	kr 802,879		kr 874
Research and development expenses	(414,749)	kr (357,485)	(241,371)
Marketing and selling expenses	(515,190)	(179,603)	(38,964)
Administrative expenses	(259,469)		(102,760)
Other operating income/expenses		(6,085)	2,501
Operating loss	(421,943)	(524,456)	(379,720)
Net financial income/(expenses)		11,083	(56,431)
Loss before income tax	(409,417)	(513,373)	(436,151)
Income tax	2,851	(3,836)	360
Loss for the year	kr (412,268)	(509,537)	(436,511)
Previously reported
Disclosure of voluntary change in accounting policy [line items]
Net sales		229,347	874
Research and development expenses		(357,485)	(241,371)
Administrative expenses		(390,232)	(141,724)
Other operating income/expenses		(6,085)	2,501
Operating loss		(524,456)	(379,720)
Net financial income/(expenses)		11,083	(56,431)
Loss before income tax		(513,373)	(436,151)
Income tax		(3,836)	360
Loss for the year		(509,537)	(436,511)
Re-classification
Disclosure of voluntary change in accounting policy [line items]
Marketing and selling expenses		(179,603)	(38,964)
Administrative expenses		kr 179,603	kr 38,964

Pledged Assets, Contingent Li_2

Pledged Assets, Contingent Liabilities and Other Obligations (Details) - SEK (kr) kr in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Pledged Assets, Contingent Liabilities and Other Obligations
Percentage of Fixed Royalty	3%
Pledged assets	kr 6,859	kr 3,915

Events After the Reporting Pe_2

Events After the Reporting Period (Details) - NefIgArd	1 Months Ended
	Mar. 31, 2023 item
Events After the Reporting Period
Number of clinical trial	3
Estimated glomerular filtration rate value	0.0001
Estimated glomerular filtration rate period	2 years